id	sid	tid	token	lemma	pos
admet-154	1	1	manuscript	manuscript	PROPN
admet-154	1	2	doi	doi	PROPN
admet-154	1	3	:	:	PUNCT
admet-154	1	4	10.5599	10.5599	NUM
admet-154	1	5	/	/	SYM
admet-154	1	6	admet.3.1.154	admet.3.1.154	PROPN
admet-154	1	7	68	68	NUM
admet-154	1	8	admet	admet	X
admet-154	1	9	&	&	CCONJ
admet-154	1	10	dmpk	dmpk	PROPN
admet-154	1	11	3(1	3(1	NUM
admet-154	1	12	)	)	PUNCT
admet-154	1	13	(	(	PUNCT
admet-154	1	14	2015	2015	NUM
admet-154	1	15	)	)	PUNCT
admet-154	1	16	68	68	NUM
admet-154	1	17	-	-	SYM
admet-154	1	18	76	76	NUM
admet-154	1	19	;	;	PUNCT
admet-154	1	20	doi	doi	NOUN
admet-154	1	21	:	:	PUNCT
admet-154	1	22	10.5599	10.5599	NUM
admet-154	1	23	/	/	SYM
admet-154	1	24	admet.3.1.154	admet.3.1.154	VERB
admet-154	1	25	open	open	ADJ
admet-154	1	26	access	access	NOUN
admet-154	1	27	:	:	PUNCT
admet-154	1	28	issn	issn	PROPN
admet-154	1	29	:	:	PUNCT
admet-154	1	30	1848	1848	NUM
admet-154	1	31	-	-	SYM
admet-154	1	32	7718	7718	NUM
admet-154	1	33	http://www.pub.iapchem.org/ojs/index.php/admet/index	http://www.pub.iapchem.org/ojs/index.php/admet/index	NOUN
admet-154	1	34	short	short	ADJ
admet-154	1	35	communication	communication	NOUN
admet-154	1	36	p	p	NOUN
admet-154	1	37	-	-	PUNCT
admet-154	1	38	glycoprotein	glycoprotein	NOUN
admet-154	1	39	-	-	PUNCT
admet-154	1	40	dependent	dependent	ADJ
admet-154	1	41	pharmacokinetics	pharmacokinetic	NOUN
admet-154	1	42	of	of	ADP
admet-154	1	43	irinotecan	irinotecan	NOUN
admet-154	1	44	and	and	CCONJ
admet-154	1	45	its	its	PRON
admet-154	1	46	active	active	ADJ
admet-154	1	47	metabolite	metabolite	NOUN
admet-154	1	48	,	,	PUNCT
admet-154	1	49	sn-38	sn-38	NOUN
admet-154	1	50	in	in	ADP
admet-154	1	51	rats	rat	NOUN
admet-154	1	52	:	:	PUNCT
admet-154	1	53	effect	effect	NOUN
admet-154	1	54	of	of	ADP
admet-154	1	55	verapamil	verapamil	NOUN
admet-154	1	56	tripta	tripta	NOUN
admet-154	1	57	garg*1	garg*1	PROPN
admet-154	1	58	,	,	PUNCT
admet-154	1	59	manu	manu	PROPN
admet-154	1	60	jaggi2	jaggi2	PROPN
admet-154	1	61	,	,	PUNCT
admet-154	1	62	roop	roop	PROPN
admet-154	1	63	k.	k.	PROPN
admet-154	1	64	khar3	khar3	PROPN
admet-154	1	65	and	and	CCONJ
admet-154	1	66	sushama	sushama	NOUN
admet-154	1	67	talegaonkar4	talegaonkar4	NOUN
admet-154	1	68	1	1	NUM
admet-154	1	69	full	full	ADJ
admet-154	1	70	affiliation	affiliation	NOUN
admet-154	1	71	,	,	PUNCT
admet-154	1	72	address	address	NOUN
admet-154	1	73	1department	1department	NUM
admet-154	1	74	of	of	ADP
admet-154	1	75	scientific	scientific	ADJ
admet-154	1	76	and	and	CCONJ
admet-154	1	77	industrial	industrial	ADJ
admet-154	1	78	research	research	NOUN
admet-154	1	79	,	,	PUNCT
admet-154	1	80	ministry	ministry	PROPN
admet-154	1	81	of	of	ADP
admet-154	1	82	science	science	NOUN
admet-154	1	83	and	and	CCONJ
admet-154	1	84	technology	technology	NOUN
admet-154	1	85	,	,	PUNCT
admet-154	1	86	new	new	ADJ
admet-154	1	87	mehrauli	mehrauli	PROPN
admet-154	1	88	road	road	PROPN
admet-154	1	89	,	,	PUNCT
admet-154	1	90	new	new	ADJ
admet-154	1	91	delhi	delhi	PROPN
admet-154	1	92	110016	110016	NUM
admet-154	1	93	,	,	PUNCT
admet-154	1	94	india	india	PROPN
admet-154	1	95	2	2	NUM
admet-154	1	96	dabur	dabur	PROPN
admet-154	1	97	research	research	PROPN
admet-154	1	98	foundation	foundation	PROPN
admet-154	1	99	,	,	PUNCT
admet-154	1	100	22	22	NUM
admet-154	1	101	,	,	PUNCT
admet-154	1	102	site	site	NOUN
admet-154	1	103	iv	iv	NUM
admet-154	1	104	,	,	PUNCT
admet-154	1	105	sahibabad	sahibabad	PROPN
admet-154	1	106	,	,	PUNCT
admet-154	1	107	ghaziabad	ghaziabad	PROPN
admet-154	1	108	,	,	PUNCT
admet-154	1	109	u.p	u.p	PROPN
admet-154	1	110	.	.	PROPN
admet-154	1	111	201010	201010	NUM
admet-154	1	112	,	,	PUNCT
admet-154	1	113	india	india	PROPN
admet-154	1	114	3	3	NUM
admet-154	1	115	principal	principal	NOUN
admet-154	1	116	,	,	PUNCT
admet-154	1	117	b.	b.	PROPN
admet-154	1	118	s.	s.	PROPN
admet-154	1	119	anangpuria	anangpuria	PROPN
admet-154	1	120	institute	institute	PROPN
admet-154	1	121	of	of	ADP
admet-154	1	122	pharmacy	pharmacy	PROPN
admet-154	1	123	,	,	PUNCT
admet-154	1	124	faridabad	faridabad	PROPN
admet-154	1	125	,	,	PUNCT
admet-154	1	126	india	india	PROPN
admet-154	1	127	4	4	NUM
admet-154	1	128	dept	dept	NOUN
admet-154	1	129	.	.	PROPN
admet-154	1	130	of	of	ADP
admet-154	1	131	pharmaceutics	pharmaceutic	NOUN
admet-154	1	132	,	,	PUNCT
admet-154	1	133	faculty	faculty	NOUN
admet-154	1	134	of	of	ADP
admet-154	1	135	pharmacy	pharmacy	NOUN
admet-154	1	136	,	,	PUNCT
admet-154	1	137	jamia	jamia	PROPN
admet-154	1	138	hamdard	hamdard	PROPN
admet-154	1	139	(	(	PUNCT
admet-154	1	140	hamdard	hamdard	PROPN
admet-154	1	141	university	university	NOUN
admet-154	1	142	,	,	PUNCT
admet-154	1	143	hamdard	hamdard	NOUN
admet-154	1	144	nagar	nagar	NOUN
admet-154	1	145	,	,	PUNCT
admet-154	1	146	new	new	ADJ
admet-154	1	147	delhi	delhi	PROPN
admet-154	1	148	110062	110062	NUM
admet-154	1	149	,	,	PUNCT
admet-154	1	150	india	india	PROPN
admet-154	1	151	*	*	PUNCT
admet-154	1	152	corresponding	correspond	VERB
admet-154	1	153	author	author	NOUN
admet-154	1	154	:	:	PUNCT
admet-154	1	155	e	e	NOUN
admet-154	1	156	-	-	NOUN
admet-154	1	157	mail	mail	NOUN
admet-154	1	158	:	:	PUNCT
admet-154	2	1	dr.tripta@gmail.com	dr.tripta@gmail.com	PROPN
admet-154	2	2	received	receive	VERB
admet-154	2	3	:	:	PUNCT
admet-154	2	4	december	december	PROPN
admet-154	2	5	09	09	NUM
admet-154	2	6	,	,	PUNCT
admet-154	2	7	2014	2014	NUM
admet-154	2	8	;	;	PUNCT
admet-154	2	9	revised	revise	VERB
admet-154	2	10	:	:	PUNCT
admet-154	2	11	january	january	PROPN
admet-154	2	12	19	19	NUM
admet-154	2	13	,	,	PUNCT
admet-154	2	14	2015	2015	NUM
admet-154	2	15	;	;	PUNCT
admet-154	2	16	published	publish	VERB
admet-154	2	17	:	:	PUNCT
admet-154	2	18	march	march	PROPN
admet-154	2	19	31	31	NUM
admet-154	2	20	,	,	PUNCT
admet-154	2	21	2015	2015	NUM
admet-154	2	22	abstract	abstract	NOUN
admet-154	2	23	we	we	PRON
admet-154	2	24	have	have	AUX
admet-154	2	25	recently	recently	ADV
admet-154	2	26	demonstrated	demonstrate	VERB
admet-154	2	27	that	that	SCONJ
admet-154	2	28	the	the	DET
admet-154	2	29	oral	oral	ADJ
admet-154	2	30	bioavailability	bioavailability	NOUN
admet-154	2	31	of	of	ADP
admet-154	2	32	irinotecan	irinotecan	NOUN
admet-154	2	33	(	(	PUNCT
admet-154	2	34	80	80	NUM
admet-154	2	35	mg	mg	PROPN
admet-154	2	36	/	/	SYM
admet-154	2	37	kg	kg	PROPN
admet-154	2	38	)	)	PUNCT
admet-154	2	39	can	can	AUX
admet-154	2	40	be	be	AUX
admet-154	2	41	increased	increase	VERB
admet-154	2	42	at	at	ADP
admet-154	2	43	least	least	ADJ
admet-154	2	44	7	7	NUM
admet-154	2	45	-	-	NOUN
admet-154	2	46	fold	fold	ADJ
admet-154	2	47	by	by	ADP
admet-154	2	48	co	co	NOUN
admet-154	2	49	-	-	NOUN
admet-154	2	50	administration	administration	NOUN
admet-154	2	51	of	of	ADP
admet-154	2	52	the	the	DET
admet-154	2	53	p	p	NOUN
admet-154	2	54	-	-	PUNCT
admet-154	2	55	gp	gp	NOUN
admet-154	2	56	blocker	blocker	NOUN
admet-154	2	57	verapamil	verapamil	NOUN
admet-154	2	58	(	(	PUNCT
admet-154	2	59	25	25	NUM
admet-154	2	60	mg	mg	PROPN
admet-154	2	61	/	/	SYM
admet-154	2	62	kg	kg	PROPN
admet-154	2	63	,	,	PUNCT
admet-154	2	64	oral	oral	ADJ
admet-154	2	65	)	)	PUNCT
admet-154	2	66	.	.	PUNCT
admet-154	3	1	as	as	ADP
admet-154	3	2	a	a	DET
admet-154	3	3	result	result	NOUN
admet-154	3	4	,	,	PUNCT
admet-154	3	5	co	co	NOUN
admet-154	3	6	-	-	NOUN
admet-154	3	7	treatment	treatment	NOUN
admet-154	3	8	with	with	ADP
admet-154	3	9	p	p	NOUN
admet-154	3	10	-	-	PUNCT
admet-154	3	11	gp	gp	NOUN
admet-154	3	12	inhibitor	inhibitor	NOUN
admet-154	3	13	could	could	AUX
admet-154	3	14	be	be	AUX
admet-154	3	15	a	a	DET
admet-154	3	16	useful	useful	ADJ
admet-154	3	17	strategy	strategy	NOUN
admet-154	3	18	for	for	ADP
admet-154	3	19	bioavailability	bioavailability	NOUN
admet-154	3	20	enhancement	enhancement	NOUN
admet-154	3	21	.	.	PUNCT
admet-154	4	1	however	however	ADV
admet-154	4	2	,	,	PUNCT
admet-154	4	3	in	in	ADP
admet-154	4	4	view	view	NOUN
admet-154	4	5	of	of	ADP
admet-154	4	6	narrow	narrow	ADJ
admet-154	4	7	therapeutic	therapeutic	ADJ
admet-154	4	8	index	index	NOUN
admet-154	4	9	,	,	PUNCT
admet-154	4	10	the	the	DET
admet-154	4	11	co	co	NOUN
admet-154	4	12	-	-	NOUN
admet-154	4	13	administration	administration	NOUN
admet-154	4	14	of	of	ADP
admet-154	4	15	irinotecan	irinotecan	NOUN
admet-154	4	16	and	and	CCONJ
admet-154	4	17	verapamil	verapamil	NOUN
admet-154	4	18	may	may	AUX
admet-154	4	19	result	result	VERB
admet-154	4	20	in	in	ADP
admet-154	4	21	unanticipated	unanticipated	ADJ
admet-154	4	22	toxicities	toxicity	NOUN
admet-154	4	23	.	.	PUNCT
admet-154	5	1	therefore	therefore	ADV
admet-154	5	2	,	,	PUNCT
admet-154	5	3	dose	dose	NOUN
admet-154	5	4	optimisation	optimisation	NOUN
admet-154	5	5	studies	study	NOUN
admet-154	5	6	of	of	ADP
admet-154	5	7	irinotecan	irinotecan	NOUN
admet-154	5	8	were	be	AUX
admet-154	5	9	performed	perform	VERB
admet-154	5	10	when	when	SCONJ
admet-154	5	11	it	it	PRON
admet-154	5	12	is	be	AUX
admet-154	5	13	given	give	VERB
admet-154	5	14	in	in	ADP
admet-154	5	15	conjunction	conjunction	NOUN
admet-154	5	16	with	with	ADP
admet-154	5	17	a	a	DET
admet-154	5	18	p	p	NOUN
admet-154	5	19	-	-	PUNCT
admet-154	5	20	gp	gp	NOUN
admet-154	5	21	inhibitor	inhibitor	NOUN
admet-154	5	22	.	.	PUNCT
admet-154	6	1	for	for	ADP
admet-154	6	2	dose	dose	NOUN
admet-154	6	3	optimization	optimization	NOUN
admet-154	6	4	study	study	NOUN
admet-154	6	5	,	,	PUNCT
admet-154	6	6	the	the	DET
admet-154	6	7	bioavailability	bioavailability	NOUN
admet-154	6	8	and	and	CCONJ
admet-154	6	9	pharmacokinetic	pharmacokinetic	ADJ
admet-154	6	10	parameters	parameter	NOUN
admet-154	6	11	were	be	AUX
admet-154	6	12	studied	study	VERB
admet-154	6	13	in	in	ADP
admet-154	6	14	rats	rat	NOUN
admet-154	6	15	after	after	ADP
admet-154	6	16	oral	oral	ADJ
admet-154	6	17	administration	administration	NOUN
admet-154	6	18	of	of	ADP
admet-154	6	19	irinotecan	irinotecan	NOUN
admet-154	6	20	at	at	ADP
admet-154	6	21	three	three	NUM
admet-154	6	22	doses	dose	NOUN
admet-154	6	23	(	(	PUNCT
admet-154	6	24	i.e.	i.e.	X
admet-154	6	25	20	20	NUM
admet-154	6	26	,	,	PUNCT
admet-154	6	27	40	40	NUM
admet-154	6	28	and	and	CCONJ
admet-154	6	29	80	80	NUM
admet-154	6	30	mg	mg	NUM
admet-154	6	31	/	/	SYM
admet-154	6	32	kg	kg	NOUN
admet-154	6	33	)	)	PUNCT
admet-154	6	34	alone	alone	ADJ
admet-154	6	35	and	and	CCONJ
admet-154	6	36	in	in	ADP
admet-154	6	37	combination	combination	NOUN
admet-154	6	38	with	with	ADP
admet-154	6	39	verapamil	verapamil	NOUN
admet-154	6	40	(	(	PUNCT
admet-154	6	41	25	25	NUM
admet-154	6	42	mg	mg	PROPN
admet-154	6	43	/	/	SYM
admet-154	6	44	kg	kg	PROPN
admet-154	6	45	,	,	PUNCT
admet-154	6	46	oral	oral	ADJ
admet-154	6	47	)	)	PUNCT
admet-154	6	48	.	.	PUNCT
admet-154	7	1	the	the	DET
admet-154	7	2	area	area	NOUN
admet-154	7	3	under	under	ADP
admet-154	7	4	the	the	DET
admet-154	7	5	plasmaconcentration	plasmaconcentration	NOUN
admet-154	7	6	time	time	NOUN
admet-154	7	7	curve	curve	NOUN
admet-154	7	8	(	(	PUNCT
admet-154	7	9	auc	auc	NOUN
admet-154	7	10	)	)	PUNCT
admet-154	7	11	of	of	ADP
admet-154	7	12	irinotecan	irinotecan	NOUN
admet-154	7	13	at	at	ADP
admet-154	7	14	20	20	NUM
admet-154	7	15	,	,	PUNCT
admet-154	7	16	40	40	NUM
admet-154	7	17	and	and	CCONJ
admet-154	7	18	80	80	NUM
admet-154	7	19	mg	mg	NUM
admet-154	7	20	/	/	SYM
admet-154	7	21	kg	kg	PROPN
admet-154	7	22	was	be	AUX
admet-154	7	23	3.51	3.51	NUM
admet-154	7	24	±	±	NUM
admet-154	7	25	1.20	1.20	NUM
admet-154	7	26	,	,	PUNCT
admet-154	7	27	8.81	8.81	NUM
admet-154	7	28	±	±	NUM
admet-154	7	29	1.93	1.93	NUM
admet-154	7	30	and	and	CCONJ
admet-154	7	31	14.03	14.03	NUM
admet-154	7	32	±	±	NUM
admet-154	7	33	2.18	2.18	NUM
admet-154	7	34	h	h	NOUN
admet-154	7	35	µg	µg	ADJ
admet-154	7	36	/	/	SYM
admet-154	7	37	ml	ml	NOUN
admet-154	7	38	,	,	PUNCT
admet-154	7	39	respectively	respectively	ADV
admet-154	7	40	which	which	PRON
admet-154	7	41	after	after	ADP
admet-154	7	42	treatment	treatment	NOUN
admet-154	7	43	with	with	ADP
admet-154	7	44	verapamil	verapamil	NOUN
admet-154	7	45	,	,	PUNCT
admet-154	7	46	increased	increase	VERB
admet-154	7	47	dose	dose	NOUN
admet-154	7	48	dependently	dependently	ADV
admet-154	7	49	to	to	ADP
admet-154	7	50	7.84	7.84	NUM
admet-154	7	51	±	±	NUM
admet-154	7	52	1.20	1.20	NUM
admet-154	7	53	,	,	PUNCT
admet-154	7	54	19.94	19.94	NUM
admet-154	7	55	±	±	NUM
admet-154	7	56	2.39	2.39	NUM
admet-154	7	57	and	and	CCONJ
admet-154	7	58	61.71	61.71	NUM
admet-154	7	59	±	±	NUM
admet-154	7	60	15.0	15.0	NUM
admet-154	7	61	h	h	NOUN
admet-154	7	62	µg	µg	ADV
admet-154	7	63	/	/	SYM
admet-154	7	64	ml	ml	NOUN
admet-154	7	65	,	,	PUNCT
admet-154	7	66	respectively	respectively	ADV
admet-154	7	67	.	.	PUNCT
admet-154	8	1	in	in	ADP
admet-154	8	2	addition	addition	NOUN
admet-154	8	3	to	to	ADP
admet-154	8	4	irinotecan	irinotecan	NOUN
admet-154	8	5	,	,	PUNCT
admet-154	8	6	plasma	plasma	NOUN
admet-154	8	7	concentrations	concentration	NOUN
admet-154	8	8	of	of	ADP
admet-154	8	9	sn-38	sn-38	NOUN
admet-154	8	10	,	,	PUNCT
admet-154	8	11	one	one	NUM
admet-154	8	12	of	of	ADP
admet-154	8	13	the	the	DET
admet-154	8	14	major	major	ADJ
admet-154	8	15	active	active	ADJ
admet-154	8	16	metabolite	metabolite	NOUN
admet-154	8	17	of	of	ADP
admet-154	8	18	irinotecan	irinotecan	NOUN
admet-154	8	19	,	,	PUNCT
admet-154	8	20	were	be	AUX
admet-154	8	21	also	also	ADV
admet-154	8	22	monitored	monitor	VERB
admet-154	8	23	.	.	PUNCT
admet-154	9	1	the	the	DET
admet-154	9	2	less	less	ADJ
admet-154	9	3	than	than	ADP
admet-154	9	4	proportional	proportional	ADJ
admet-154	9	5	increase	increase	NOUN
admet-154	9	6	in	in	ADP
admet-154	9	7	sn-38	sn-38	NOUN
admet-154	9	8	auc	auc	NOUN
admet-154	9	9	from	from	ADP
admet-154	9	10	20	20	NUM
admet-154	9	11	to	to	PART
admet-154	9	12	80	80	NUM
admet-154	9	13	mg	mg	NOUN
admet-154	9	14	/	/	SYM
admet-154	9	15	kg	kg	PROPN
admet-154	9	16	is	be	AUX
admet-154	9	17	consistent	consistent	ADJ
admet-154	9	18	with	with	ADP
admet-154	9	19	the	the	DET
admet-154	9	20	saturation	saturation	NOUN
admet-154	9	21	of	of	ADP
admet-154	9	22	carboxylesterase	carboxylesterase	NOUN
admet-154	9	23	.	.	PUNCT
admet-154	10	1	our	our	PRON
admet-154	10	2	results	result	NOUN
admet-154	10	3	indicate	indicate	VERB
admet-154	10	4	that	that	DET
admet-154	10	5	oral	oral	ADJ
admet-154	10	6	drug	drug	NOUN
admet-154	10	7	treatment	treatment	NOUN
admet-154	10	8	of	of	ADP
admet-154	10	9	irinotecan	irinotecan	NOUN
admet-154	10	10	in	in	ADP
admet-154	10	11	presence	presence	NOUN
admet-154	10	12	of	of	ADP
admet-154	10	13	temporary	temporary	ADJ
admet-154	10	14	p	p	NOUN
admet-154	10	15	-	-	PUNCT
admet-154	10	16	gp	gp	NOUN
admet-154	10	17	inhibition	inhibition	NOUN
admet-154	10	18	could	could	AUX
admet-154	10	19	be	be	AUX
admet-154	10	20	as	as	ADV
admet-154	10	21	equally	equally	ADV
admet-154	10	22	safe	safe	ADJ
admet-154	10	23	and	and	CCONJ
admet-154	10	24	effective	effective	ADJ
admet-154	10	25	as	as	ADP
admet-154	10	26	intravenous	intravenous	ADJ
admet-154	10	27	administration	administration	NOUN
admet-154	10	28	.	.	PUNCT
admet-154	11	1	nevertheless	nevertheless	ADV
admet-154	11	2	,	,	PUNCT
admet-154	11	3	safe	safe	ADJ
admet-154	11	4	p	p	NOUN
admet-154	11	5	-	-	PUNCT
admet-154	11	6	gp	gp	NOUN
admet-154	11	7	inhibitors	inhibitor	NOUN
admet-154	11	8	need	need	VERB
admet-154	11	9	to	to	PART
admet-154	11	10	be	be	AUX
admet-154	11	11	identified	identify	VERB
admet-154	11	12	as	as	ADP
admet-154	11	13	alternatives	alternative	NOUN
admet-154	11	14	to	to	ADP
admet-154	11	15	verapamil	verapamil	NOUN
admet-154	11	16	for	for	ADP
admet-154	11	17	development	development	NOUN
admet-154	11	18	of	of	ADP
admet-154	11	19	efficacious	efficacious	ADJ
admet-154	11	20	oral	oral	ADJ
admet-154	11	21	irinotecan	irinotecan	NOUN
admet-154	11	22	formulations	formulation	NOUN
admet-154	11	23	.	.	PUNCT
admet-154	12	1	keywords	keyword	NOUN
admet-154	12	2	irinotecan	irinotecan	NOUN
admet-154	12	3	,	,	PUNCT
admet-154	12	4	bioavailability	bioavailability	NOUN
admet-154	12	5	,	,	PUNCT
admet-154	12	6	verapamil	verapamil	NOUN
admet-154	12	7	,	,	PUNCT
admet-154	12	8	p	p	NOUN
admet-154	12	9	-	-	PUNCT
admet-154	12	10	glycoprotein	glycoprotein	NOUN
admet-154	12	11	,	,	PUNCT
admet-154	12	12	pharmacokinetics	pharmacokinetic	NOUN
admet-154	12	13	introduction	introduction	NOUN
admet-154	12	14	irinotecan	irinotecan	NOUN
admet-154	12	15	is	be	AUX
admet-154	12	16	a	a	DET
admet-154	12	17	worldwide	worldwide	ADV
admet-154	12	18	approved	approve	VERB
admet-154	12	19	anti	anti	ADJ
admet-154	12	20	-	-	ADJ
admet-154	12	21	cancer	cancer	ADJ
admet-154	12	22	agent	agent	NOUN
admet-154	12	23	for	for	ADP
admet-154	12	24	the	the	DET
admet-154	12	25	treatment	treatment	NOUN
admet-154	12	26	of	of	ADP
admet-154	12	27	colorectal	colorectal	ADJ
admet-154	12	28	cancers	cancer	NOUN
admet-154	12	29	and	and	CCONJ
admet-154	12	30	other	other	ADJ
admet-154	12	31	malignancies	malignancy	NOUN
admet-154	12	32	.	.	PUNCT
admet-154	13	1	it	it	PRON
admet-154	13	2	is	be	AUX
admet-154	13	3	currently	currently	ADV
admet-154	13	4	marketed	market	VERB
admet-154	13	5	for	for	ADP
admet-154	13	6	intravenous	intravenous	ADJ
admet-154	13	7	use	use	NOUN
admet-154	13	8	although	although	SCONJ
admet-154	13	9	few	few	ADJ
admet-154	13	10	reports	report	NOUN
admet-154	13	11	of	of	ADP
admet-154	13	12	oral	oral	ADJ
admet-154	13	13	irinotecan	irinotecan	NOUN
admet-154	13	14	administration	administration	NOUN
admet-154	13	15	exist	exist	VERB
admet-154	13	16	which	which	PRON
admet-154	13	17	demonstrate	demonstrate	VERB
admet-154	13	18	its	its	PRON
admet-154	13	19	low	low	ADJ
admet-154	13	20	and	and	CCONJ
admet-154	13	21	highly	highly	ADV
admet-154	13	22	variable	variable	ADJ
admet-154	13	23	oral	oral	ADJ
admet-154	13	24	bioavailability	bioavailability	NOUN
admet-154	13	25	[	[	X
admet-154	13	26	1	1	NUM
admet-154	13	27	-	-	SYM
admet-154	13	28	4	4	NUM
admet-154	13	29	]	]	PUNCT
admet-154	13	30	.	.	PUNCT
admet-154	14	1	as	as	SCONJ
admet-154	14	2	a	a	DET
admet-154	14	3	result	result	NOUN
admet-154	14	4	novel	novel	NOUN
admet-154	14	5	formulations	formulation	NOUN
admet-154	14	6	of	of	ADP
admet-154	14	7	irinotecan	irinotecan	NOUN
admet-154	14	8	exhibiting	exhibit	VERB
admet-154	14	9	better	well	ADJ
admet-154	14	10	oral	oral	ADJ
admet-154	14	11	absorption	absorption	NOUN
admet-154	14	12	and	and	CCONJ
admet-154	14	13	bioavailability	bioavailability	NOUN
admet-154	14	14	need	need	VERB
admet-154	14	15	to	to	PART
admet-154	14	16	be	be	AUX
admet-154	14	17	developed	develop	VERB
admet-154	14	18	.	.	PUNCT
admet-154	15	1	http://www.pub.iapchem.org/ojs/index.php/admet/index	http://www.pub.iapchem.org/ojs/index.php/admet/index	PROPN
admet-154	15	2	mailto:dr.tripta@gmail.com	mailto:dr.tripta@gmail.com	PROPN
admet-154	15	3	admet	admet	PROPN
admet-154	15	4	&	&	CCONJ
admet-154	15	5	dmpk	dmpk	PROPN
admet-154	15	6	3(1	3(1	NUM
admet-154	15	7	)	)	PUNCT
admet-154	15	8	(	(	PUNCT
admet-154	15	9	2015	2015	NUM
admet-154	15	10	)	)	PUNCT
admet-154	15	11	68	68	NUM
admet-154	15	12	-	-	SYM
admet-154	15	13	76	76	NUM
admet-154	15	14	p	p	NOUN
admet-154	15	15	-	-	PUNCT
admet-154	15	16	gp	gp	NOUN
admet-154	15	17	pharmacokinetics	pharmacokinetic	NOUN
admet-154	15	18	of	of	ADP
admet-154	15	19	irinotecan	irinotecan	PROPN
admet-154	15	20	doi	doi	PROPN
admet-154	15	21	:	:	PUNCT
admet-154	15	22	10.5599	10.5599	NUM
admet-154	15	23	/	/	SYM
admet-154	15	24	admet.3.1.154	admet.3.1.154	SYM
admet-154	15	25	69	69	NUM
admet-154	15	26	in	in	ADP
admet-154	15	27	our	our	PRON
admet-154	15	28	previous	previous	ADJ
admet-154	15	29	studies	study	NOUN
admet-154	15	30	,	,	PUNCT
admet-154	15	31	irinotecan	irinotecan	NOUN
admet-154	15	32	at	at	ADP
admet-154	15	33	1	1	NUM
admet-154	15	34	and	and	CCONJ
admet-154	15	35	10	10	NUM
admet-154	15	36	µm	µm	NUM
admet-154	15	37	showed	show	VERB
admet-154	15	38	much	much	ADV
admet-154	15	39	higher	high	ADJ
admet-154	15	40	basal	basal	NOUN
admet-154	15	41	-	-	PUNCT
admet-154	15	42	to	to	ADP
admet-154	15	43	-	-	PUNCT
admet-154	15	44	apical	apical	ADJ
admet-154	15	45	transport	transport	NOUN
admet-154	15	46	than	than	ADP
admet-154	15	47	apical	apical	ADJ
admet-154	15	48	-	-	PUNCT
admet-154	15	49	to	to	ADP
admet-154	15	50	-	-	PUNCT
admet-154	15	51	basal	basal	NOUN
admet-154	15	52	transport	transport	NOUN
admet-154	15	53	in	in	ADP
admet-154	15	54	caco-2	caco-2	NUM
admet-154	15	55	cells	cell	NOUN
admet-154	15	56	saturable	saturable	ADJ
admet-154	15	57	at	at	ADP
admet-154	15	58	100	100	NUM
admet-154	15	59	µm	µm	ADP
admet-154	15	60	concentrations	concentration	NOUN
admet-154	15	61	.	.	PUNCT
admet-154	16	1	this	this	PRON
admet-154	16	2	could	could	AUX
admet-154	16	3	be	be	AUX
admet-154	16	4	due	due	ADJ
admet-154	16	5	to	to	ADP
admet-154	16	6	the	the	DET
admet-154	16	7	active	active	ADJ
admet-154	16	8	carrier	carrier	NOUN
admet-154	16	9	mediated	mediate	VERB
admet-154	16	10	transport	transport	NOUN
admet-154	16	11	of	of	ADP
admet-154	16	12	irinotecan	irinotecan	NOUN
admet-154	16	13	by	by	ADP
admet-154	16	14	the	the	DET
admet-154	16	15	intestinal	intestinal	ADJ
admet-154	16	16	drug	drug	NOUN
admet-154	16	17	efflux	efflux	NOUN
admet-154	16	18	pump	pump	NOUN
admet-154	16	19	,	,	PUNCT
admet-154	16	20	p	p	NOUN
admet-154	16	21	-	-	PUNCT
admet-154	16	22	glycoprotein	glycoprotein	NOUN
admet-154	16	23	(	(	PUNCT
admet-154	16	24	p	p	NOUN
admet-154	16	25	-	-	PUNCT
admet-154	16	26	gp	gp	NOUN
admet-154	16	27	)	)	PUNCT
admet-154	16	28	.	.	PUNCT
admet-154	17	1	keeping	keep	VERB
admet-154	17	2	this	this	PRON
admet-154	17	3	in	in	ADP
admet-154	17	4	view	view	NOUN
admet-154	17	5	,	,	PUNCT
admet-154	17	6	pharmacokinetic	pharmacokinetic	ADJ
admet-154	17	7	studies	study	NOUN
admet-154	17	8	of	of	ADP
admet-154	17	9	irinotecan	irinotecan	NOUN
admet-154	17	10	were	be	AUX
admet-154	17	11	conducted	conduct	VERB
admet-154	17	12	with	with	ADP
admet-154	17	13	verapamil	verapamil	NOUN
admet-154	17	14	in	in	ADP
admet-154	17	15	wistar	wistar	PROPN
admet-154	17	16	rats	rat	NOUN
admet-154	17	17	.	.	PUNCT
admet-154	18	1	verapamil	verapamil	PROPN
admet-154	18	2	increased	increase	VERB
admet-154	18	3	the	the	DET
admet-154	18	4	absolute	absolute	ADJ
admet-154	18	5	bioavailability	bioavailability	NOUN
admet-154	18	6	(	(	PUNCT
admet-154	18	7	f	f	X
admet-154	18	8	)	)	PUNCT
admet-154	18	9	of	of	ADP
admet-154	18	10	irinotecan	irinotecan	NOUN
admet-154	18	11	by	by	ADP
admet-154	18	12	4.3	4.3	NUM
admet-154	18	13	fold	fold	VERB
admet-154	18	14	and	and	CCONJ
admet-154	18	15	decreased	decrease	VERB
admet-154	18	16	its	its	PRON
admet-154	18	17	biliary	biliary	ADJ
admet-154	18	18	excretion	excretion	NOUN
admet-154	18	19	.	.	PUNCT
admet-154	19	1	it	it	PRON
admet-154	19	2	appears	appear	VERB
admet-154	19	3	that	that	SCONJ
admet-154	19	4	the	the	DET
admet-154	19	5	concomitant	concomitant	ADJ
admet-154	19	6	and	and	CCONJ
admet-154	19	7	synergistic	synergistic	ADJ
admet-154	19	8	inhibition	inhibition	NOUN
admet-154	19	9	of	of	ADP
admet-154	19	10	p	p	NOUN
admet-154	19	11	-	-	PUNCT
admet-154	19	12	gp	gp	NOUN
admet-154	19	13	present	present	NOUN
admet-154	19	14	in	in	ADP
admet-154	19	15	rat	rat	NOUN
admet-154	19	16	intestine	intestine	NOUN
admet-154	19	17	and	and	CCONJ
admet-154	19	18	liver	liver	NOUN
admet-154	19	19	is	be	AUX
admet-154	19	20	a	a	DET
admet-154	19	21	plausible	plausible	ADJ
admet-154	19	22	explanation	explanation	NOUN
admet-154	19	23	for	for	ADP
admet-154	19	24	prominent	prominent	ADJ
admet-154	19	25	increase	increase	NOUN
admet-154	19	26	in	in	ADP
admet-154	19	27	oral	oral	ADJ
admet-154	19	28	bioavailability	bioavailability	NOUN
admet-154	19	29	of	of	ADP
admet-154	19	30	irinotecan	irinotecan	NOUN
admet-154	19	31	[	[	X
admet-154	19	32	5	5	NUM
admet-154	19	33	]	]	PUNCT
admet-154	19	34	.	.	PUNCT
admet-154	20	1	however	however	ADV
admet-154	20	2	,	,	PUNCT
admet-154	20	3	in	in	ADP
admet-154	20	4	view	view	NOUN
admet-154	20	5	of	of	ADP
admet-154	20	6	narrow	narrow	ADJ
admet-154	20	7	therapeutic	therapeutic	ADJ
admet-154	20	8	index	index	NOUN
admet-154	20	9	,	,	PUNCT
admet-154	20	10	the	the	DET
admet-154	20	11	co	co	NOUN
admet-154	20	12	-	-	NOUN
admet-154	20	13	administration	administration	NOUN
admet-154	20	14	of	of	ADP
admet-154	20	15	irinotecan	irinotecan	NOUN
admet-154	20	16	and	and	CCONJ
admet-154	20	17	verapamil	verapamil	NOUN
admet-154	20	18	may	may	AUX
admet-154	20	19	result	result	VERB
admet-154	20	20	in	in	ADP
admet-154	20	21	unanticipated	unanticipated	ADJ
admet-154	20	22	toxicities	toxicity	NOUN
admet-154	20	23	.	.	PUNCT
admet-154	21	1	co	co	NOUN
admet-154	21	2	-	-	NOUN
admet-154	21	3	administration	administration	NOUN
admet-154	21	4	of	of	ADP
admet-154	21	5	p	p	PROPN
admet-154	21	6	-	-	PUNCT
admet-154	21	7	gp	gp	NOUN
admet-154	21	8	inhibitor	inhibitor	NOUN
admet-154	21	9	would	would	AUX
admet-154	21	10	maintain	maintain	VERB
admet-154	21	11	irinotecan	irinotecan	ADJ
admet-154	21	12	plasma	plasma	NOUN
admet-154	21	13	concentrations	concentration	NOUN
admet-154	21	14	in	in	ADP
admet-154	21	15	the	the	DET
admet-154	21	16	same	same	ADJ
admet-154	21	17	range	range	NOUN
admet-154	21	18	even	even	ADV
admet-154	21	19	at	at	ADP
admet-154	21	20	lower	low	ADJ
admet-154	21	21	doses	dose	NOUN
admet-154	21	22	as	as	ADP
admet-154	21	23	compared	compare	VERB
admet-154	21	24	to	to	ADP
admet-154	21	25	when	when	SCONJ
admet-154	21	26	it	it	PRON
admet-154	21	27	is	be	AUX
admet-154	21	28	administered	administer	VERB
admet-154	21	29	alone	alone	ADV
admet-154	21	30	at	at	ADP
admet-154	21	31	high	high	ADJ
admet-154	21	32	dose	dose	NOUN
admet-154	21	33	.	.	PUNCT
admet-154	22	1	we	we	PRON
admet-154	22	2	propose	propose	VERB
admet-154	22	3	that	that	SCONJ
admet-154	22	4	oral	oral	ADJ
admet-154	22	5	drug	drug	NOUN
admet-154	22	6	treatment	treatment	NOUN
admet-154	22	7	of	of	ADP
admet-154	22	8	irinotecan	irinotecan	NOUN
admet-154	22	9	in	in	ADP
admet-154	22	10	presence	presence	NOUN
admet-154	22	11	of	of	ADP
admet-154	22	12	temporary	temporary	ADJ
admet-154	22	13	p	p	NOUN
admet-154	22	14	-	-	PUNCT
admet-154	22	15	gp	gp	NOUN
admet-154	22	16	inhibition	inhibition	NOUN
admet-154	22	17	could	could	AUX
admet-154	22	18	be	be	AUX
admet-154	22	19	as	as	ADV
admet-154	22	20	equally	equally	ADV
admet-154	22	21	safe	safe	ADJ
admet-154	22	22	and	and	CCONJ
admet-154	22	23	effective	effective	ADJ
admet-154	22	24	as	as	ADP
admet-154	22	25	intravenous	intravenous	ADJ
admet-154	22	26	administration	administration	NOUN
admet-154	22	27	.	.	PUNCT
admet-154	23	1	in	in	ADP
admet-154	23	2	the	the	DET
admet-154	23	3	current	current	ADJ
admet-154	23	4	investigation	investigation	NOUN
admet-154	23	5	,	,	PUNCT
admet-154	23	6	the	the	DET
admet-154	23	7	bioavailability	bioavailability	NOUN
admet-154	23	8	and	and	CCONJ
admet-154	23	9	pharmacokinetic	pharmacokinetic	ADJ
admet-154	23	10	parameters	parameter	NOUN
admet-154	23	11	were	be	AUX
admet-154	23	12	studied	study	VERB
admet-154	23	13	in	in	ADP
admet-154	23	14	female	female	ADJ
admet-154	23	15	wistar	wistar	PROPN
admet-154	23	16	rats	rat	NOUN
admet-154	23	17	after	after	ADP
admet-154	23	18	oral	oral	ADJ
admet-154	23	19	administration	administration	NOUN
admet-154	23	20	of	of	ADP
admet-154	23	21	irinotecan	irinotecan	NOUN
admet-154	23	22	alone	alone	ADV
admet-154	23	23	and	and	CCONJ
admet-154	23	24	in	in	ADP
admet-154	23	25	combination	combination	NOUN
admet-154	23	26	with	with	ADP
admet-154	23	27	verapamil	verapamil	NOUN
admet-154	23	28	(	(	PUNCT
admet-154	23	29	25	25	NUM
admet-154	23	30	mg	mg	PROPN
admet-154	23	31	/	/	SYM
admet-154	23	32	kg	kg	PROPN
admet-154	23	33	,	,	PUNCT
admet-154	23	34	oral	oral	ADJ
admet-154	23	35	)	)	PUNCT
admet-154	23	36	at	at	ADP
admet-154	23	37	three	three	NUM
admet-154	23	38	doses	dose	NOUN
admet-154	23	39	(	(	PUNCT
admet-154	23	40	i.e.	i.e.	X
admet-154	23	41	20	20	NUM
admet-154	23	42	,	,	PUNCT
admet-154	23	43	40	40	NUM
admet-154	23	44	and	and	CCONJ
admet-154	23	45	80	80	NUM
admet-154	23	46	mg	mg	NUM
admet-154	23	47	/	/	SYM
admet-154	23	48	kg	kg	PROPN
admet-154	23	49	)	)	PUNCT
admet-154	23	50	.	.	PUNCT
admet-154	24	1	the	the	DET
admet-154	24	2	main	main	ADJ
admet-154	24	3	objective	objective	NOUN
admet-154	24	4	of	of	ADP
admet-154	24	5	the	the	DET
admet-154	24	6	study	study	NOUN
admet-154	24	7	is	be	AUX
admet-154	24	8	to	to	PART
admet-154	24	9	evaluate	evaluate	VERB
admet-154	24	10	the	the	DET
admet-154	24	11	magnitude	magnitude	NOUN
admet-154	24	12	of	of	ADP
admet-154	24	13	improvement	improvement	NOUN
admet-154	24	14	in	in	ADP
admet-154	24	15	oral	oral	ADJ
admet-154	24	16	delivery	delivery	NOUN
admet-154	24	17	of	of	ADP
admet-154	24	18	irinotecan	irinotecan	NOUN
admet-154	24	19	via	via	ADP
admet-154	24	20	co	co	NOUN
admet-154	24	21	-	-	NOUN
admet-154	24	22	treatment	treatment	NOUN
admet-154	24	23	with	with	ADP
admet-154	24	24	oral	oral	ADJ
admet-154	24	25	p	p	NOUN
admet-154	24	26	-	-	PUNCT
admet-154	24	27	gp	gp	NOUN
admet-154	24	28	inhibitor	inhibitor	NOUN
admet-154	24	29	.	.	PUNCT
admet-154	25	1	experimental	experimental	ADJ
admet-154	25	2	chemicals	chemical	NOUN
admet-154	25	3	and	and	CCONJ
admet-154	25	4	animals	animal	NOUN
admet-154	25	5	irinotecan	irinotecan	NOUN
admet-154	25	6	(	(	PUNCT
admet-154	25	7	>	>	SYM
admet-154	25	8	99	99	NUM
admet-154	25	9	%	%	NOUN
admet-154	25	10	)	)	PUNCT
admet-154	25	11	,	,	PUNCT
admet-154	25	12	sn-38	sn-38	X
admet-154	25	13	(	(	PUNCT
admet-154	25	14	>	>	SYM
admet-154	25	15	96	96	NUM
admet-154	25	16	%	%	NOUN
admet-154	25	17	)	)	PUNCT
admet-154	25	18	,	,	PUNCT
admet-154	25	19	topotecan	topotecan	NOUN
admet-154	25	20	(	(	PUNCT
admet-154	25	21	>	>	SYM
admet-154	25	22	98	98	NUM
admet-154	25	23	%	%	NOUN
admet-154	25	24	)	)	PUNCT
admet-154	25	25	and	and	CCONJ
admet-154	25	26	irinotecan	irinotecan	ADJ
admet-154	25	27	hydrochloride	hydrochloride	NOUN
admet-154	25	28	injection	injection	NOUN
admet-154	25	29	(	(	PUNCT
admet-154	25	30	20	20	NUM
admet-154	25	31	mg	mg	NUM
admet-154	25	32	ml-1	ml-1	PRON
admet-154	25	33	)	)	PUNCT
admet-154	25	34	originated	originate	VERB
admet-154	25	35	from	from	ADP
admet-154	25	36	dabur	dabur	PROPN
admet-154	25	37	pharma	pharma	PROPN
admet-154	25	38	limited	limit	VERB
admet-154	25	39	(	(	PUNCT
admet-154	25	40	u.p	u.p	PROPN
admet-154	25	41	,	,	PUNCT
admet-154	25	42	india	india	PROPN
admet-154	25	43	)	)	PUNCT
admet-154	25	44	.	.	PUNCT
admet-154	26	1	all	all	DET
admet-154	26	2	chemical	chemical	NOUN
admet-154	26	3	and	and	CCONJ
admet-154	26	4	reagents	reagent	NOUN
admet-154	26	5	were	be	AUX
admet-154	26	6	of	of	ADP
admet-154	26	7	analytical	analytical	ADJ
admet-154	26	8	or	or	CCONJ
admet-154	26	9	hplc	hplc	NOUN
admet-154	26	10	grade	grade	NOUN
admet-154	26	11	as	as	ADP
admet-154	26	12	appropriate	appropriate	ADJ
admet-154	26	13	and	and	CCONJ
admet-154	26	14	procured	procure	VERB
admet-154	26	15	locally	locally	ADV
admet-154	26	16	.	.	PUNCT
admet-154	27	1	healthy	healthy	ADJ
admet-154	27	2	female	female	ADJ
admet-154	27	3	wistar	wistar	PROPN
admet-154	27	4	rats	rat	NOUN
admet-154	27	5	(	(	PUNCT
admet-154	27	6	180	180	NUM
admet-154	27	7	-	-	SYM
admet-154	27	8	200	200	NUM
admet-154	27	9	g	g	NOUN
admet-154	27	10	,	,	PUNCT
admet-154	27	11	n=5	n=5	NUM
admet-154	27	12	)	)	PUNCT
admet-154	27	13	used	use	VERB
admet-154	27	14	for	for	ADP
admet-154	27	15	pharmacokinetic	pharmacokinetic	ADJ
admet-154	27	16	studies	study	NOUN
admet-154	27	17	were	be	AUX
admet-154	27	18	obtained	obtain	VERB
admet-154	27	19	from	from	ADP
admet-154	27	20	breeding	breed	VERB
admet-154	27	21	stock	stock	NOUN
admet-154	27	22	of	of	ADP
admet-154	27	23	dabur	dabur	PROPN
admet-154	27	24	research	research	PROPN
admet-154	27	25	foundation	foundation	PROPN
admet-154	27	26	(	(	PUNCT
admet-154	27	27	ghaziabad	ghaziabad	PROPN
admet-154	27	28	,	,	PUNCT
admet-154	27	29	u.p	u.p	PROPN
admet-154	27	30	,	,	PUNCT
admet-154	27	31	india	india	PROPN
admet-154	27	32	)	)	PUNCT
admet-154	27	33	.	.	PUNCT
admet-154	28	1	rats	rat	NOUN
admet-154	28	2	housed	house	VERB
admet-154	28	3	in	in	ADP
admet-154	28	4	cages	cage	NOUN
admet-154	28	5	were	be	AUX
admet-154	28	6	kept	keep	VERB
admet-154	28	7	in	in	ADP
admet-154	28	8	a	a	DET
admet-154	28	9	room	room	NOUN
admet-154	28	10	under	under	ADP
admet-154	28	11	controlled	control	VERB
admet-154	28	12	temperature	temperature	NOUN
admet-154	28	13	(	(	PUNCT
admet-154	28	14	20	20	NUM
admet-154	28	15	-	-	SYM
admet-154	28	16	22	22	NUM
admet-154	28	17	°	°	NOUN
admet-154	28	18	c	c	NOUN
admet-154	28	19	)	)	PUNCT
admet-154	28	20	and	and	CCONJ
admet-154	28	21	12	12	NUM
admet-154	28	22	h	h	NOUN
admet-154	28	23	day	day	NOUN
admet-154	28	24	-	-	PUNCT
admet-154	28	25	night	night	NOUN
admet-154	28	26	cycle	cycle	NOUN
admet-154	28	27	.	.	PUNCT
admet-154	29	1	animals	animal	NOUN
admet-154	29	2	were	be	AUX
admet-154	29	3	used	use	VERB
admet-154	29	4	for	for	ADP
admet-154	29	5	pharmacokinetic	pharmacokinetic	ADJ
admet-154	29	6	studies	study	NOUN
admet-154	29	7	after	after	ADP
admet-154	29	8	one	one	NUM
admet-154	29	9	-	-	PUNCT
admet-154	29	10	week	week	NOUN
admet-154	29	11	acclimatization	acclimatization	NOUN
admet-154	29	12	with	with	ADP
admet-154	29	13	free	free	ADJ
admet-154	29	14	access	access	NOUN
admet-154	29	15	to	to	ADP
admet-154	29	16	water	water	NOUN
admet-154	29	17	and	and	CCONJ
admet-154	29	18	feed	feed	NOUN
admet-154	29	19	.	.	PUNCT
admet-154	30	1	all	all	DET
admet-154	30	2	animal	animal	NOUN
admet-154	30	3	procedures	procedure	NOUN
admet-154	30	4	were	be	AUX
admet-154	30	5	approved	approve	VERB
admet-154	30	6	by	by	ADP
admet-154	30	7	institutional	institutional	ADJ
admet-154	30	8	animal	animal	NOUN
admet-154	30	9	ethics	ethic	NOUN
admet-154	30	10	committee	committee	NOUN
admet-154	30	11	(	(	PUNCT
admet-154	30	12	dabur	dabur	PROPN
admet-154	30	13	research	research	PROPN
admet-154	30	14	foundation	foundation	PROPN
admet-154	30	15	,	,	PUNCT
admet-154	30	16	u.p	u.p	PROPN
admet-154	30	17	,	,	PUNCT
admet-154	30	18	india	india	PROPN
admet-154	30	19	)	)	PUNCT
admet-154	30	20	.	.	PUNCT
admet-154	31	1	verapamil	verapamil	NOUN
admet-154	31	2	(	(	PUNCT
admet-154	31	3	sigma	sigma	PROPN
admet-154	31	4	-	-	PUNCT
admet-154	31	5	aldrich	aldrich	PROPN
admet-154	31	6	,	,	PUNCT
admet-154	31	7	st	st	PROPN
admet-154	31	8	.	.	PROPN
admet-154	31	9	louis	louis	PROPN
admet-154	31	10	,	,	PUNCT
admet-154	31	11	mo	mo	PROPN
admet-154	31	12	,	,	PUNCT
admet-154	31	13	usa	usa	PROPN
admet-154	31	14	)	)	PUNCT
admet-154	31	15	solutions	solution	NOUN
admet-154	31	16	were	be	AUX
admet-154	31	17	prepared	prepare	VERB
admet-154	31	18	in	in	ADP
admet-154	31	19	distilled	distil	VERB
admet-154	31	20	water	water	NOUN
admet-154	31	21	containing	contain	VERB
admet-154	31	22	5	5	NUM
admet-154	31	23	%	%	NOUN
admet-154	31	24	dmso	dmso	NOUN
admet-154	31	25	.	.	PUNCT
admet-154	32	1	the	the	DET
admet-154	32	2	purity	purity	NOUN
admet-154	32	3	of	of	ADP
admet-154	32	4	both	both	DET
admet-154	32	5	irinotecan	irinotecan	NOUN
admet-154	32	6	and	and	CCONJ
admet-154	32	7	verapamil	verapamil	NOUN
admet-154	32	8	solutions	solution	NOUN
admet-154	32	9	was	be	AUX
admet-154	32	10	>	>	X
admet-154	32	11	96	96	NUM
admet-154	32	12	%	%	NOUN
admet-154	32	13	and	and	CCONJ
admet-154	32	14	was	be	AUX
admet-154	32	15	checked	check	VERB
admet-154	32	16	before	before	ADP
admet-154	32	17	administration	administration	NOUN
admet-154	32	18	into	into	ADP
admet-154	32	19	rats	rat	NOUN
admet-154	32	20	by	by	ADP
admet-154	32	21	hplc	hplc	NOUN
admet-154	32	22	[	[	X
admet-154	32	23	5	5	NUM
admet-154	32	24	]	]	PUNCT
admet-154	32	25	.	.	PUNCT
admet-154	33	1	in	in	ADP
admet-154	33	2	-	-	PUNCT
admet-154	33	3	vivo	vivo	NOUN
admet-154	33	4	studies	study	NOUN
admet-154	33	5	the	the	DET
admet-154	33	6	animals	animal	NOUN
admet-154	33	7	were	be	AUX
admet-154	33	8	divided	divide	VERB
admet-154	33	9	into	into	ADP
admet-154	33	10	three	three	NUM
admet-154	33	11	different	different	ADJ
admet-154	33	12	dose	dose	NOUN
admet-154	33	13	levels	level	NOUN
admet-154	33	14	of	of	ADP
admet-154	33	15	20	20	NUM
admet-154	33	16	,	,	PUNCT
admet-154	33	17	40	40	NUM
admet-154	33	18	and	and	CCONJ
admet-154	33	19	80	80	NUM
admet-154	33	20	mg	mg	NUM
admet-154	33	21	/	/	SYM
admet-154	33	22	kg	kg	PROPN
admet-154	33	23	.	.	PUNCT
admet-154	34	1	within	within	ADP
admet-154	34	2	each	each	DET
admet-154	34	3	dose	dose	NOUN
admet-154	34	4	level	level	NOUN
admet-154	34	5	,	,	PUNCT
admet-154	34	6	the	the	DET
admet-154	34	7	animals	animal	NOUN
admet-154	34	8	were	be	AUX
admet-154	34	9	further	far	ADV
admet-154	34	10	sub	sub	ADJ
admet-154	34	11	-	-	VERB
admet-154	34	12	divided	divide	VERB
admet-154	34	13	into	into	ADP
admet-154	34	14	a	a	DET
admet-154	34	15	control	control	NOUN
admet-154	34	16	group	group	NOUN
admet-154	34	17	and	and	CCONJ
admet-154	34	18	a	a	DET
admet-154	34	19	pre	pre	ADJ
admet-154	34	20	-	-	ADJ
admet-154	34	21	treated	treat	VERB
admet-154	34	22	group	group	NOUN
admet-154	34	23	.	.	PUNCT
admet-154	35	1	rats	rat	NOUN
admet-154	35	2	in	in	ADP
admet-154	35	3	control	control	NOUN
admet-154	35	4	group	group	NOUN
admet-154	35	5	received	receive	VERB
admet-154	35	6	irinotecan	irinotecan	NOUN
admet-154	35	7	orally	orally	ADV
admet-154	35	8	via	via	ADP
admet-154	35	9	gavage	gavage	NOUN
admet-154	35	10	using	use	VERB
admet-154	35	11	a	a	DET
admet-154	35	12	ball	ball	NOUN
admet-154	35	13	-	-	PUNCT
admet-154	35	14	tipped	tip	VERB
admet-154	35	15	needle	needle	NOUN
admet-154	35	16	.	.	PUNCT
admet-154	36	1	the	the	DET
admet-154	36	2	pretreatment	pretreatment	NOUN
admet-154	36	3	group	group	NOUN
admet-154	36	4	received	receive	VERB
admet-154	36	5	oral	oral	ADJ
admet-154	36	6	verapamil	verapamil	NOUN
admet-154	36	7	(	(	PUNCT
admet-154	36	8	25	25	NUM
admet-154	36	9	mg	mg	PROPN
admet-154	36	10	/	/	SYM
admet-154	36	11	kg	kg	PROPN
admet-154	36	12	)	)	PUNCT
admet-154	36	13	,	,	PUNCT
admet-154	36	14	2	2	NUM
admet-154	36	15	h	h	NOUN
admet-154	36	16	prior	prior	ADV
admet-154	36	17	to	to	ADP
admet-154	36	18	irinotecan	irinotecan	PROPN
admet-154	36	19	administration	administration	NOUN
admet-154	36	20	.	.	PUNCT
admet-154	37	1	in	in	ADP
admet-154	37	2	the	the	DET
admet-154	37	3	20	20	NUM
admet-154	37	4	mg	mg	PROPN
admet-154	37	5	/	/	SYM
admet-154	37	6	kg	kg	PROPN
admet-154	37	7	-	-	PUNCT
admet-154	37	8	dose	dose	NOUN
admet-154	37	9	group	group	NOUN
admet-154	37	10	,	,	PUNCT
admet-154	37	11	three	three	NUM
admet-154	37	12	additional	additional	ADJ
admet-154	37	13	rats	rat	NOUN
admet-154	37	14	received	receive	VERB
admet-154	37	15	the	the	DET
admet-154	37	16	irinotecan	irinotecan	NOUN
admet-154	37	17	only	only	ADV
admet-154	37	18	as	as	ADP
admet-154	37	19	single	single	ADJ
admet-154	37	20	dose	dose	NOUN
admet-154	37	21	injection	injection	NOUN
admet-154	37	22	via	via	ADP
admet-154	37	23	the	the	DET
admet-154	37	24	lateral	lateral	ADJ
admet-154	37	25	tail	tail	NOUN
admet-154	37	26	vein	vein	NOUN
admet-154	37	27	.	.	PUNCT
admet-154	38	1	blood	blood	NOUN
admet-154	38	2	samples	sample	NOUN
admet-154	38	3	were	be	AUX
admet-154	38	4	withdrawn	withdraw	VERB
admet-154	38	5	prior	prior	ADV
admet-154	38	6	to	to	ADP
admet-154	38	7	dosing	dosing	NOUN
admet-154	38	8	and	and	CCONJ
admet-154	38	9	at	at	ADP
admet-154	38	10	0.5	0.5	NUM
admet-154	38	11	,	,	PUNCT
admet-154	38	12	1	1	NUM
admet-154	38	13	,	,	PUNCT
admet-154	38	14	2	2	NUM
admet-154	38	15	,	,	PUNCT
admet-154	38	16	3	3	NUM
admet-154	38	17	,	,	PUNCT
admet-154	38	18	4	4	NUM
admet-154	38	19	,	,	PUNCT
admet-154	38	20	6	6	NUM
admet-154	38	21	,	,	PUNCT
admet-154	38	22	8	8	NUM
admet-154	38	23	,	,	PUNCT
admet-154	38	24	10	10	NUM
admet-154	38	25	,	,	PUNCT
admet-154	38	26	12	12	NUM
admet-154	38	27	and	and	CCONJ
admet-154	38	28	24	24	NUM
admet-154	38	29	h	h	NOUN
admet-154	38	30	post	post	ADJ
admet-154	38	31	-	-	ADJ
admet-154	38	32	dosing	dosing	ADJ
admet-154	38	33	from	from	ADP
admet-154	38	34	retro	retro	ADJ
admet-154	38	35	-	-	PUNCT
admet-154	38	36	orbital	orbital	ADJ
admet-154	38	37	plexus	plexus	NOUN
admet-154	38	38	into	into	ADP
admet-154	38	39	microtubes	microtube	NOUN
admet-154	38	40	containing	contain	VERB
admet-154	38	41	the	the	DET
admet-154	38	42	anticoagulant	anticoagulant	NOUN
admet-154	38	43	[	[	X
admet-154	38	44	5	5	NUM
admet-154	38	45	]	]	PUNCT
admet-154	38	46	.	.	PUNCT
admet-154	39	1	plasma	plasma	PROPN
admet-154	39	2	was	be	AUX
admet-154	39	3	obtained	obtain	VERB
admet-154	39	4	immediately	immediately	ADV
admet-154	39	5	and	and	CCONJ
admet-154	39	6	processed	process	VERB
admet-154	39	7	by	by	ADP
admet-154	39	8	protein	protein	NOUN
admet-154	39	9	precipitation	precipitation	NOUN
admet-154	39	10	.	.	PUNCT
admet-154	40	1	samples	sample	NOUN
admet-154	40	2	were	be	AUX
admet-154	40	3	stored	store	VERB
admet-154	40	4	at	at	ADP
admet-154	40	5	-80	-80	NOUN
admet-154	40	6	°	°	ADP
admet-154	40	7	c	c	NOUN
admet-154	40	8	until	until	ADP
admet-154	40	9	hplc	hplc	NOUN
admet-154	40	10	analysis	analysis	NOUN
admet-154	40	11	.	.	PUNCT
admet-154	41	1	garg	garg	PROPN
admet-154	41	2	et	et	PROPN
admet-154	41	3	al	al	PROPN
admet-154	41	4	.	.	PROPN
admet-154	41	5	admet	admet	PROPN
admet-154	41	6	&	&	CCONJ
admet-154	41	7	dmpk	dmpk	PROPN
admet-154	41	8	3(1	3(1	NUM
admet-154	41	9	)	)	PUNCT
admet-154	41	10	(	(	PUNCT
admet-154	41	11	2015	2015	NUM
admet-154	41	12	)	)	PUNCT
admet-154	41	13	68	68	NUM
admet-154	41	14	-	-	SYM
admet-154	41	15	76	76	NUM
admet-154	41	16	70	70	NUM
admet-154	41	17	analytical	analytical	ADJ
admet-154	41	18	assay	assay	NOUN
admet-154	41	19	procedures	procedure	NOUN
admet-154	41	20	the	the	DET
admet-154	41	21	concentrations	concentration	NOUN
admet-154	41	22	of	of	ADP
admet-154	41	23	irinotecan	irinotecan	NOUN
admet-154	41	24	and	and	CCONJ
admet-154	41	25	sn-38	sn-38	NOUN
admet-154	41	26	in	in	ADP
admet-154	41	27	plasma	plasma	NOUN
admet-154	41	28	were	be	AUX
admet-154	41	29	determined	determine	VERB
admet-154	41	30	using	use	VERB
admet-154	41	31	high	high	ADJ
admet-154	41	32	performance	performance	NOUN
admet-154	41	33	liquid	liquid	ADJ
admet-154	41	34	chromatographic	chromatographic	ADJ
admet-154	41	35	(	(	PUNCT
admet-154	41	36	hplc	hplc	NOUN
admet-154	41	37	)	)	PUNCT
admet-154	41	38	method	method	NOUN
admet-154	41	39	using	use	VERB
admet-154	41	40	ultraviolet	ultraviolet	ADJ
admet-154	41	41	detection	detection	NOUN
admet-154	41	42	(	(	PUNCT
admet-154	41	43	λmax	λmax	NOUN
admet-154	41	44	=	=	SYM
admet-154	41	45	254	254	NUM
admet-154	41	46	nm	nm	NOUN
admet-154	41	47	,	,	PUNCT
admet-154	41	48	380	380	NUM
admet-154	41	49	nm	nm	NOUN
admet-154	41	50	)	)	PUNCT
admet-154	41	51	as	as	SCONJ
admet-154	41	52	described	describe	VERB
admet-154	41	53	previously	previously	ADV
admet-154	41	54	[	[	X
admet-154	41	55	6	6	NUM
admet-154	41	56	]	]	PUNCT
admet-154	41	57	.	.	PUNCT
admet-154	42	1	the	the	DET
admet-154	42	2	sample	sample	NOUN
admet-154	42	3	pre	pre	NOUN
admet-154	42	4	-	-	NOUN
admet-154	42	5	treatment	treatment	NOUN
admet-154	42	6	from	from	ADP
admet-154	42	7	plasma	plasma	NOUN
admet-154	42	8	involved	involve	VERB
admet-154	42	9	a	a	DET
admet-154	42	10	single	single	ADJ
admet-154	42	11	protein	protein	NOUN
admet-154	42	12	precipitation	precipitation	NOUN
admet-154	42	13	step	step	NOUN
admet-154	42	14	with	with	ADP
admet-154	42	15	cold	cold	ADJ
admet-154	42	16	acetonitrile	acetonitrile	NOUN
admet-154	42	17	.	.	PUNCT
admet-154	43	1	topotecan	topotecan	PROPN
admet-154	43	2	,	,	PUNCT
admet-154	43	3	a	a	DET
admet-154	43	4	structurally	structurally	ADV
admet-154	43	5	related	relate	VERB
admet-154	43	6	camptothecin	camptothecin	NOUN
admet-154	43	7	,	,	PUNCT
admet-154	43	8	was	be	AUX
admet-154	43	9	used	use	VERB
admet-154	43	10	as	as	ADP
admet-154	43	11	an	an	DET
admet-154	43	12	internal	internal	ADJ
admet-154	43	13	standard	standard	NOUN
admet-154	43	14	.	.	PUNCT
admet-154	44	1	method	method	NOUN
admet-154	44	2	was	be	AUX
admet-154	44	3	found	find	VERB
admet-154	44	4	to	to	PART
admet-154	44	5	be	be	AUX
admet-154	44	6	selective	selective	ADJ
admet-154	44	7	,	,	PUNCT
admet-154	44	8	linear	linear	ADJ
admet-154	44	9	(	(	PUNCT
admet-154	44	10	r2≈0.999	r2≈0.999	NOUN
admet-154	44	11	)	)	PUNCT
admet-154	44	12	,	,	PUNCT
admet-154	44	13	accurate	accurate	ADJ
admet-154	44	14	(	(	PUNCT
admet-154	44	15	recovery	recovery	NOUN
admet-154	44	16	±	±	NUM
admet-154	44	17	15	15	NUM
admet-154	44	18	%	%	NOUN
admet-154	44	19	)	)	PUNCT
admet-154	44	20	and	and	CCONJ
admet-154	44	21	precise	precise	ADJ
admet-154	44	22	(	(	PUNCT
admet-154	44	23	<	<	X
admet-154	44	24	5	5	NUM
admet-154	44	25	%	%	NOUN
admet-154	44	26	c.v	c.v	PROPN
admet-154	44	27	.	.	PROPN
admet-154	44	28	)	)	PUNCT
admet-154	44	29	in	in	ADP
admet-154	44	30	the	the	DET
admet-154	44	31	selected	select	VERB
admet-154	44	32	concentration	concentration	NOUN
admet-154	44	33	ranges	range	VERB
admet-154	44	34	for	for	ADP
admet-154	44	35	both	both	CCONJ
admet-154	44	36	the	the	DET
admet-154	44	37	analytes	analyte	NOUN
admet-154	44	38	.	.	PUNCT
admet-154	45	1	the	the	DET
admet-154	45	2	quantification	quantification	NOUN
admet-154	45	3	limit	limit	NOUN
admet-154	45	4	for	for	ADP
admet-154	45	5	irinotecan	irinotecan	NOUN
admet-154	45	6	was	be	AUX
admet-154	45	7	40	40	NUM
admet-154	45	8	ng	ng	PROPN
admet-154	45	9	ml-1	ml-1	PUNCT
admet-154	46	1	and	and	CCONJ
admet-154	46	2	for	for	ADP
admet-154	46	3	sn-38	sn-38	NOUN
admet-154	46	4	was	be	AUX
admet-154	46	5	25	25	NUM
admet-154	46	6	ng	ng	PROPN
admet-154	46	7	ml-1	ml-1	PUNCT
admet-154	47	1	[	[	X
admet-154	47	2	6	6	NUM
admet-154	47	3	]	]	PUNCT
admet-154	47	4	.	.	PUNCT
admet-154	48	1	pharmacokinetic	pharmacokinetic	ADJ
admet-154	48	2	data	datum	NOUN
admet-154	48	3	analysis	analysis	NOUN
admet-154	48	4	pharmacokinetic	pharmacokinetic	ADJ
admet-154	48	5	parameters	parameter	NOUN
admet-154	48	6	were	be	AUX
admet-154	48	7	calculated	calculate	VERB
admet-154	48	8	by	by	ADP
admet-154	48	9	non	non	ADJ
admet-154	48	10	-	-	ADJ
admet-154	48	11	compartment	compartment	ADJ
admet-154	48	12	model	model	NOUN
admet-154	48	13	using	use	VERB
admet-154	48	14	winnon	winnon	NOUN
admet-154	48	15	-	-	PUNCT
admet-154	48	16	lin	lin	PROPN
admet-154	48	17	5.0	5.0	NUM
admet-154	48	18	programme	programme	NOUN
admet-154	48	19	(	(	PUNCT
admet-154	48	20	pharsight	pharsight	NOUN
admet-154	48	21	,	,	PUNCT
admet-154	48	22	mountain	mountain	NOUN
admet-154	48	23	view	view	NOUN
admet-154	48	24	,	,	PUNCT
admet-154	48	25	ca	ca	PROPN
admet-154	48	26	,	,	PUNCT
admet-154	48	27	usa	usa	PROPN
admet-154	48	28	)	)	PUNCT
admet-154	48	29	.	.	PUNCT
admet-154	49	1	the	the	DET
admet-154	49	2	plasma	plasma	NOUN
admet-154	49	3	irinotecan	irinotecan	NOUN
admet-154	49	4	and	and	CCONJ
admet-154	49	5	sn-38	sn-38	NOUN
admet-154	49	6	concentration	concentration	NOUN
admet-154	49	7	-	-	PUNCT
admet-154	49	8	versus	versus	ADP
admet-154	49	9	-	-	PUNCT
admet-154	49	10	time	time	NOUN
admet-154	49	11	curves	curve	NOUN
admet-154	49	12	were	be	AUX
admet-154	49	13	used	use	VERB
admet-154	49	14	to	to	PART
admet-154	49	15	determine	determine	VERB
admet-154	49	16	maximum	maximum	ADJ
admet-154	49	17	plasma	plasma	NOUN
admet-154	49	18	concentration	concentration	NOUN
admet-154	49	19	(	(	PUNCT
admet-154	49	20	cmax	cmax	NOUN
admet-154	49	21	)	)	PUNCT
admet-154	49	22	,	,	PUNCT
admet-154	49	23	time	time	NOUN
admet-154	49	24	to	to	PART
admet-154	49	25	achieve	achieve	VERB
admet-154	49	26	maximum	maximum	ADJ
admet-154	49	27	plasma	plasma	NOUN
admet-154	49	28	concentration	concentration	NOUN
admet-154	49	29	(	(	PUNCT
admet-154	49	30	tmax	tmax	ADV
admet-154	49	31	)	)	PUNCT
admet-154	49	32	,	,	PUNCT
admet-154	49	33	mean	mean	VERB
admet-154	49	34	residence	residence	NOUN
admet-154	49	35	time	time	NOUN
admet-154	49	36	(	(	PUNCT
admet-154	49	37	mrt	mrt	PROPN
admet-154	49	38	)	)	PUNCT
admet-154	49	39	,	,	PUNCT
admet-154	49	40	area	area	NOUN
admet-154	49	41	under	under	ADP
admet-154	49	42	the	the	DET
admet-154	49	43	concentration	concentration	NOUN
admet-154	49	44	time	time	NOUN
admet-154	49	45	curve	curve	NOUN
admet-154	49	46	to	to	ADP
admet-154	49	47	the	the	DET
admet-154	49	48	respective	respective	ADJ
admet-154	49	49	sampling	sampling	NOUN
admet-154	49	50	point	point	NOUN
admet-154	49	51	(	(	PUNCT
admet-154	49	52	auc0	auc0	PROPN
admet-154	49	53	-	-	PUNCT
admet-154	49	54	t	t	PROPN
admet-154	49	55	)	)	PUNCT
admet-154	49	56	,	,	PUNCT
admet-154	49	57	volume	volume	NOUN
admet-154	49	58	of	of	ADP
admet-154	49	59	distribution	distribution	NOUN
admet-154	49	60	(	(	PUNCT
admet-154	49	61	vd	vd	NOUN
admet-154	49	62	)	)	PUNCT
admet-154	49	63	,	,	PUNCT
admet-154	49	64	elimination	elimination	NOUN
admet-154	49	65	rate	rate	NOUN
admet-154	49	66	constant	constant	ADJ
admet-154	49	67	(	(	PUNCT
admet-154	49	68	kel	kel	NOUN
admet-154	49	69	)	)	PUNCT
admet-154	49	70	,	,	PUNCT
admet-154	49	71	half	half	ADJ
admet-154	49	72	-	-	PUNCT
admet-154	49	73	life	life	NOUN
admet-154	49	74	(	(	PUNCT
admet-154	49	75	t1/2	t1/2	NOUN
admet-154	49	76	)	)	PUNCT
admet-154	49	77	and	and	CCONJ
admet-154	49	78	total	total	ADJ
admet-154	49	79	body	body	NOUN
admet-154	49	80	clearance	clearance	NOUN
admet-154	49	81	.	.	PUNCT
admet-154	50	1	c0	c0	PROPN
admet-154	50	2	was	be	AUX
admet-154	50	3	the	the	DET
admet-154	50	4	initial	initial	ADJ
admet-154	50	5	plasma	plasma	NOUN
admet-154	50	6	concentration	concentration	NOUN
admet-154	50	7	of	of	ADP
admet-154	50	8	drugs	drug	NOUN
admet-154	50	9	obtained	obtain	VERB
admet-154	50	10	by	by	ADP
admet-154	50	11	back	back	ADJ
admet-154	50	12	-	-	PUNCT
admet-154	50	13	extrapolation	extrapolation	NOUN
admet-154	50	14	to	to	ADP
admet-154	50	15	y	y	NOUN
admet-154	50	16	-	-	PUNCT
admet-154	50	17	axis	axis	NOUN
admet-154	50	18	.	.	PUNCT
admet-154	51	1	the	the	DET
admet-154	51	2	absolute	absolute	ADJ
admet-154	51	3	bioavailability	bioavailability	NOUN
admet-154	51	4	(	(	PUNCT
admet-154	51	5	f	f	X
admet-154	51	6	)	)	PUNCT
admet-154	51	7	of	of	ADP
admet-154	51	8	irinotecan	irinotecan	NOUN
admet-154	51	9	after	after	ADP
admet-154	51	10	the	the	DET
admet-154	51	11	oral	oral	ADJ
admet-154	51	12	administration	administration	NOUN
admet-154	51	13	(	(	PUNCT
admet-154	51	14	80	80	NUM
admet-154	51	15	mg	mg	PROPN
admet-154	51	16	/	/	SYM
admet-154	51	17	kg	kg	NOUN
admet-154	51	18	)	)	PUNCT
admet-154	51	19	compared	compare	VERB
admet-154	51	20	to	to	ADP
admet-154	51	21	the	the	DET
admet-154	51	22	intravenous	intravenous	ADJ
admet-154	51	23	(	(	PUNCT
admet-154	51	24	i.v	i.v	PROPN
admet-154	51	25	)	)	PUNCT
admet-154	51	26	administration	administration	NOUN
admet-154	51	27	(	(	PUNCT
admet-154	51	28	20	20	NUM
admet-154	51	29	mg	mg	NUM
admet-154	51	30	/	/	SYM
admet-154	51	31	kg	kg	PROPN
admet-154	51	32	)	)	PUNCT
admet-154	51	33	was	be	AUX
admet-154	51	34	calculated	calculate	VERB
admet-154	51	35	as	as	SCONJ
admet-154	51	36	follows	follow	VERB
admet-154	51	37	:	:	PUNCT
admet-154	51	38	oral	oral	ADJ
admet-154	51	39	iv	iv	X
admet-154	51	40	auc	auc	NOUN
admet-154	51	41	i.v	i.v	PRON
admet-154	51	42	dose	dose	NOUN
admet-154	51	43	x	x	PUNCT
admet-154	51	44	100	100	NUM
admet-154	51	45	auc	auc	NOUN
admet-154	51	46	oral	oral	ADJ
admet-154	51	47	dose	dose	NOUN
admet-154	51	48	f	f	PROPN
admet-154	52	1			PROPN
admet-154	53	1	(	(	PUNCT
admet-154	53	2	1	1	NUM
admet-154	53	3	)	)	PUNCT
admet-154	53	4	statistical	statistical	ADJ
admet-154	53	5	analysis	analysis	NOUN
admet-154	53	6	data	datum	NOUN
admet-154	53	7	of	of	ADP
admet-154	53	8	five	five	NUM
admet-154	53	9	different	different	ADJ
admet-154	53	10	experiments	experiment	NOUN
admet-154	53	11	/	/	SYM
admet-154	53	12	animals	animal	NOUN
admet-154	53	13	was	be	AUX
admet-154	53	14	reported	report	VERB
admet-154	53	15	as	as	ADP
admet-154	53	16	mean	mean	NOUN
admet-154	53	17	±	±	NUM
admet-154	53	18	standard	standard	ADJ
admet-154	53	19	error	error	NOUN
admet-154	53	20	of	of	ADP
admet-154	53	21	means	mean	NOUN
admet-154	53	22	(	(	PUNCT
admet-154	53	23	s.e.m	s.e.m	NOUN
admet-154	53	24	)	)	PUNCT
admet-154	53	25	unless	unless	SCONJ
admet-154	53	26	otherwise	otherwise	ADV
admet-154	53	27	noted	note	VERB
admet-154	53	28	.	.	PUNCT
admet-154	54	1	statistical	statistical	ADJ
admet-154	54	2	analysis	analysis	NOUN
admet-154	54	3	was	be	AUX
admet-154	54	4	performed	perform	VERB
admet-154	54	5	using	use	VERB
admet-154	54	6	graphpad	graphpad	NOUN
admet-154	54	7	prism	prism	NOUN
admet-154	54	8	software	software	NOUN
admet-154	54	9	version	version	NOUN
admet-154	54	10	4.0	4.0	NUM
admet-154	54	11	(	(	PUNCT
admet-154	54	12	san	san	PROPN
admet-154	54	13	diego	diego	PROPN
admet-154	54	14	,	,	PUNCT
admet-154	54	15	ca	ca	PROPN
admet-154	54	16	,	,	PUNCT
admet-154	54	17	usa	usa	PROPN
admet-154	54	18	)	)	PUNCT
admet-154	54	19	.	.	PUNCT
admet-154	55	1	student	student	NOUN
admet-154	55	2	’s	’s	PART
admet-154	55	3	unpaired	unpaired	ADJ
admet-154	55	4	t	t	PROPN
admet-154	55	5	-	-	PUNCT
admet-154	55	6	test	test	NOUN
admet-154	55	7	was	be	AUX
admet-154	55	8	used	use	VERB
admet-154	55	9	to	to	PART
admet-154	55	10	test	test	VERB
admet-154	55	11	the	the	DET
admet-154	55	12	significance	significance	NOUN
admet-154	55	13	of	of	ADP
admet-154	55	14	differences	difference	NOUN
admet-154	55	15	between	between	ADP
admet-154	55	16	the	the	DET
admet-154	55	17	controls	control	NOUN
admet-154	55	18	and	and	CCONJ
admet-154	55	19	treated	treat	VERB
admet-154	55	20	groups	group	NOUN
admet-154	55	21	.	.	PUNCT
admet-154	56	1	differences	difference	NOUN
admet-154	56	2	between	between	ADP
admet-154	56	3	the	the	DET
admet-154	56	4	concentration	concentration	NOUN
admet-154	56	5	time	time	NOUN
admet-154	56	6	profiles	profile	NOUN
admet-154	56	7	over	over	ADP
admet-154	56	8	the	the	DET
admet-154	56	9	entire	entire	ADJ
admet-154	56	10	range	range	NOUN
admet-154	56	11	tested	test	VERB
admet-154	56	12	were	be	AUX
admet-154	56	13	analyzed	analyze	VERB
admet-154	56	14	by	by	ADP
admet-154	56	15	two	two	NUM
admet-154	56	16	-	-	PUNCT
admet-154	56	17	way	way	NOUN
admet-154	56	18	anova	anova	X
admet-154	56	19	(	(	PUNCT
admet-154	56	20	bonferoni	bonferoni	NOUN
admet-154	56	21	post	post	PROPN
admet-154	56	22	test	test	NOUN
admet-154	56	23	)	)	PUNCT
admet-154	56	24	.	.	PUNCT
admet-154	57	1	the	the	DET
admet-154	57	2	differences	difference	NOUN
admet-154	57	3	were	be	AUX
admet-154	57	4	considered	consider	VERB
admet-154	57	5	to	to	PART
admet-154	57	6	be	be	AUX
admet-154	57	7	significant	significant	ADJ
admet-154	57	8	at	at	ADP
admet-154	57	9	p	p	X
admet-154	57	10	<	<	X
admet-154	57	11	0.05	0.05	NUM
admet-154	57	12	.	.	PUNCT
admet-154	58	1	results	result	VERB
admet-154	58	2	plasma	plasma	NOUN
admet-154	58	3	concentration	concentration	NOUN
admet-154	58	4	versus	versus	ADP
admet-154	58	5	time	time	NOUN
admet-154	58	6	curves	curve	NOUN
admet-154	58	7	of	of	ADP
admet-154	58	8	irinotecan	irinotecan	NOUN
admet-154	58	9	following	follow	VERB
admet-154	58	10	oral	oral	ADJ
admet-154	58	11	administration	administration	NOUN
admet-154	58	12	at	at	ADP
admet-154	58	13	three	three	NUM
admet-154	58	14	dose	dose	NOUN
admet-154	58	15	levels	level	NOUN
admet-154	58	16	(	(	PUNCT
admet-154	58	17	20	20	NUM
admet-154	58	18	,	,	PUNCT
admet-154	58	19	40	40	NUM
admet-154	58	20	and	and	CCONJ
admet-154	58	21	80	80	NUM
admet-154	58	22	mg	mg	NUM
admet-154	58	23	/	/	SYM
admet-154	58	24	kg	kg	NOUN
admet-154	58	25	)	)	PUNCT
admet-154	58	26	in	in	ADP
admet-154	58	27	the	the	DET
admet-154	58	28	absence	absence	NOUN
admet-154	58	29	and	and	CCONJ
admet-154	58	30	presence	presence	NOUN
admet-154	58	31	of	of	ADP
admet-154	58	32	a	a	DET
admet-154	58	33	concomitant	concomitant	ADJ
admet-154	58	34	verapamil	verapamil	NOUN
admet-154	58	35	oral	oral	NOUN
admet-154	58	36	dose	dose	PROPN
admet-154	58	37	(	(	PUNCT
admet-154	58	38	25	25	NUM
admet-154	58	39	mg	mg	PROPN
admet-154	58	40	/	/	SYM
admet-154	58	41	kg	kg	NOUN
admet-154	58	42	)	)	PUNCT
admet-154	58	43	are	be	AUX
admet-154	58	44	depicted	depict	VERB
admet-154	58	45	in	in	ADP
admet-154	58	46	figure	figure	NOUN
admet-154	58	47	1	1	NUM
admet-154	58	48	.	.	PUNCT
admet-154	58	49	tables	table	NOUN
admet-154	58	50	1	1	NUM
admet-154	58	51	,	,	PUNCT
admet-154	58	52	2	2	NUM
admet-154	58	53	and	and	CCONJ
admet-154	58	54	3	3	NUM
admet-154	58	55	show	show	VERB
admet-154	58	56	the	the	DET
admet-154	58	57	pharmacokinetic	pharmacokinetic	ADJ
admet-154	58	58	parameters	parameter	NOUN
admet-154	58	59	for	for	ADP
admet-154	58	60	each	each	DET
admet-154	58	61	dose	dose	NOUN
admet-154	58	62	and	and	CCONJ
admet-154	58	63	administration	administration	NOUN
admet-154	58	64	route	route	NOUN
admet-154	58	65	.	.	PUNCT
admet-154	59	1	the	the	DET
admet-154	59	2	plasma	plasma	NOUN
admet-154	59	3	concentrations	concentration	NOUN
admet-154	59	4	of	of	ADP
admet-154	59	5	irinotecan	irinotecan	NOUN
admet-154	59	6	following	follow	VERB
admet-154	59	7	oral	oral	ADJ
admet-154	59	8	administration	administration	NOUN
admet-154	59	9	reached	reach	VERB
admet-154	59	10	peak	peak	NOUN
admet-154	59	11	values	value	NOUN
admet-154	59	12	at	at	ADP
admet-154	59	13	the	the	DET
admet-154	59	14	2	2	NUM
admet-154	59	15	-	-	SYM
admet-154	59	16	3	3	NUM
admet-154	59	17	h	h	NOUN
admet-154	59	18	,	,	PUNCT
admet-154	59	19	indicating	indicate	VERB
admet-154	59	20	that	that	SCONJ
admet-154	59	21	the	the	DET
admet-154	59	22	absorption	absorption	NOUN
admet-154	59	23	of	of	ADP
admet-154	59	24	irinotecan	irinotecan	NOUN
admet-154	59	25	is	be	AUX
admet-154	59	26	from	from	ADP
admet-154	59	27	the	the	DET
admet-154	59	28	intestine	intestine	NOUN
admet-154	59	29	.	.	PUNCT
admet-154	60	1	irinotecan	irinotecan	PROPN
admet-154	60	2	was	be	AUX
admet-154	60	3	absorbed	absorb	VERB
admet-154	60	4	rapidly	rapidly	ADV
admet-154	60	5	after	after	SCONJ
admet-154	60	6	oral	oral	ADJ
admet-154	60	7	administration	administration	NOUN
admet-154	60	8	and	and	CCONJ
admet-154	60	9	the	the	DET
admet-154	60	10	observed	observed	ADJ
admet-154	60	11	time	time	NOUN
admet-154	60	12	to	to	PART
admet-154	60	13	peak	peak	VERB
admet-154	60	14	irinotecan	irinotecan	NOUN
admet-154	60	15	and	and	CCONJ
admet-154	60	16	sn-38	sn-38	NOUN
admet-154	60	17	levels	level	NOUN
admet-154	60	18	was	be	AUX
admet-154	60	19	within	within	ADP
admet-154	60	20	2	2	NUM
admet-154	60	21	h	h	NOUN
admet-154	60	22	of	of	ADP
admet-154	60	23	administration	administration	NOUN
admet-154	60	24	.	.	PUNCT
admet-154	61	1	after	after	ADP
admet-154	61	2	an	an	DET
admet-154	61	3	initial	initial	ADJ
admet-154	61	4	absorption	absorption	NOUN
admet-154	61	5	phase	phase	NOUN
admet-154	61	6	,	,	PUNCT
admet-154	61	7	plasma	plasma	NOUN
admet-154	61	8	concentrations	concentration	NOUN
admet-154	61	9	of	of	ADP
admet-154	61	10	irinotecan	irinotecan	NOUN
admet-154	61	11	declined	decline	VERB
admet-154	61	12	admet	admet	PROPN
admet-154	61	13	&	&	CCONJ
admet-154	61	14	dmpk	dmpk	PROPN
admet-154	61	15	3(1	3(1	NUM
admet-154	61	16	)	)	PUNCT
admet-154	61	17	(	(	PUNCT
admet-154	61	18	2015	2015	NUM
admet-154	61	19	)	)	PUNCT
admet-154	61	20	68	68	NUM
admet-154	61	21	-	-	SYM
admet-154	61	22	76	76	NUM
admet-154	61	23	p	p	NOUN
admet-154	61	24	-	-	PUNCT
admet-154	61	25	gp	gp	NOUN
admet-154	61	26	pharmacokinetics	pharmacokinetic	NOUN
admet-154	61	27	of	of	ADP
admet-154	61	28	irinotecan	irinotecan	PROPN
admet-154	61	29	doi	doi	PROPN
admet-154	61	30	:	:	PUNCT
admet-154	61	31	10.5599	10.5599	NUM
admet-154	61	32	/	/	SYM
admet-154	61	33	admet.3.1.154	admet.3.1.154	PROPN
admet-154	61	34	71	71	NUM
admet-154	61	35	monoexponentially	monoexponentially	ADV
admet-154	61	36	.	.	PUNCT
admet-154	62	1	verapamil	verapamil	PROPN
admet-154	62	2	administration	administration	PROPN
admet-154	62	3	was	be	AUX
admet-154	62	4	associated	associate	VERB
admet-154	62	5	with	with	ADP
admet-154	62	6	an	an	DET
admet-154	62	7	increase	increase	NOUN
admet-154	62	8	in	in	ADP
admet-154	62	9	irinotecan	irinotecan	NOUN
admet-154	62	10	and	and	CCONJ
admet-154	62	11	sn-38	sn-38	NOUN
admet-154	62	12	plasma	plasma	NOUN
admet-154	62	13	concentrations	concentration	NOUN
admet-154	62	14	following	follow	VERB
admet-154	62	15	both	both	CCONJ
admet-154	62	16	i.v	i.v	PROPN
admet-154	62	17	and	and	CCONJ
admet-154	62	18	oral	oral	ADJ
admet-154	62	19	administration	administration	NOUN
admet-154	62	20	.	.	PUNCT
admet-154	63	1	oral	oral	ADJ
admet-154	63	2	irinotecan	irinotecan	ADJ
admet-154	63	3	concentrations	concentration	NOUN
admet-154	63	4	increased	increase	VERB
admet-154	63	5	significantly	significantly	ADV
admet-154	63	6	leading	lead	VERB
admet-154	63	7	to	to	ADP
admet-154	63	8	pronounced	pronounce	VERB
admet-154	63	9	alteration	alteration	NOUN
admet-154	63	10	in	in	ADP
admet-154	63	11	the	the	DET
admet-154	63	12	pharmacokinetics	pharmacokinetic	NOUN
admet-154	63	13	.	.	PUNCT
admet-154	64	1	the	the	DET
admet-154	64	2	overall	overall	ADJ
admet-154	64	3	auc	auc	NOUN
admet-154	64	4	was	be	AUX
admet-154	64	5	raised	raise	VERB
admet-154	64	6	paralleled	parallel	VERB
admet-154	64	7	with	with	ADP
admet-154	64	8	a	a	DET
admet-154	64	9	reduction	reduction	NOUN
admet-154	64	10	in	in	ADP
admet-154	64	11	irinotecan	irinotecan	ADJ
admet-154	64	12	cl	cl	NOUN
admet-154	64	13	and	and	CCONJ
admet-154	64	14	increase	increase	VERB
admet-154	64	15	in	in	ADP
admet-154	64	16	half	half	ADJ
admet-154	64	17	-	-	PUNCT
admet-154	64	18	life	life	NOUN
admet-154	64	19	(	(	PUNCT
admet-154	64	20	p	p	X
admet-154	64	21	<	<	X
admet-154	64	22	0.05	0.05	NUM
admet-154	64	23	)	)	PUNCT
admet-154	64	24	.	.	PUNCT
admet-154	65	1	the	the	DET
admet-154	65	2	oral	oral	ADJ
admet-154	65	3	bioavailability	bioavailability	NOUN
admet-154	65	4	of	of	ADP
admet-154	65	5	irinotecan	irinotecan	NOUN
admet-154	65	6	was	be	AUX
admet-154	65	7	30	30	NUM
admet-154	65	8	-	-	SYM
admet-154	65	9	40	40	NUM
admet-154	65	10	%	%	NOUN
admet-154	65	11	without	without	ADP
admet-154	65	12	verapamil	verapamil	NOUN
admet-154	65	13	,	,	PUNCT
admet-154	65	14	which	which	PRON
admet-154	65	15	was	be	AUX
admet-154	65	16	increased	increase	VERB
admet-154	65	17	significantly	significantly	ADV
admet-154	65	18	when	when	SCONJ
admet-154	65	19	given	give	VERB
admet-154	65	20	with	with	ADP
admet-154	65	21	verapamil	verapamil	NOUN
admet-154	65	22	.	.	PUNCT
admet-154	66	1	figure	figure	NOUN
admet-154	66	2	1	1	NUM
admet-154	66	3	.	.	PUNCT
admet-154	67	1	mean	mean	ADJ
admet-154	67	2	plasma	plasma	NOUN
admet-154	67	3	irinotecan	irinotecan	NOUN
admet-154	67	4	(	(	PUNCT
admet-154	67	5	cpt-11	cpt-11	NOUN
admet-154	67	6	)	)	PUNCT
admet-154	67	7	concentration	concentration	NOUN
admet-154	67	8	-	-	PUNCT
admet-154	67	9	time	time	NOUN
admet-154	67	10	plot	plot	NOUN
admet-154	67	11	for	for	ADP
admet-154	67	12	a	a	PRON
admet-154	67	13	)	)	PUNCT
admet-154	67	14	20	20	NUM
admet-154	67	15	,	,	PUNCT
admet-154	67	16	b	b	NOUN
admet-154	67	17	)	)	PUNCT
admet-154	67	18	40	40	NUM
admet-154	67	19	and	and	CCONJ
admet-154	67	20	c	c	X
admet-154	67	21	)	)	PUNCT
admet-154	67	22	80	80	NUM
admet-154	67	23	mg	mg	NUM
admet-154	67	24	/	/	SYM
admet-154	67	25	kg	kg	PROPN
admet-154	67	26	after	after	ADP
admet-154	67	27	oral	oral	ADJ
admet-154	67	28	administration	administration	NOUN
admet-154	67	29	in	in	ADP
admet-154	67	30	control	control	PROPN
admet-154	67	31	(	(	PUNCT
admet-154	67	32	-	-	PUNCT
admet-154	67	33	●	●	NOUN
admet-154	67	34	-	-	PUNCT
admet-154	67	35	)	)	PUNCT
admet-154	67	36	and	and	CCONJ
admet-154	67	37	in	in	ADP
admet-154	67	38	verapamil	verapamil	NOUN
admet-154	67	39	(	(	PUNCT
admet-154	67	40	ver	ver	NOUN
admet-154	67	41	)	)	PUNCT
admet-154	67	42	treated	treat	VERB
admet-154	67	43	(	(	PUNCT
admet-154	67	44	-	-	PUNCT
admet-154	67	45	■	■	NOUN
admet-154	67	46	-	-	PUNCT
admet-154	67	47	)	)	PUNCT
admet-154	67	48	rats	rat	NOUN
admet-154	67	49	.	.	PUNCT
admet-154	68	1	verapamil	verapamil	NOUN
admet-154	68	2	at	at	ADP
admet-154	68	3	25	25	NUM
admet-154	68	4	mg	mg	NOUN
admet-154	68	5	/	/	SYM
admet-154	68	6	kg	kg	PROPN
admet-154	68	7	was	be	AUX
admet-154	68	8	administered	administer	VERB
admet-154	68	9	orally	orally	ADV
admet-154	68	10	2	2	NUM
admet-154	68	11	h	h	NOUN
admet-154	68	12	prior	prior	ADV
admet-154	68	13	to	to	ADP
admet-154	68	14	irinotecan	irinotecan	PROPN
admet-154	68	15	dosing	dosing	NOUN
admet-154	68	16	.	.	PUNCT
admet-154	69	1	each	each	DET
admet-154	69	2	data	datum	NOUN
admet-154	69	3	point	point	NOUN
admet-154	69	4	represents	represent	VERB
admet-154	69	5	the	the	DET
admet-154	69	6	mean	mean	ADJ
admet-154	69	7	±	±	NUM
admet-154	69	8	sem	sem	NOUN
admet-154	69	9	of	of	ADP
admet-154	69	10	five	five	NUM
admet-154	69	11	different	different	ADJ
admet-154	69	12	rats	rat	NOUN
admet-154	69	13	.	.	PUNCT
admet-154	70	1	*	*	PUNCT
admet-154	70	2	*	*	PUNCT
admet-154	70	3	statistical	statistical	ADJ
admet-154	70	4	significant	significant	ADJ
admet-154	70	5	difference	difference	NOUN
admet-154	70	6	between	between	ADP
admet-154	70	7	control	control	NOUN
admet-154	70	8	and	and	CCONJ
admet-154	70	9	verapamil	verapamil	NOUN
admet-154	70	10	treated	treat	VERB
admet-154	70	11	rats	rat	NOUN
admet-154	70	12	,	,	PUNCT
admet-154	70	13	p<0.01	p<0.01	PRON
admet-154	70	14	a	a	PRON
admet-154	70	15	)	)	PUNCT
admet-154	70	16	b	b	NOUN
admet-154	70	17	)	)	PUNCT
admet-154	70	18	c	c	NOUN
admet-154	70	19	)	)	PUNCT
admet-154	71	1	*	*	PUNCT
admet-154	72	1	*	*	PUNCT
admet-154	73	1	*	*	PUNCT
admet-154	73	2	*	*	PUNCT
admet-154	74	1	*	*	PUNCT
admet-154	74	2	*	*	PUNCT
admet-154	75	1	*	*	PUNCT
admet-154	75	2	*	*	PUNCT
admet-154	76	1	*	*	PUNCT
admet-154	76	2	*	*	PUNCT
admet-154	77	1	*	*	PUNCT
admet-154	77	2	*	*	PUNCT
admet-154	77	3	*	*	PUNCT
admet-154	77	4	*	*	PUNCT
admet-154	77	5	garg	garg	PROPN
admet-154	77	6	et	et	PROPN
admet-154	77	7	al	al	PROPN
admet-154	77	8	.	.	PROPN
admet-154	77	9	admet	admet	PROPN
admet-154	77	10	&	&	CCONJ
admet-154	77	11	dmpk	dmpk	PROPN
admet-154	77	12	3(1	3(1	NUM
admet-154	77	13	)	)	PUNCT
admet-154	77	14	(	(	PUNCT
admet-154	77	15	2015	2015	NUM
admet-154	77	16	)	)	PUNCT
admet-154	77	17	68	68	NUM
admet-154	77	18	-	-	SYM
admet-154	77	19	76	76	NUM
admet-154	77	20	72	72	NUM
admet-154	77	21	table	table	NOUN
admet-154	77	22	1	1	NUM
admet-154	77	23	.	.	PUNCT
admet-154	77	24	pharmacokinetic	pharmacokinetic	ADJ
admet-154	77	25	parameters	parameter	NOUN
admet-154	77	26	of	of	ADP
admet-154	77	27	irinotecan	irinotecan	NOUN
admet-154	77	28	with	with	ADP
admet-154	77	29	and	and	CCONJ
admet-154	77	30	without	without	ADP
admet-154	77	31	pre	pre	NOUN
admet-154	77	32	-	-	NOUN
admet-154	77	33	treatment	treatment	NOUN
admet-154	77	34	with	with	ADP
admet-154	77	35	oral	oral	ADJ
admet-154	77	36	verapamil	verapamil	NOUN
admet-154	77	37	(	(	PUNCT
admet-154	77	38	25	25	NUM
admet-154	77	39	mg	mg	PROPN
admet-154	77	40	/	/	SYM
admet-154	77	41	kg	kg	PROPN
admet-154	77	42	)	)	PUNCT
admet-154	77	43	,	,	PUNCT
admet-154	77	44	after	after	ADP
admet-154	77	45	oral	oral	ADJ
admet-154	77	46	and	and	CCONJ
admet-154	77	47	intravenous	intravenous	ADJ
admet-154	77	48	(	(	PUNCT
admet-154	77	49	20	20	NUM
admet-154	77	50	mg	mg	NUM
admet-154	77	51	/	/	SYM
admet-154	77	52	kg	kg	PROPN
admet-154	77	53	)	)	PUNCT
admet-154	77	54	administration	administration	NOUN
admet-154	77	55	of	of	ADP
admet-154	77	56	irinotecan	irinotecan	NOUN
admet-154	77	57	in	in	ADP
admet-154	77	58	rats	rat	NOUN
admet-154	77	59	[	[	X
admet-154	77	60	5	5	NUM
admet-154	77	61	]	]	PUNCT
admet-154	77	62	.	.	PUNCT
admet-154	78	1	pk	pk	NOUN
admet-154	78	2	parameters	parameter	NOUN
admet-154	78	3	of	of	ADP
admet-154	78	4	irinotecan	irinotecan	PROPN
admet-154	78	5	irinotecan	irinotecan	NOUN
admet-154	78	6	dose	dose	VERB
admet-154	78	7	20	20	NUM
admet-154	78	8	mg	mg	PROPN
admet-154	78	9	/	/	SYM
admet-154	78	10	kg	kg	PROPN
admet-154	78	11	,	,	PUNCT
admet-154	78	12	i.v	i.v	PRON
admet-154	78	13	20	20	NUM
admet-154	78	14	mg	mg	PROPN
admet-154	78	15	/	/	SYM
admet-154	78	16	kg	kg	PROPN
admet-154	78	17	,	,	PUNCT
admet-154	78	18	oral	oral	ADJ
admet-154	78	19	control	control	NOUN
admet-154	78	20	control	control	PROPN
admet-154	78	21	treated	treat	VERB
admet-154	78	22	change	change	NOUN
admet-154	78	23	auc0	auc0	NOUN
admet-154	78	24	-	-	PUNCT
admet-154	78	25	last	last	ADJ
admet-154	78	26	(	(	PUNCT
admet-154	79	1	h	h	NOUN
admet-154	79	2	µg	µg	ADJ
admet-154	79	3	/	/	SYM
admet-154	79	4	ml	ml	VERB
admet-154	79	5	)	)	PUNCT
admet-154	79	6	10.76	10.76	NUM
admet-154	79	7	±	±	NUM
admet-154	79	8	2.0	2.0	NUM
admet-154	79	9	3.51	3.51	NUM
admet-154	79	10	±	±	NUM
admet-154	79	11	1.20	1.20	NUM
admet-154	79	12	7.84	7.84	NUM
admet-154	79	13	±	±	NUM
admet-154	79	14	1.20	1.20	NUM
admet-154	79	15	*	*	PUNCT
admet-154	79	16	+220	+220	NUM
admet-154	79	17	%	%	NOUN
admet-154	79	18	c0	c0	NOUN
admet-154	79	19	(	(	PUNCT
admet-154	79	20	µg	µg	NOUN
admet-154	79	21	/	/	SYM
admet-154	79	22	ml	ml	NOUN
admet-154	79	23	)	)	PUNCT
admet-154	79	24	9.51	9.51	NUM
admet-154	79	25	±	±	NUM
admet-154	79	26	1.4	1.4	NUM
admet-154	79	27	--	--	PUNCT
admet-154	79	28	cmax	cmax	NOUN
admet-154	79	29	(	(	PUNCT
admet-154	79	30	µg	µg	NOUN
admet-154	79	31	/	/	SYM
admet-154	79	32	ml	ml	NOUN
admet-154	79	33	)	)	PUNCT
admet-154	79	34	2.47	2.47	NUM
admet-154	79	35	±	±	NUM
admet-154	79	36	0.41	0.41	NUM
admet-154	79	37	0.63	0.63	NUM
admet-154	79	38	±	±	NUM
admet-154	79	39	0.27	0.27	NUM
admet-154	79	40	1.05	1.05	NUM
admet-154	79	41	±	±	NUM
admet-154	79	42	0.23	0.23	NUM
admet-154	79	43	*	*	SYM
admet-154	79	44	+66	+66	NUM
admet-154	79	45	%	%	NOUN
admet-154	79	46	tmax	tmax	ADP
admet-154	79	47	(	(	PUNCT
admet-154	79	48	h	h	NOUN
admet-154	79	49	)	)	PUNCT
admet-154	79	50	-3.21	-3.21	NOUN
admet-154	79	51	±	±	NUM
admet-154	79	52	0.95	0.95	NUM
admet-154	79	53	2.94	2.94	NUM
admet-154	79	54	±	±	NUM
admet-154	79	55	1.17	1.17	NUM
admet-154	79	56	mrt	mrt	PROPN
admet-154	79	57	(	(	PUNCT
admet-154	79	58	h	h	NOUN
admet-154	79	59	)	)	PUNCT
admet-154	79	60	-5.52	-5.52	ADJ
admet-154	79	61	±	±	NUM
admet-154	79	62	0.20	0.20	NUM
admet-154	79	63	5.49	5.49	NUM
admet-154	79	64	±	±	NOUN
admet-154	79	65	0.11	0.11	NUM
admet-154	79	66	t1/2	t1/2	PROPN
admet-154	79	67	(	(	PUNCT
admet-154	79	68	h	h	NOUN
admet-154	79	69	)	)	PUNCT
admet-154	79	70	3.1	3.1	NUM
admet-154	79	71	±	±	NUM
admet-154	79	72	0.60	0.60	NUM
admet-154	79	73	3.24	3.24	NUM
admet-154	79	74	±	±	NUM
admet-154	79	75	0.22	0.22	NUM
admet-154	79	76	3.11	3.11	NUM
admet-154	79	77	±	±	NUM
admet-154	79	78	0.06	0.06	NUM
admet-154	79	79	clobs	clobs	NOUN
admet-154	79	80	(	(	PUNCT
admet-154	79	81	ml	ml	NOUN
admet-154	79	82	/	/	SYM
admet-154	79	83	h	h	NOUN
admet-154	79	84	/	/	SYM
admet-154	79	85	kg	kg	NOUN
admet-154	79	86	)	)	PUNCT
admet-154	79	87	1206.4	1206.4	NUM
admet-154	79	88	±	±	NUM
admet-154	79	89	159.7	159.7	NUM
admet-154	79	90	5664.8	5664.8	NUM
admet-154	79	91	±	±	NUM
admet-154	79	92	363.9	363.9	NUM
admet-154	79	93	2573.8	2573.8	NUM
admet-154	79	94	±	±	NOUN
admet-154	79	95	498.4	498.4	NUM
admet-154	79	96	*	*	PUNCT
admet-154	79	97	-54	-54	NUM
admet-154	79	98	%	%	NOUN
admet-154	79	99	vss	vss	NOUN
admet-154	79	100	,	,	PUNCT
admet-154	79	101	obs	obs	PROPN
admet-154	79	102	(	(	PUNCT
admet-154	79	103	ml	ml	PROPN
admet-154	79	104	/	/	SYM
admet-154	79	105	kg	kg	PROPN
admet-154	79	106	4852.2	4852.2	NUM
admet-154	79	107	±	±	NUM
admet-154	79	108	703.8	703.8	NUM
admet-154	79	109	27368.4	27368.4	NUM
admet-154	79	110	±	±	NUM
admet-154	79	111	2440.9	2440.9	NUM
admet-154	79	112	12115.4	12115.4	NUM
admet-154	79	113	±	±	NOUN
admet-154	79	114	3105.5	3105.5	NUM
admet-154	79	115	*	*	PUNCT
admet-154	79	116	-56	-56	PROPN
admet-154	79	117	%	%	NOUN
admet-154	79	118	kel	kel	NOUN
admet-154	79	119	(	(	PUNCT
admet-154	79	120	h	h	NOUN
admet-154	79	121	-1	-1	PUNCT
admet-154	79	122	)	)	PUNCT
admet-154	80	1	0.232	0.232	NUM
admet-154	80	2	±	±	NUM
admet-154	80	3	0.05	0.05	NUM
admet-154	80	4	0.214	0.214	NUM
admet-154	80	5	±	±	NUM
admet-154	80	6	0.0.02	0.0.02	NUM
admet-154	80	7	0.214	0.214	NUM
admet-154	80	8	±	±	NUM
admet-154	80	9	0.0.02	0.0.02	NUM
admet-154	81	1	f	f	PROPN
admet-154	81	2	(	(	PUNCT
admet-154	81	3	%	%	NOUN
admet-154	81	4	)	)	PUNCT
admet-154	81	5	32	32	NUM
admet-154	81	6	72	72	NUM
admet-154	81	7	each	each	DET
admet-154	81	8	value	value	NOUN
admet-154	81	9	represents	represent	VERB
admet-154	81	10	the	the	DET
admet-154	81	11	mean	mean	ADJ
admet-154	81	12	±	±	NUM
admet-154	81	13	sem	sem	NOUN
admet-154	81	14	of	of	ADP
admet-154	81	15	five	five	NUM
admet-154	81	16	rats	rat	NOUN
admet-154	81	17	.	.	PUNCT
admet-154	82	1	*	*	PUNCT
admet-154	82	2	statistical	statistical	ADJ
admet-154	82	3	significant	significant	ADJ
admet-154	82	4	difference	difference	NOUN
admet-154	82	5	between	between	ADP
admet-154	82	6	control	control	NOUN
admet-154	82	7	and	and	CCONJ
admet-154	82	8	verapamil	verapamil	NOUN
admet-154	82	9	treated	treat	VERB
admet-154	82	10	rats	rat	NOUN
admet-154	82	11	,	,	PUNCT
admet-154	82	12	p<0.05	p<0.05	NOUN
admet-154	82	13	table	table	NOUN
admet-154	82	14	2	2	NUM
admet-154	82	15	.	.	PUNCT
admet-154	82	16	pharmacokinetic	pharmacokinetic	ADJ
admet-154	82	17	parameters	parameter	NOUN
admet-154	82	18	of	of	ADP
admet-154	82	19	irinotecan	irinotecan	NOUN
admet-154	82	20	with	with	ADP
admet-154	82	21	and	and	CCONJ
admet-154	82	22	without	without	ADP
admet-154	82	23	pre	pre	NOUN
admet-154	82	24	-	-	NOUN
admet-154	82	25	treatment	treatment	NOUN
admet-154	82	26	with	with	ADP
admet-154	82	27	oral	oral	ADJ
admet-154	82	28	verapamil	verapamil	NOUN
admet-154	82	29	(	(	PUNCT
admet-154	82	30	25	25	NUM
admet-154	82	31	mg	mg	PROPN
admet-154	82	32	/	/	SYM
admet-154	82	33	kg	kg	PROPN
admet-154	82	34	)	)	PUNCT
admet-154	82	35	,	,	PUNCT
admet-154	82	36	after	after	ADP
admet-154	82	37	oral	oral	ADJ
admet-154	82	38	(	(	PUNCT
admet-154	82	39	40	40	NUM
admet-154	82	40	mg	mg	PROPN
admet-154	82	41	/	/	SYM
admet-154	82	42	kg	kg	PROPN
admet-154	82	43	)	)	PUNCT
admet-154	82	44	administration	administration	NOUN
admet-154	82	45	of	of	ADP
admet-154	82	46	irinotecan	irinotecan	NOUN
admet-154	82	47	in	in	ADP
admet-154	82	48	rats	rat	NOUN
admet-154	82	49	.	.	PUNCT
admet-154	83	1	pk	pk	NOUN
admet-154	83	2	parameters	parameter	NOUN
admet-154	83	3	of	of	ADP
admet-154	83	4	irinotecan	irinotecan	PROPN
admet-154	83	5	irinotecan	irinotecan	NOUN
admet-154	83	6	dose	dose	VERB
admet-154	83	7	40	40	NUM
admet-154	83	8	mg	mg	PROPN
admet-154	83	9	/	/	SYM
admet-154	83	10	kg	kg	PROPN
admet-154	83	11	,	,	PUNCT
admet-154	83	12	oral	oral	ADJ
admet-154	83	13	control	control	NOUN
admet-154	83	14	treated	treat	VERB
admet-154	83	15	change	change	NOUN
admet-154	83	16	auc0	auc0	NOUN
admet-154	83	17	-	-	PUNCT
admet-154	83	18	last	last	ADJ
admet-154	83	19	(	(	PUNCT
admet-154	83	20	h*µg	h*µg	NOUN
admet-154	83	21	/	/	SYM
admet-154	83	22	ml	ml	VERB
admet-154	83	23	)	)	PUNCT
admet-154	83	24	8.81	8.81	NUM
admet-154	83	25	±	±	NUM
admet-154	83	26	1.93	1.93	NUM
admet-154	83	27	19.94	19.94	NUM
admet-154	83	28	±	±	NUM
admet-154	83	29	2.39	2.39	NUM
admet-154	83	30	*	*	SYM
admet-154	84	1	+126	+126	NUM
admet-154	84	2	%	%	NOUN
admet-154	84	3	cmax	cmax	NOUN
admet-154	84	4	(	(	PUNCT
admet-154	84	5	µg	µg	NOUN
admet-154	84	6	/	/	SYM
admet-154	84	7	ml	ml	NOUN
admet-154	84	8	)	)	PUNCT
admet-154	84	9	1.48	1.48	NUM
admet-154	84	10	±	±	NUM
admet-154	84	11	0.57	0.57	NUM
admet-154	84	12	2.24	2.24	NUM
admet-154	84	13	±	±	NOUN
admet-154	84	14	0.54	0.54	NUM
admet-154	84	15	+51	+51	PROPN
admet-154	84	16	%	%	NOUN
admet-154	84	17	tmax	tmax	ADP
admet-154	84	18	(	(	PUNCT
admet-154	84	19	h	h	NOUN
admet-154	84	20	)	)	PUNCT
admet-154	84	21	2.33	2.33	NUM
admet-154	84	22	±	±	NUM
admet-154	84	23	0.58	0.58	NUM
admet-154	84	24	4.67	4.67	NUM
admet-154	84	25	±	±	NUM
admet-154	84	26	1.15	1.15	NUM
admet-154	84	27	mrt	mrt	PROPN
admet-154	84	28	(	(	PUNCT
admet-154	84	29	h	h	NOUN
admet-154	84	30	)	)	PUNCT
admet-154	84	31	5.21	5.21	NUM
admet-154	84	32	±	±	NUM
admet-154	84	33	0.63	0.63	NUM
admet-154	84	34	6.19	6.19	NUM
admet-154	84	35	±	±	NUM
admet-154	84	36	1.10	1.10	NUM
admet-154	84	37	t1/2	t1/2	NOUN
admet-154	84	38	(	(	PUNCT
admet-154	84	39	h	h	NOUN
admet-154	84	40	)	)	PUNCT
admet-154	84	41	4.25	4.25	NUM
admet-154	84	42	±	±	NUM
admet-154	84	43	2.08	2.08	NUM
admet-154	84	44	3.59	3.59	NUM
admet-154	84	45	±	±	NUM
admet-154	84	46	1.84	1.84	NUM
admet-154	84	47	clobs	clob	NOUN
admet-154	84	48	(	(	PUNCT
admet-154	84	49	ml	ml	NOUN
admet-154	84	50	/	/	SYM
admet-154	84	51	h	h	NOUN
admet-154	84	52	/	/	SYM
admet-154	84	53	kg	kg	NOUN
admet-154	84	54	)	)	PUNCT
admet-154	84	55	4578.7	4578.7	NUM
admet-154	84	56	±	±	NUM
admet-154	84	57	1073.02	1073.02	NUM
admet-154	84	58	1981.9	1981.9	NUM
admet-154	84	59	±	±	NUM
admet-154	84	60	299.7	299.7	NUM
admet-154	84	61	*	*	PUNCT
admet-154	84	62	-56	-56	PROPN
admet-154	84	63	%	%	NOUN
admet-154	84	64	vss	vss	NOUN
admet-154	84	65	,	,	PUNCT
admet-154	84	66	obs	obs	PROPN
admet-154	84	67	(	(	PUNCT
admet-154	84	68	ml	ml	PROPN
admet-154	84	69	/	/	SYM
admet-154	84	70	kg	kg	PROPN
admet-154	84	71	26088.9	26088.9	NUM
admet-154	84	72	±	±	NOUN
admet-154	84	73	6232.1	6232.1	NUM
admet-154	84	74	9761.5	9761.5	NUM
admet-154	84	75	±	±	NOUN
admet-154	84	76	3385.9	3385.9	NUM
admet-154	84	77	*	*	SYM
admet-154	84	78	-62	-62	NUM
admet-154	84	79	%	%	NOUN
admet-154	84	80	kel	kel	NOUN
admet-154	84	81	(	(	PUNCT
admet-154	84	82	h	h	NOUN
admet-154	84	83	-1	-1	PUNCT
admet-154	84	84	)	)	PUNCT
admet-154	84	85	0.186	0.186	NUM
admet-154	84	86	±	±	NUM
admet-154	84	87	0.07	0.07	NUM
admet-154	84	88	0.223	0.223	NUM
admet-154	84	89	±	±	NUM
admet-154	84	90	0.09	0.09	NUM
admet-154	84	91	f	f	PROPN
admet-154	84	92	(	(	PUNCT
admet-154	84	93	%	%	NOUN
admet-154	84	94	)	)	PUNCT
admet-154	84	95	41	41	NUM
admet-154	84	96	93	93	NUM
admet-154	84	97	each	each	DET
admet-154	84	98	value	value	NOUN
admet-154	84	99	represents	represent	VERB
admet-154	84	100	the	the	DET
admet-154	84	101	mean	mean	ADJ
admet-154	84	102	±	±	NUM
admet-154	84	103	sem	sem	NOUN
admet-154	84	104	of	of	ADP
admet-154	84	105	five	five	NUM
admet-154	84	106	rats	rat	NOUN
admet-154	84	107	.	.	PUNCT
admet-154	85	1	*	*	PUNCT
admet-154	85	2	statistical	statistical	ADJ
admet-154	85	3	significant	significant	ADJ
admet-154	85	4	difference	difference	NOUN
admet-154	85	5	between	between	ADP
admet-154	85	6	control	control	NOUN
admet-154	85	7	and	and	CCONJ
admet-154	85	8	verapamil	verapamil	NOUN
admet-154	85	9	treated	treat	VERB
admet-154	85	10	rats	rat	NOUN
admet-154	85	11	,	,	PUNCT
admet-154	85	12	p<0.05	p<0.05	NOUN
admet-154	85	13	table	table	NOUN
admet-154	85	14	3	3	NUM
admet-154	85	15	.	.	PUNCT
admet-154	85	16	pharmacokinetic	pharmacokinetic	ADJ
admet-154	85	17	parameters	parameter	NOUN
admet-154	85	18	of	of	ADP
admet-154	85	19	irinotecan	irinotecan	NOUN
admet-154	85	20	with	with	ADP
admet-154	85	21	and	and	CCONJ
admet-154	85	22	without	without	ADP
admet-154	85	23	pre	pre	NOUN
admet-154	85	24	-	-	NOUN
admet-154	85	25	treatment	treatment	NOUN
admet-154	85	26	with	with	ADP
admet-154	85	27	oral	oral	ADJ
admet-154	85	28	verapamil	verapamil	NOUN
admet-154	85	29	(	(	PUNCT
admet-154	85	30	25	25	NUM
admet-154	85	31	mg	mg	PROPN
admet-154	85	32	/	/	SYM
admet-154	85	33	kg	kg	PROPN
admet-154	85	34	)	)	PUNCT
admet-154	85	35	,	,	PUNCT
admet-154	85	36	after	after	ADP
admet-154	85	37	oral	oral	ADJ
admet-154	85	38	(	(	PUNCT
admet-154	85	39	80	80	NUM
admet-154	85	40	mg	mg	PROPN
admet-154	85	41	/	/	SYM
admet-154	85	42	kg	kg	PROPN
admet-154	85	43	)	)	PUNCT
admet-154	85	44	administration	administration	NOUN
admet-154	85	45	of	of	ADP
admet-154	85	46	irinotecan	irinotecan	NOUN
admet-154	85	47	in	in	ADP
admet-154	85	48	rats	rat	NOUN
admet-154	85	49	[	[	X
admet-154	85	50	5	5	NUM
admet-154	85	51	]	]	PUNCT
admet-154	85	52	.	.	PUNCT
admet-154	86	1	pk	pk	NOUN
admet-154	86	2	parameters	parameter	NOUN
admet-154	86	3	of	of	ADP
admet-154	86	4	irinotecan	irinotecan	PROPN
admet-154	86	5	irinotecan	irinotecan	NOUN
admet-154	86	6	dose	dose	VERB
admet-154	86	7	80	80	NUM
admet-154	86	8	mg	mg	PROPN
admet-154	86	9	/	/	SYM
admet-154	86	10	kg	kg	PROPN
admet-154	86	11	,	,	PUNCT
admet-154	86	12	oral	oral	ADJ
admet-154	86	13	control	control	NOUN
admet-154	86	14	treated	treat	VERB
admet-154	86	15	change	change	NOUN
admet-154	86	16	auc0	auc0	NOUN
admet-154	86	17	-	-	PUNCT
admet-154	86	18	last	last	ADJ
admet-154	86	19	(	(	PUNCT
admet-154	86	20	h*µg	h*µg	NOUN
admet-154	86	21	/	/	SYM
admet-154	86	22	ml	ml	VERB
admet-154	86	23	)	)	PUNCT
admet-154	86	24	14.03	14.03	NUM
admet-154	86	25	±	±	NUM
admet-154	86	26	2.18	2.18	NUM
admet-154	86	27	61.71	61.71	NUM
admet-154	86	28	±	±	NUM
admet-154	86	29	15.0	15.0	NUM
admet-154	86	30	*	*	PUNCT
admet-154	86	31	*	*	PUNCT
admet-154	86	32	+440	+440	NUM
admet-154	86	33	%	%	NOUN
admet-154	86	34	cmax	cmax	NOUN
admet-154	86	35	(	(	PUNCT
admet-154	86	36	µg	µg	NOUN
admet-154	86	37	/	/	SYM
admet-154	86	38	ml	ml	NOUN
admet-154	86	39	)	)	PUNCT
admet-154	86	40	2.93	2.93	NUM
admet-154	86	41	±	±	NUM
admet-154	86	42	0.37	0.37	NUM
admet-154	86	43	10.75	10.75	NUM
admet-154	86	44	±	±	NUM
admet-154	86	45	1.0	1.0	NUM
admet-154	86	46	*	*	PUNCT
admet-154	87	1	+266	+266	NOUN
admet-154	87	2	%	%	X
admet-154	87	3	tmax	tmax	ADP
admet-154	87	4	(	(	PUNCT
admet-154	87	5	h	h	NOUN
admet-154	87	6	)	)	PUNCT
admet-154	87	7	2.6	2.6	NUM
admet-154	87	8	±	±	NUM
admet-154	87	9	0.89	0.89	NUM
admet-154	87	10	1.75	1.75	NUM
admet-154	87	11	±	±	NUM
admet-154	87	12	1.8	1.8	NUM
admet-154	87	13	mrt	mrt	PROPN
admet-154	87	14	(	(	PUNCT
admet-154	87	15	h	h	NOUN
admet-154	87	16	)	)	PUNCT
admet-154	87	17	3.6	3.6	NUM
admet-154	87	18	±	±	NUM
admet-154	87	19	0.69	0.69	NUM
admet-154	87	20	5.13	5.13	NUM
admet-154	87	21	±	±	NUM
admet-154	87	22	1.48	1.48	NUM
admet-154	87	23	t1/2	t1/2	PROPN
admet-154	87	24	(	(	PUNCT
admet-154	87	25	h	h	NOUN
admet-154	87	26	)	)	PUNCT
admet-154	87	27	2.24	2.24	NUM
admet-154	87	28	±	±	NUM
admet-154	87	29	0.51	0.51	NUM
admet-154	87	30	4.18	4.18	NUM
admet-154	87	31	±	±	NUM
admet-154	87	32	1.2	1.2	NUM
admet-154	87	33	*	*	NOUN
admet-154	87	34	clobs	clobs	PROPN
admet-154	87	35	(	(	PUNCT
admet-154	87	36	ml	ml	NOUN
admet-154	87	37	/	/	SYM
admet-154	87	38	h	h	NOUN
admet-154	87	39	/	/	SYM
admet-154	87	40	kg	kg	NOUN
admet-154	87	41	)	)	PUNCT
admet-154	87	42	5613.8	5613.8	NUM
admet-154	87	43	±	±	NUM
admet-154	87	44	1126.3	1126.3	NUM
admet-154	87	45	897.09	897.09	NUM
admet-154	87	46	±	±	NOUN
admet-154	87	47	177.9	177.9	NUM
admet-154	87	48	*	*	PUNCT
admet-154	87	49	-84	-84	NUM
admet-154	87	50	%	%	NOUN
admet-154	87	51	vss	vss	NOUN
admet-154	87	52	,	,	PUNCT
admet-154	87	53	obs	obs	PROPN
admet-154	87	54	(	(	PUNCT
admet-154	87	55	ml	ml	PROPN
admet-154	87	56	/	/	SYM
admet-154	87	57	kg	kg	PROPN
admet-154	87	58	32197.0	32197.0	NUM
admet-154	87	59	±	±	NUM
admet-154	87	60	8067.1	8067.1	NUM
admet-154	87	61	7571.1	7571.1	NUM
admet-154	87	62	±	±	NUM
admet-154	87	63	151.3	151.3	NUM
admet-154	87	64	*	*	PUNCT
admet-154	87	65	-76	-76	NUM
admet-154	87	66	%	%	NOUN
admet-154	87	67	kel	kel	NOUN
admet-154	87	68	(	(	PUNCT
admet-154	87	69	h	h	NOUN
admet-154	87	70	-1	-1	PUNCT
admet-154	87	71	)	)	PUNCT
admet-154	87	72	0.293	0.293	NUM
admet-154	87	73	±	±	NUM
admet-154	87	74	0.09	0.09	NUM
admet-154	87	75	0.17	0.17	NUM
admet-154	87	76	±	±	NUM
admet-154	87	77	0.05	0.05	NUM
admet-154	87	78	*	*	SYM
admet-154	87	79	f	f	X
admet-154	87	80	(	(	PUNCT
admet-154	87	81	%	%	INTJ
admet-154	87	82	)	)	PUNCT
admet-154	87	83	33	33	NUM
admet-154	87	84	143	143	NUM
admet-154	87	85	each	each	DET
admet-154	87	86	value	value	NOUN
admet-154	87	87	represents	represent	VERB
admet-154	87	88	the	the	DET
admet-154	87	89	mean	mean	ADJ
admet-154	87	90	±	±	NUM
admet-154	87	91	sem	sem	NOUN
admet-154	87	92	of	of	ADP
admet-154	87	93	five	five	NUM
admet-154	87	94	rats	rat	NOUN
admet-154	87	95	.	.	PUNCT
admet-154	88	1	*	*	PUNCT
admet-154	88	2	statistical	statistical	ADJ
admet-154	88	3	significant	significant	ADJ
admet-154	88	4	difference	difference	NOUN
admet-154	88	5	between	between	ADP
admet-154	88	6	control	control	NOUN
admet-154	88	7	and	and	CCONJ
admet-154	88	8	verapamil	verapamil	NOUN
admet-154	88	9	treated	treat	VERB
admet-154	88	10	rats	rat	NOUN
admet-154	88	11	,	,	PUNCT
admet-154	88	12	p<0.05	p<0.05	NOUN
admet-154	88	13	admet	admet	PROPN
admet-154	88	14	&	&	CCONJ
admet-154	88	15	dmpk	dmpk	PROPN
admet-154	88	16	3(1	3(1	NUM
admet-154	88	17	)	)	PUNCT
admet-154	88	18	(	(	PUNCT
admet-154	88	19	2015	2015	NUM
admet-154	88	20	)	)	PUNCT
admet-154	88	21	68	68	NUM
admet-154	88	22	-	-	SYM
admet-154	88	23	76	76	NUM
admet-154	88	24	p	p	NOUN
admet-154	88	25	-	-	PUNCT
admet-154	88	26	gp	gp	NOUN
admet-154	88	27	pharmacokinetics	pharmacokinetic	NOUN
admet-154	88	28	of	of	ADP
admet-154	88	29	irinotecan	irinotecan	PROPN
admet-154	88	30	doi	doi	PROPN
admet-154	88	31	:	:	PUNCT
admet-154	88	32	10.5599	10.5599	NUM
admet-154	88	33	/	/	SYM
admet-154	88	34	admet.3.1.154	admet.3.1.154	VERB
admet-154	88	35	73	73	NUM
admet-154	88	36	the	the	DET
admet-154	88	37	plasma	plasma	NOUN
admet-154	88	38	concentrations	concentration	NOUN
admet-154	88	39	versus	versus	ADP
admet-154	88	40	time	time	NOUN
admet-154	88	41	curves	curve	NOUN
admet-154	88	42	of	of	ADP
admet-154	88	43	sn-38	sn-38	NOUN
admet-154	88	44	,	,	PUNCT
admet-154	88	45	after	after	SCONJ
admet-154	88	46	oral	oral	ADJ
admet-154	88	47	administration	administration	NOUN
admet-154	88	48	of	of	ADP
admet-154	88	49	irinotecan	irinotecan	NOUN
admet-154	88	50	at	at	ADP
admet-154	88	51	three	three	NUM
admet-154	88	52	doses	dose	NOUN
admet-154	88	53	are	be	AUX
admet-154	88	54	shown	show	VERB
admet-154	88	55	in	in	ADP
admet-154	88	56	figure	figure	NOUN
admet-154	88	57	2	2	NUM
admet-154	88	58	.	.	PUNCT
admet-154	88	59	oral	oral	ADJ
admet-154	88	60	pharmacokinetic	pharmacokinetic	ADJ
admet-154	88	61	parameters	parameter	NOUN
admet-154	88	62	of	of	ADP
admet-154	88	63	sn-38	sn-38	NOUN
admet-154	88	64	were	be	AUX
admet-154	88	65	significantly	significantly	ADV
admet-154	88	66	modified	modify	VERB
admet-154	88	67	by	by	ADP
admet-154	88	68	verapamil	verapamil	NOUN
admet-154	88	69	(	(	PUNCT
admet-154	88	70	p	p	X
admet-154	88	71	<	<	X
admet-154	88	72	0.05	0.05	NUM
admet-154	88	73	)	)	PUNCT
admet-154	88	74	(	(	PUNCT
admet-154	88	75	table	table	NOUN
admet-154	88	76	4	4	NUM
admet-154	88	77	)	)	PUNCT
admet-154	88	78	.	.	PUNCT
admet-154	89	1	sn-38	sn-38	PROPN
admet-154	89	2	showed	show	VERB
admet-154	89	3	biphasic	biphasic	ADJ
admet-154	89	4	plasma	plasma	NOUN
admet-154	89	5	disposition	disposition	NOUN
admet-154	89	6	after	after	ADP
admet-154	89	7	oral	oral	ADJ
admet-154	89	8	administration	administration	NOUN
admet-154	89	9	,	,	PUNCT
admet-154	89	10	with	with	ADP
admet-154	89	11	a	a	DET
admet-154	89	12	terminal	terminal	ADJ
admet-154	89	13	half	half	ADJ
admet-154	89	14	-	-	PUNCT
admet-154	89	15	life	life	NOUN
admet-154	89	16	of	of	ADP
admet-154	89	17	about	about	ADV
admet-154	89	18	1	1	NUM
admet-154	89	19	-	-	SYM
admet-154	89	20	2	2	NUM
admet-154	89	21	h.	h.	NOUN
admet-154	89	22	figure	figure	NOUN
admet-154	89	23	2	2	NUM
admet-154	89	24	.	.	PUNCT
admet-154	89	25	plasma	plasma	NOUN
admet-154	89	26	concentrations	concentration	NOUN
admet-154	89	27	of	of	ADP
admet-154	89	28	sn-38	sn-38	NOUN
admet-154	89	29	following	follow	VERB
admet-154	89	30	irinotecan	irinotecan	NOUN
admet-154	89	31	(	(	PUNCT
admet-154	89	32	cpt-11	cpt-11	NOUN
admet-154	89	33	)	)	PUNCT
admet-154	89	34	administration	administration	NOUN
admet-154	89	35	in	in	ADP
admet-154	89	36	control	control	NOUN
admet-154	89	37	and	and	CCONJ
admet-154	89	38	verapamil	verapamil	NOUN
admet-154	89	39	(	(	PUNCT
admet-154	89	40	ver	ver	NOUN
admet-154	89	41	)	)	PUNCT
admet-154	89	42	treated	treat	VERB
admet-154	89	43	female	female	ADJ
admet-154	89	44	wistar	wistar	PROPN
admet-154	89	45	rats	rat	NOUN
admet-154	89	46	.	.	PUNCT
admet-154	90	1	the	the	DET
admet-154	90	2	control	control	NOUN
admet-154	90	3	group	group	NOUN
admet-154	90	4	was	be	AUX
admet-154	90	5	given	give	VERB
admet-154	90	6	an	an	DET
admet-154	90	7	oral	oral	ADJ
admet-154	90	8	dose	dose	NOUN
admet-154	90	9	of	of	ADP
admet-154	90	10	a	a	PRON
admet-154	90	11	)	)	PUNCT
admet-154	90	12	20	20	NUM
admet-154	90	13	,	,	PUNCT
admet-154	90	14	b	b	NOUN
admet-154	90	15	)	)	PUNCT
admet-154	90	16	40	40	NUM
admet-154	90	17	and	and	CCONJ
admet-154	90	18	c	c	X
admet-154	90	19	)	)	PUNCT
admet-154	90	20	80	80	NUM
admet-154	90	21	mg	mg	PROPN
admet-154	90	22	/	/	SYM
admet-154	90	23	kg	kg	NOUN
admet-154	90	24	irinotecan	irinotecan	NOUN
admet-154	90	25	only	only	ADV
admet-154	90	26	(	(	PUNCT
admet-154	90	27	-	-	PUNCT
admet-154	90	28	♦	♦	NOUN
admet-154	90	29	-	-	PUNCT
admet-154	90	30	)	)	PUNCT
admet-154	90	31	.	.	PUNCT
admet-154	91	1	the	the	DET
admet-154	91	2	treated	treat	VERB
admet-154	91	3	(	(	PUNCT
admet-154	91	4	-	-	PUNCT
admet-154	91	5	■	■	NOUN
admet-154	91	6	-	-	PUNCT
admet-154	91	7	)	)	PUNCT
admet-154	91	8	were	be	AUX
admet-154	91	9	administered	administer	VERB
admet-154	91	10	verapamil	verapamil	NOUN
admet-154	91	11	at	at	ADP
admet-154	91	12	25	25	NUM
admet-154	91	13	mg	mg	PROPN
admet-154	91	14	/	/	SYM
admet-154	91	15	kg	kg	PROPN
admet-154	91	16	orally	orally	ADV
admet-154	91	17	2	2	NUM
admet-154	91	18	h	h	NOUN
admet-154	91	19	prior	prior	ADV
admet-154	91	20	to	to	ADP
admet-154	91	21	irinotecan	irinotecan	PROPN
admet-154	91	22	dosing	dosing	NOUN
admet-154	91	23	.	.	PUNCT
admet-154	92	1	each	each	DET
admet-154	92	2	data	datum	NOUN
admet-154	92	3	point	point	NOUN
admet-154	92	4	represents	represent	VERB
admet-154	92	5	the	the	DET
admet-154	92	6	mean	mean	ADJ
admet-154	92	7	±	±	NUM
admet-154	92	8	sem	sem	NOUN
admet-154	92	9	of	of	ADP
admet-154	92	10	five	five	NUM
admet-154	92	11	different	different	ADJ
admet-154	92	12	rats	rat	NOUN
admet-154	92	13	.	.	PUNCT
admet-154	93	1	*	*	PUNCT
admet-154	93	2	*	*	PUNCT
admet-154	93	3	statistical	statistical	ADJ
admet-154	93	4	significant	significant	ADJ
admet-154	93	5	difference	difference	NOUN
admet-154	93	6	between	between	ADP
admet-154	93	7	control	control	NOUN
admet-154	93	8	and	and	CCONJ
admet-154	93	9	verapamil	verapamil	NOUN
admet-154	93	10	treated	treat	VERB
admet-154	93	11	rats	rat	NOUN
admet-154	93	12	,	,	PUNCT
admet-154	93	13	p<0.01	p<0.01	PRON
admet-154	93	14	a	a	PRON
admet-154	93	15	)	)	PUNCT
admet-154	93	16	b	b	NOUN
admet-154	93	17	)	)	PUNCT
admet-154	93	18	c	c	NOUN
admet-154	93	19	)	)	PUNCT
admet-154	94	1	*	*	PUNCT
admet-154	95	1	*	*	PUNCT
admet-154	96	1	*	*	PUNCT
admet-154	96	2	*	*	PUNCT
admet-154	96	3	*	*	PUNCT
admet-154	96	4	*	*	PUNCT
admet-154	96	5	garg	garg	PROPN
admet-154	96	6	et	et	PROPN
admet-154	96	7	al	al	PROPN
admet-154	96	8	.	.	PROPN
admet-154	96	9	admet	admet	PROPN
admet-154	96	10	&	&	CCONJ
admet-154	96	11	dmpk	dmpk	PROPN
admet-154	96	12	3(1	3(1	NUM
admet-154	96	13	)	)	PUNCT
admet-154	96	14	(	(	PUNCT
admet-154	96	15	2015	2015	NUM
admet-154	96	16	)	)	PUNCT
admet-154	96	17	68	68	NUM
admet-154	96	18	-	-	SYM
admet-154	96	19	76	76	NUM
admet-154	96	20	74	74	NUM
admet-154	96	21	table	table	NOUN
admet-154	96	22	4	4	NUM
admet-154	96	23	.	.	PUNCT
admet-154	96	24	pharmacokinetic	pharmacokinetic	ADJ
admet-154	96	25	parameters	parameter	NOUN
admet-154	96	26	of	of	ADP
admet-154	96	27	sn-38	sn-38	ADJ
admet-154	96	28	,	,	PUNCT
admet-154	96	29	major	major	ADJ
admet-154	96	30	metabolite	metabolite	NOUN
admet-154	96	31	of	of	ADP
admet-154	96	32	irinotecan	irinotecan	NOUN
admet-154	96	33	,	,	PUNCT
admet-154	96	34	with	with	ADP
admet-154	96	35	and	and	CCONJ
admet-154	96	36	without	without	ADP
admet-154	96	37	pre	pre	NOUN
admet-154	96	38	-	-	NOUN
admet-154	96	39	treatment	treatment	NOUN
admet-154	96	40	with	with	ADP
admet-154	96	41	oral	oral	ADJ
admet-154	96	42	verapamil	verapamil	NOUN
admet-154	96	43	(	(	PUNCT
admet-154	96	44	25	25	NUM
admet-154	96	45	mg	mg	PROPN
admet-154	96	46	/	/	SYM
admet-154	96	47	kg	kg	PROPN
admet-154	96	48	)	)	PUNCT
admet-154	96	49	,	,	PUNCT
admet-154	96	50	after	after	ADP
admet-154	96	51	oral	oral	ADJ
admet-154	96	52	(	(	PUNCT
admet-154	96	53	20	20	NUM
admet-154	96	54	,	,	PUNCT
admet-154	96	55	40	40	NUM
admet-154	96	56	and	and	CCONJ
admet-154	96	57	80	80	NUM
admet-154	96	58	mg	mg	NUM
admet-154	96	59	/	/	SYM
admet-154	96	60	kg	kg	NOUN
admet-154	96	61	)	)	PUNCT
admet-154	96	62	and	and	CCONJ
admet-154	96	63	intravenous	intravenous	ADJ
admet-154	96	64	(	(	PUNCT
admet-154	96	65	20	20	NUM
admet-154	96	66	mg	mg	NUM
admet-154	96	67	/	/	SYM
admet-154	96	68	kg	kg	PROPN
admet-154	96	69	)	)	PUNCT
admet-154	96	70	administration	administration	NOUN
admet-154	96	71	of	of	ADP
admet-154	96	72	irinotecan	irinotecan	NOUN
admet-154	96	73	in	in	ADP
admet-154	96	74	rats	rat	NOUN
admet-154	96	75	irinotecan	irinotecan	NOUN
admet-154	96	76	dose	dose	NOUN
admet-154	96	77	groups	group	NOUN
admet-154	96	78	pk	pk	NOUN
admet-154	96	79	parameter	parameter	NOUN
admet-154	96	80	of	of	ADP
admet-154	96	81	sn-38	sn-38	NOUN
admet-154	96	82	auc0	auc0	PROPN
admet-154	96	83	-	-	PUNCT
admet-154	96	84	last	last	ADJ
admet-154	96	85	(	(	PUNCT
admet-154	96	86	h	h	NOUN
admet-154	96	87	µg	µg	ADJ
admet-154	96	88	/	/	SYM
admet-154	96	89	ml	ml	NOUN
admet-154	96	90	)	)	PUNCT
admet-154	96	91	c0	c0	NOUN
admet-154	96	92	(	(	PUNCT
admet-154	96	93	µg	µg	NOUN
admet-154	96	94	/	/	SYM
admet-154	96	95	ml	ml	NOUN
admet-154	96	96	)	)	PUNCT
admet-154	96	97	cmax	cmax	NOUN
admet-154	96	98	(	(	PUNCT
admet-154	96	99	µg	µg	NOUN
admet-154	96	100	/	/	SYM
admet-154	96	101	ml	ml	NOUN
admet-154	96	102	)	)	PUNCT
admet-154	96	103	tmax	tmax	ADV
admet-154	96	104	(	(	PUNCT
admet-154	96	105	h	h	NOUN
admet-154	96	106	)	)	PUNCT
admet-154	96	107	t1/2	t1/2	NOUN
admet-154	96	108	(	(	PUNCT
admet-154	96	109	h	h	NOUN
admet-154	96	110	)	)	PUNCT
admet-154	96	111	20	20	NUM
admet-154	96	112	mg	mg	PROPN
admet-154	96	113	/	/	SYM
admet-154	96	114	kg	kg	PROPN
admet-154	96	115	,	,	PUNCT
admet-154	96	116	i.v	i.v	PRON
admet-154	96	117	control	control	VERB
admet-154	96	118	8.7	8.7	NUM
admet-154	96	119	±	±	NUM
admet-154	96	120	0.49	0.49	NUM
admet-154	96	121	2.10	2.10	NUM
admet-154	96	122	±	±	NUM
admet-154	96	123	0.61	0.61	NUM
admet-154	96	124	--1.1	--1.1	PUNCT
admet-154	96	125	±	±	NUM
admet-154	97	1	0.16	0.16	NUM
admet-154	97	2	20	20	NUM
admet-154	97	3	mg	mg	PROPN
admet-154	97	4	/	/	SYM
admet-154	97	5	kg	kg	PROPN
admet-154	97	6	,	,	PUNCT
admet-154	97	7	oral	oral	ADJ
admet-154	97	8	control	control	NOUN
admet-154	97	9	0.70	0.70	NUM
admet-154	97	10	±	±	NUM
admet-154	97	11	0.026	0.026	NUM
admet-154	97	12	-0.10	-0.10	NUM
admet-154	97	13	±	±	NUM
admet-154	97	14	0.01	0.01	NUM
admet-154	97	15	2	2	NUM
admet-154	97	16	2.18	2.18	NUM
admet-154	97	17	±	±	NOUN
admet-154	97	18	0.69	0.69	NUM
admet-154	97	19	treated	treat	VERB
admet-154	97	20	0.94	0.94	NUM
admet-154	97	21	±	±	NUM
admet-154	97	22	0.08	0.08	NUM
admet-154	97	23	*	*	PUNCT
admet-154	97	24	-0.27	-0.27	NUM
admet-154	97	25	±	±	NUM
admet-154	97	26	0.03	0.03	NUM
admet-154	97	27	*	*	SYM
admet-154	97	28	2	2	NUM
admet-154	97	29	2.83	2.83	NUM
admet-154	97	30	±	±	NUM
admet-154	97	31	1.11	1.11	NUM
admet-154	97	32	change	change	NOUN
admet-154	97	33	+34	+34	ADJ
admet-154	97	34	%	%	NOUN
admet-154	97	35	+170	+170	NUM
admet-154	97	36	%	%	NOUN
admet-154	97	37	40	40	NUM
admet-154	97	38	mg	mg	NUM
admet-154	97	39	/	/	SYM
admet-154	97	40	kg	kg	PROPN
admet-154	97	41	,	,	PUNCT
admet-154	97	42	oral	oral	ADJ
admet-154	97	43	control	control	NOUN
admet-154	97	44	1.76	1.76	NUM
admet-154	97	45	±	±	NUM
admet-154	97	46	0.01	0.01	NUM
admet-154	97	47	-0.26	-0.26	X
admet-154	97	48	±	±	NUM
admet-154	97	49	0.01	0.01	NUM
admet-154	97	50	1.0	1.0	NUM
admet-154	97	51	±	±	NUM
admet-154	97	52	0.87	0.87	NUM
admet-154	97	53	2.56	2.56	NUM
admet-154	97	54	±	±	NOUN
admet-154	97	55	0.19	0.19	NUM
admet-154	97	56	treated	treat	VERB
admet-154	97	57	2.30	2.30	NUM
admet-154	97	58	±	±	NUM
admet-154	97	59	0.30	0.30	NUM
admet-154	97	60	*	*	NOUN
admet-154	97	61	-0.56	-0.56	NUM
admet-154	97	62	±	±	NUM
admet-154	97	63	0.02	0.02	NUM
admet-154	97	64	*	*	SYM
admet-154	97	65	2	2	NUM
admet-154	97	66	2.35	2.35	NUM
admet-154	97	67	±	±	NOUN
admet-154	97	68	0.73	0.73	NUM
admet-154	97	69	change	change	NOUN
admet-154	97	70	+30	+30	ADJ
admet-154	97	71	%	%	NOUN
admet-154	97	72	+115	+115	NUM
admet-154	97	73	%	%	NOUN
admet-154	97	74	80	80	NUM
admet-154	97	75	mg	mg	PROPN
admet-154	97	76	/	/	SYM
admet-154	97	77	kg	kg	PROPN
admet-154	97	78	,	,	PUNCT
admet-154	97	79	oral	oral	ADJ
admet-154	97	80	control	control	NOUN
admet-154	97	81	1.81	1.81	NUM
admet-154	97	82	±	±	NUM
admet-154	97	83	0.30	0.30	NUM
admet-154	97	84	-0.48	-0.48	NUM
admet-154	97	85	±	±	NUM
admet-154	97	86	0.07	0.07	NUM
admet-154	97	87	2.8	2.8	NUM
admet-154	97	88	±	±	NUM
admet-154	97	89	0.45	0.45	NUM
admet-154	97	90	1.47	1.47	NUM
admet-154	97	91	±	±	NOUN
admet-154	97	92	0.35	0.35	NUM
admet-154	97	93	treated	treat	VERB
admet-154	97	94	2.99	2.99	NUM
admet-154	97	95	±	±	NUM
admet-154	97	96	0.34	0.34	NUM
admet-154	97	97	*	*	PUNCT
admet-154	97	98	-0.62	-0.62	NUM
admet-154	97	99	±	±	NUM
admet-154	97	100	0.06	0.06	NUM
admet-154	97	101	*	*	NUM
admet-154	97	102	4.2	4.2	NUM
admet-154	97	103	±	±	NUM
admet-154	97	104	1.64	1.64	NUM
admet-154	97	105	1.28	1.28	NUM
admet-154	97	106	±	±	NUM
admet-154	97	107	0.26	0.26	NUM
admet-154	97	108	change	change	NOUN
admet-154	97	109	+65	+65	PROPN
admet-154	97	110	%	%	NOUN
admet-154	97	111	+29	+29	NOUN
admet-154	97	112	%	%	NOUN
admet-154	97	113	discussion	discussion	NOUN
admet-154	97	114	oral	oral	ADJ
admet-154	97	115	anti	anti	ADJ
admet-154	97	116	-	-	ADJ
admet-154	97	117	cancer	cancer	ADJ
admet-154	97	118	chemotherapy	chemotherapy	NOUN
admet-154	97	119	has	have	AUX
admet-154	97	120	gained	gain	VERB
admet-154	97	121	wide	wide	ADJ
admet-154	97	122	acceptance	acceptance	NOUN
admet-154	97	123	and	and	CCONJ
admet-154	97	124	became	become	VERB
admet-154	97	125	standard	standard	ADJ
admet-154	97	126	approach	approach	NOUN
admet-154	97	127	for	for	ADP
admet-154	97	128	the	the	DET
admet-154	97	129	treatment	treatment	NOUN
admet-154	97	130	of	of	ADP
admet-154	97	131	cancer	cancer	NOUN
admet-154	97	132	due	due	ADP
admet-154	97	133	to	to	ADP
admet-154	97	134	various	various	ADJ
admet-154	97	135	advantages	advantage	NOUN
admet-154	97	136	such	such	ADJ
admet-154	97	137	as	as	ADP
admet-154	97	138	greater	great	ADJ
admet-154	97	139	safety	safety	NOUN
admet-154	97	140	and	and	CCONJ
admet-154	97	141	flexibility	flexibility	NOUN
admet-154	97	142	,	,	PUNCT
admet-154	97	143	more	more	ADV
admet-154	97	144	convenient	convenient	ADJ
admet-154	97	145	and	and	CCONJ
admet-154	97	146	cost	cost	NOUN
admet-154	97	147	-	-	PUNCT
admet-154	97	148	effectiveness	effectiveness	NOUN
admet-154	97	149	.	.	PUNCT
admet-154	98	1	unfortunately	unfortunately	ADV
admet-154	98	2	,	,	PUNCT
admet-154	98	3	the	the	DET
admet-154	98	4	majority	majority	NOUN
admet-154	98	5	of	of	ADP
admet-154	98	6	anticancer	anticancer	NOUN
admet-154	98	7	drugs	drug	NOUN
admet-154	98	8	have	have	VERB
admet-154	98	9	a	a	DET
admet-154	98	10	low	low	ADJ
admet-154	98	11	and	and	CCONJ
admet-154	98	12	highly	highly	ADV
admet-154	98	13	variable	variable	ADJ
admet-154	98	14	oral	oral	ADJ
admet-154	98	15	bioavailability	bioavailability	NOUN
admet-154	98	16	making	make	VERB
admet-154	98	17	intravenous	intravenous	ADJ
admet-154	98	18	route	route	NOUN
admet-154	98	19	as	as	ADP
admet-154	98	20	the	the	DET
admet-154	98	21	only	only	ADJ
admet-154	98	22	alternative	alternative	NOUN
admet-154	98	23	.	.	PUNCT
admet-154	99	1	data	datum	NOUN
admet-154	99	2	available	available	ADJ
admet-154	99	3	on	on	ADP
admet-154	99	4	irinotecan	irinotecan	ADJ
admet-154	99	5	absorption	absorption	NOUN
admet-154	99	6	and	and	CCONJ
admet-154	99	7	disposition	disposition	NOUN
admet-154	99	8	showed	show	VERB
admet-154	99	9	discouraging	discourage	VERB
admet-154	99	10	results	result	NOUN
admet-154	99	11	with	with	ADP
admet-154	99	12	variable	variable	ADJ
admet-154	99	13	absorption	absorption	NOUN
admet-154	99	14	,	,	PUNCT
admet-154	99	15	poor	poor	ADJ
admet-154	99	16	efficacy	efficacy	NOUN
admet-154	99	17	and	and	CCONJ
admet-154	99	18	toxicity	toxicity	NOUN
admet-154	99	19	profiles	profile	NOUN
admet-154	99	20	[	[	X
admet-154	99	21	7	7	NUM
admet-154	99	22	]	]	PUNCT
admet-154	99	23	.	.	PUNCT
admet-154	100	1	as	as	SCONJ
admet-154	100	2	a	a	DET
admet-154	100	3	result	result	NOUN
admet-154	100	4	novel	novel	NOUN
admet-154	100	5	formulations	formulation	NOUN
admet-154	100	6	of	of	ADP
admet-154	100	7	irinotecan	irinotecan	NOUN
admet-154	100	8	exhibiting	exhibit	VERB
admet-154	100	9	better	well	ADJ
admet-154	100	10	oral	oral	ADJ
admet-154	100	11	absorption	absorption	NOUN
admet-154	100	12	and	and	CCONJ
admet-154	100	13	bioavailability	bioavailability	NOUN
admet-154	100	14	need	need	VERB
admet-154	100	15	to	to	PART
admet-154	100	16	be	be	AUX
admet-154	100	17	developed	develop	VERB
admet-154	100	18	.	.	PUNCT
admet-154	101	1	verapamil	verapamil	NOUN
admet-154	101	2	is	be	AUX
admet-154	101	3	the	the	DET
admet-154	101	4	most	most	ADV
admet-154	101	5	extensively	extensively	ADV
admet-154	101	6	characterized	characterize	VERB
admet-154	101	7	p	p	NOUN
admet-154	101	8	-	-	PUNCT
admet-154	101	9	gp	gp	NOUN
admet-154	101	10	inhibitor	inhibitor	NOUN
admet-154	101	11	and	and	CCONJ
admet-154	101	12	multi	multi	ADJ
admet-154	101	13	-	-	ADJ
admet-154	101	14	drug	drug	ADJ
admet-154	101	15	resistance	resistance	NOUN
admet-154	101	16	(	(	PUNCT
admet-154	101	17	mdr	mdr	NOUN
admet-154	101	18	)	)	PUNCT
admet-154	101	19	reversal	reversal	NOUN
admet-154	101	20	agent	agent	NOUN
admet-154	101	21	that	that	PRON
admet-154	101	22	has	have	AUX
admet-154	101	23	entered	enter	VERB
admet-154	101	24	clinical	clinical	ADJ
admet-154	101	25	trials	trial	NOUN
admet-154	101	26	[	[	X
admet-154	101	27	8	8	NUM
admet-154	101	28	]	]	PUNCT
admet-154	101	29	.	.	PUNCT
admet-154	102	1	therefore	therefore	ADV
admet-154	102	2	,	,	PUNCT
admet-154	102	3	the	the	DET
admet-154	102	4	effect	effect	NOUN
admet-154	102	5	of	of	ADP
admet-154	102	6	co	co	NOUN
admet-154	102	7	-	-	NOUN
admet-154	102	8	administration	administration	NOUN
admet-154	102	9	of	of	ADP
admet-154	102	10	verapamil	verapamil	NOUN
admet-154	102	11	on	on	ADP
admet-154	102	12	the	the	DET
admet-154	102	13	oral	oral	ADJ
admet-154	102	14	bioavailability	bioavailability	NOUN
admet-154	102	15	and	and	CCONJ
admet-154	102	16	pharmacokinetics	pharmacokinetic	NOUN
admet-154	102	17	of	of	ADP
admet-154	102	18	irinotecan	irinotecan	NOUN
admet-154	102	19	at	at	ADP
admet-154	102	20	various	various	ADJ
admet-154	102	21	doses	dose	NOUN
admet-154	102	22	was	be	AUX
admet-154	102	23	the	the	DET
admet-154	102	24	subject	subject	NOUN
admet-154	102	25	of	of	ADP
admet-154	102	26	current	current	ADJ
admet-154	102	27	investigation	investigation	NOUN
admet-154	102	28	.	.	PUNCT
admet-154	103	1	the	the	DET
admet-154	103	2	irinotecan	irinotecan	PROPN
admet-154	103	3	auc	auc	NOUN
admet-154	103	4	increased	increase	VERB
admet-154	103	5	linearly	linearly	ADV
admet-154	103	6	with	with	ADP
admet-154	103	7	dose	dose	VERB
admet-154	103	8	from	from	ADP
admet-154	103	9	20	20	NUM
admet-154	103	10	to	to	PART
admet-154	103	11	80	80	NUM
admet-154	103	12	mg	mg	NUM
admet-154	103	13	/	/	SYM
admet-154	103	14	kg	kg	NOUN
admet-154	103	15	indicating	indicate	VERB
admet-154	103	16	linear	linear	ADJ
admet-154	103	17	pharmacokinetics	pharmacokinetic	NOUN
admet-154	103	18	.	.	PUNCT
admet-154	104	1	after	after	ADP
admet-154	104	2	treatment	treatment	NOUN
admet-154	104	3	with	with	ADP
admet-154	104	4	verapamil	verapamil	NOUN
admet-154	104	5	,	,	PUNCT
admet-154	104	6	irinotecan	irinotecan	NOUN
admet-154	104	7	increased	increase	VERB
admet-154	104	8	linearly	linearly	ADV
admet-154	104	9	with	with	ADP
admet-154	104	10	dose	dose	VERB
admet-154	104	11	from	from	ADP
admet-154	104	12	20	20	NUM
admet-154	104	13	to	to	PART
admet-154	104	14	40	40	NUM
admet-154	104	15	mg	mg	PROPN
admet-154	104	16	/	/	SYM
admet-154	104	17	kg	kg	PROPN
admet-154	104	18	,	,	PUNCT
admet-154	104	19	but	but	CCONJ
admet-154	104	20	from	from	ADP
admet-154	104	21	40	40	NUM
admet-154	104	22	to	to	PART
admet-154	104	23	80	80	NUM
admet-154	104	24	mg	mg	NOUN
admet-154	104	25	/	/	SYM
admet-154	104	26	kg	kg	NOUN
admet-154	104	27	the	the	DET
admet-154	104	28	irinotecan	irinotecan	NOUN
admet-154	104	29	auc	auc	X
admet-154	104	30	increased	increase	VERB
admet-154	104	31	non	non	ADJ
admet-154	104	32	-	-	ADJ
admet-154	104	33	linearly	linearly	ADJ
admet-154	104	34	(	(	PUNCT
admet-154	104	35	i.e.	i.e.	X
admet-154	104	36	twofold	twofold	ADV
admet-154	104	37	increase	increase	NOUN
admet-154	104	38	in	in	ADP
admet-154	104	39	dose	dose	NOUN
admet-154	104	40	,	,	PUNCT
admet-154	104	41	sevenfold	sevenfold	ADJ
admet-154	104	42	increase	increase	NOUN
admet-154	104	43	in	in	ADP
admet-154	104	44	auc	auc	NOUN
admet-154	104	45	)	)	PUNCT
admet-154	104	46	.	.	PUNCT
admet-154	105	1	overall	overall	ADV
admet-154	105	2	,	,	PUNCT
admet-154	105	3	the	the	DET
admet-154	105	4	oral	oral	ADJ
admet-154	105	5	combination	combination	NOUN
admet-154	105	6	of	of	ADP
admet-154	105	7	irinotecan	irinotecan	NOUN
admet-154	105	8	with	with	ADP
admet-154	105	9	verapamil	verapamil	NOUN
admet-154	105	10	was	be	AUX
admet-154	105	11	well	well	ADV
admet-154	105	12	tolerated	tolerate	VERB
admet-154	105	13	in	in	ADP
admet-154	105	14	rat	rat	NOUN
admet-154	105	15	without	without	ADP
admet-154	105	16	acute	acute	ADJ
admet-154	105	17	toxicities	toxicity	NOUN
admet-154	105	18	.	.	PUNCT
admet-154	106	1	a	a	DET
admet-154	106	2	disproportionate	disproportionate	ADJ
admet-154	106	3	increase	increase	NOUN
admet-154	106	4	in	in	ADP
admet-154	106	5	oral	oral	ADJ
admet-154	106	6	bioavailability	bioavailability	NOUN
admet-154	106	7	was	be	AUX
admet-154	106	8	seen	see	VERB
admet-154	106	9	at	at	ADP
admet-154	106	10	80	80	NUM
admet-154	106	11	mg	mg	NOUN
admet-154	106	12	/	/	SYM
admet-154	106	13	kg	kg	NOUN
admet-154	106	14	with	with	ADP
admet-154	106	15	the	the	DET
admet-154	106	16	same	same	ADJ
admet-154	106	17	dose	dose	NOUN
admet-154	106	18	of	of	ADP
admet-154	106	19	p	p	NOUN
admet-154	106	20	-	-	PUNCT
admet-154	106	21	gp	gp	NOUN
admet-154	106	22	inhibitor	inhibitor	NOUN
admet-154	106	23	(	(	PUNCT
admet-154	106	24	four	four	NUM
admet-154	106	25	fold	fold	ADJ
admet-154	106	26	increase	increase	NOUN
admet-154	106	27	in	in	ADP
admet-154	106	28	irinotecan	irinotecan	PROPN
admet-154	106	29	dose	dose	PROPN
admet-154	106	30	resulted	result	VERB
admet-154	106	31	in	in	ADP
admet-154	106	32	sevenfold	sevenfold	ADJ
admet-154	106	33	increase	increase	NOUN
admet-154	106	34	in	in	ADP
admet-154	106	35	auc	auc	NOUN
admet-154	106	36	)	)	PUNCT
admet-154	106	37	.	.	PUNCT
admet-154	107	1	the	the	DET
admet-154	107	2	increase	increase	NOUN
admet-154	107	3	in	in	ADP
admet-154	107	4	systemic	systemic	ADJ
admet-154	107	5	exposure	exposure	NOUN
admet-154	107	6	to	to	ADP
admet-154	107	7	irinotecan	irinotecan	NOUN
admet-154	107	8	in	in	ADP
admet-154	107	9	combination	combination	NOUN
admet-154	107	10	with	with	ADP
admet-154	107	11	verapamil	verapamil	NOUN
admet-154	107	12	is	be	AUX
admet-154	107	13	of	of	ADP
admet-154	107	14	the	the	DET
admet-154	107	15	same	same	ADJ
admet-154	107	16	order	order	NOUN
admet-154	107	17	of	of	ADP
admet-154	107	18	magnitude	magnitude	NOUN
admet-154	107	19	as	as	ADP
admet-154	107	20	that	that	PRON
admet-154	107	21	with	with	ADP
admet-154	107	22	high	high	ADJ
admet-154	107	23	dose	dose	NOUN
admet-154	107	24	of	of	ADP
admet-154	107	25	irinotecan	irinotecan	NOUN
admet-154	107	26	.	.	PUNCT
admet-154	108	1	p	p	X
admet-154	108	2	-	-	PUNCT
admet-154	108	3	gp	gp	NOUN
admet-154	108	4	inhibition	inhibition	NOUN
admet-154	108	5	may	may	AUX
admet-154	108	6	enable	enable	VERB
admet-154	108	7	chronic	chronic	ADJ
admet-154	108	8	oral	oral	ADJ
admet-154	108	9	therapy	therapy	NOUN
admet-154	108	10	with	with	ADP
admet-154	108	11	irinotecan	irinotecan	PROPN
admet-154	108	12	.	.	PUNCT
admet-154	109	1	however	however	ADV
admet-154	109	2	,	,	PUNCT
admet-154	109	3	safe	safe	ADJ
admet-154	109	4	p	p	NOUN
admet-154	109	5	-	-	PUNCT
admet-154	109	6	gp	gp	NOUN
admet-154	109	7	inhibitors	inhibitor	NOUN
admet-154	109	8	need	need	VERB
admet-154	109	9	to	to	PART
admet-154	109	10	be	be	AUX
admet-154	109	11	identified	identify	VERB
admet-154	109	12	as	as	ADP
admet-154	109	13	alternatives	alternative	NOUN
admet-154	109	14	to	to	ADP
admet-154	109	15	verapamil	verapamil	NOUN
admet-154	109	16	.	.	PUNCT
admet-154	110	1	this	this	PRON
admet-154	110	2	was	be	AUX
admet-154	110	3	tested	test	VERB
admet-154	110	4	by	by	ADP
admet-154	110	5	decreasing	decrease	VERB
admet-154	110	6	the	the	DET
admet-154	110	7	dose	dose	NOUN
admet-154	110	8	in	in	ADP
admet-154	110	9	the	the	DET
admet-154	110	10	same	same	ADJ
admet-154	110	11	proportion	proportion	NOUN
admet-154	110	12	as	as	ADP
admet-154	110	13	clearance	clearance	NOUN
admet-154	110	14	of	of	ADP
admet-154	110	15	irinotecan	irinotecan	NOUN
admet-154	110	16	is	be	AUX
admet-154	110	17	decreased	decrease	VERB
admet-154	110	18	by	by	ADP
admet-154	110	19	verapamil	verapamil	PROPN
admet-154	110	20	administration	administration	NOUN
admet-154	110	21	.	.	PUNCT
admet-154	111	1	irinotecan	irinotecan	PROPN
admet-154	111	2	has	have	AUX
admet-154	111	3	been	be	AUX
admet-154	111	4	reported	report	VERB
admet-154	111	5	to	to	PART
admet-154	111	6	undergo	undergo	VERB
admet-154	111	7	metabolic	metabolic	NOUN
admet-154	111	8	saturation	saturation	NOUN
admet-154	111	9	(	(	PUNCT
admet-154	111	10	non	non	ADJ
admet-154	111	11	-	-	ADJ
admet-154	111	12	linear	linear	ADJ
admet-154	111	13	clearance	clearance	NOUN
admet-154	111	14	)	)	PUNCT
admet-154	111	15	at	at	ADP
admet-154	111	16	higher	high	ADJ
admet-154	111	17	concentrations	concentration	NOUN
admet-154	111	18	which	which	PRON
admet-154	111	19	were	be	AUX
admet-154	111	20	achievable	achievable	ADJ
admet-154	111	21	in	in	ADP
admet-154	111	22	this	this	DET
admet-154	111	23	study	study	NOUN
admet-154	111	24	,	,	PUNCT
admet-154	111	25	by	by	ADP
admet-154	111	26	verapamil	verapamil	NOUN
admet-154	111	27	pre	pre	NOUN
admet-154	111	28	-	-	NOUN
admet-154	111	29	treatment	treatment	ADJ
admet-154	111	30	[	[	X
admet-154	111	31	9	9	NUM
admet-154	111	32	]	]	PUNCT
admet-154	111	33	.	.	PUNCT
admet-154	112	1	the	the	DET
admet-154	112	2	irinotecan	irinotecan	PROPN
admet-154	112	3	admet	admet	PROPN
admet-154	112	4	&	&	CCONJ
admet-154	112	5	dmpk	dmpk	PROPN
admet-154	112	6	3(1	3(1	NUM
admet-154	112	7	)	)	PUNCT
admet-154	112	8	(	(	PUNCT
admet-154	112	9	2015	2015	NUM
admet-154	112	10	)	)	PUNCT
admet-154	112	11	68	68	NUM
admet-154	112	12	-	-	SYM
admet-154	112	13	76	76	NUM
admet-154	112	14	p	p	NOUN
admet-154	112	15	-	-	PUNCT
admet-154	112	16	gp	gp	NOUN
admet-154	112	17	pharmacokinetics	pharmacokinetic	NOUN
admet-154	112	18	of	of	ADP
admet-154	112	19	irinotecan	irinotecan	PROPN
admet-154	112	20	doi	doi	PROPN
admet-154	112	21	:	:	PUNCT
admet-154	112	22	10.5599	10.5599	NUM
admet-154	112	23	/	/	SYM
admet-154	112	24	admet.3.1.154	admet.3.1.154	PROPN
admet-154	112	25	75	75	NUM
admet-154	112	26	clearance	clearance	NOUN
admet-154	112	27	in	in	ADP
admet-154	112	28	the	the	DET
admet-154	112	29	control	control	NOUN
admet-154	112	30	groups	group	NOUN
admet-154	112	31	was	be	AUX
admet-154	112	32	unaffected	unaffected	ADJ
admet-154	112	33	by	by	ADP
admet-154	112	34	the	the	DET
admet-154	112	35	increase	increase	NOUN
admet-154	112	36	in	in	ADP
admet-154	112	37	dose	dose	NOUN
admet-154	112	38	and	and	CCONJ
admet-154	112	39	remained	remain	VERB
admet-154	112	40	almost	almost	ADV
admet-154	112	41	constant	constant	ADJ
admet-154	112	42	.	.	PUNCT
admet-154	113	1	the	the	DET
admet-154	113	2	decrease	decrease	NOUN
admet-154	113	3	in	in	ADP
admet-154	113	4	irinotecan	irinotecan	ADJ
admet-154	113	5	clearance	clearance	NOUN
admet-154	113	6	following	follow	VERB
admet-154	113	7	verapamil	verapamil	NOUN
admet-154	113	8	pre	pre	NOUN
admet-154	113	9	-	-	NOUN
admet-154	113	10	treatment	treatment	NOUN
admet-154	113	11	is	be	AUX
admet-154	113	12	~50	~50	NUM
admet-154	113	13	%	%	NOUN
admet-154	113	14	at	at	ADP
admet-154	113	15	both	both	PRON
admet-154	113	16	20	20	NUM
admet-154	113	17	and	and	CCONJ
admet-154	113	18	40	40	NUM
admet-154	113	19	mg	mg	NUM
admet-154	113	20	/	/	SYM
admet-154	113	21	kg	kg	PROPN
admet-154	113	22	.	.	PUNCT
admet-154	114	1	however	however	ADV
admet-154	114	2	,	,	PUNCT
admet-154	114	3	~80	~80	X
admet-154	114	4	%	%	NOUN
admet-154	114	5	decrease	decrease	NOUN
admet-154	114	6	in	in	ADP
admet-154	114	7	irinotecan	irinotecan	ADJ
admet-154	114	8	clearance	clearance	NOUN
admet-154	114	9	is	be	AUX
admet-154	114	10	observed	observe	VERB
admet-154	114	11	at	at	ADP
admet-154	114	12	80	80	NUM
admet-154	114	13	mg	mg	PROPN
admet-154	114	14	/	/	SYM
admet-154	114	15	kg	kg	PROPN
admet-154	114	16	.	.	PUNCT
admet-154	115	1	hydrolysis	hydrolysis	NOUN
admet-154	115	2	of	of	ADP
admet-154	115	3	irinotecan	irinotecan	NOUN
admet-154	115	4	by	by	ADP
admet-154	115	5	carboxylesterase	carboxylesterase	NOUN
admet-154	115	6	enzyme	enzyme	NOUN
admet-154	115	7	has	have	AUX
admet-154	115	8	been	be	AUX
admet-154	115	9	reported	report	VERB
admet-154	115	10	to	to	PART
admet-154	115	11	be	be	AUX
admet-154	115	12	responsible	responsible	ADJ
admet-154	115	13	for	for	ADP
admet-154	115	14	the	the	DET
admet-154	115	15	conversion	conversion	NOUN
admet-154	115	16	of	of	ADP
admet-154	115	17	irinotecan	irinotecan	NOUN
admet-154	115	18	to	to	PART
admet-154	115	19	sn-38	sn-38	VERB
admet-154	116	1	[	[	X
admet-154	116	2	7	7	NUM
admet-154	116	3	]	]	PUNCT
admet-154	116	4	.	.	PUNCT
admet-154	117	1	the	the	DET
admet-154	117	2	detecachievabletion	detecachievabletion	NOUN
admet-154	117	3	of	of	ADP
admet-154	117	4	sn-38	sn-38	NOUN
admet-154	117	5	at	at	ADP
admet-154	117	6	early	early	ADJ
admet-154	117	7	time	time	NOUN
admet-154	117	8	points	point	NOUN
admet-154	117	9	may	may	AUX
admet-154	117	10	be	be	AUX
admet-154	117	11	a	a	DET
admet-154	117	12	consequence	consequence	NOUN
admet-154	117	13	of	of	ADP
admet-154	117	14	the	the	DET
admet-154	117	15	presence	presence	NOUN
admet-154	117	16	of	of	ADP
admet-154	117	17	carboxylesterase	carboxylesterase	NOUN
admet-154	117	18	in	in	ADP
admet-154	117	19	rat	rat	NOUN
admet-154	117	20	plasma	plasma	NOUN
admet-154	117	21	,	,	PUNCT
admet-154	117	22	first	first	ADV
admet-154	117	23	pass	pass	VERB
admet-154	117	24	metabolism	metabolism	NOUN
admet-154	117	25	of	of	ADP
admet-154	117	26	irinotecan	irinotecan	NOUN
admet-154	117	27	or	or	CCONJ
admet-154	117	28	metabolism	metabolism	NOUN
admet-154	117	29	of	of	ADP
admet-154	117	30	irinotecan	irinotecan	NOUN
admet-154	117	31	by	by	ADP
admet-154	117	32	intestinal	intestinal	ADJ
admet-154	117	33	carboxylesterase	carboxylesterase	NOUN
admet-154	117	34	,	,	PUNCT
admet-154	117	35	and	and	CCONJ
admet-154	117	36	subsequent	subsequent	ADJ
admet-154	117	37	absorption	absorption	NOUN
admet-154	117	38	of	of	ADP
admet-154	117	39	sn-38	sn-38	NOUN
admet-154	117	40	.	.	PUNCT
admet-154	118	1	the	the	DET
admet-154	118	2	less	less	ADJ
admet-154	118	3	than	than	ADP
admet-154	118	4	proportional	proportional	ADJ
admet-154	118	5	increase	increase	NOUN
admet-154	118	6	in	in	ADP
admet-154	118	7	sn-38	sn-38	NOUN
admet-154	118	8	auc	auc	NOUN
admet-154	118	9	from	from	ADP
admet-154	118	10	20	20	NUM
admet-154	118	11	to	to	PART
admet-154	118	12	80	80	NUM
admet-154	118	13	mg	mg	NOUN
admet-154	118	14	/	/	SYM
admet-154	118	15	kg	kg	PROPN
admet-154	118	16	is	be	AUX
admet-154	118	17	consistent	consistent	ADJ
admet-154	118	18	with	with	ADP
admet-154	118	19	the	the	DET
admet-154	118	20	saturation	saturation	NOUN
admet-154	118	21	of	of	ADP
admet-154	118	22	carboxylesterase	carboxylesterase	NOUN
admet-154	119	1	[	[	X
admet-154	119	2	9	9	NUM
admet-154	119	3	]	]	PUNCT
admet-154	119	4	.	.	PUNCT
admet-154	120	1	figure	figure	VERB
admet-154	120	2	3	3	NUM
admet-154	120	3	.	.	PUNCT
admet-154	121	1	role	role	NOUN
admet-154	121	2	of	of	ADP
admet-154	121	3	p	p	NOUN
admet-154	121	4	-	-	PUNCT
admet-154	121	5	gp	gp	NOUN
admet-154	121	6	in	in	ADP
admet-154	121	7	determining	determine	VERB
admet-154	121	8	pharmacokinetics	pharmacokinetic	NOUN
admet-154	121	9	of	of	ADP
admet-154	121	10	irinotecan	irinotecan	NOUN
admet-154	121	11	(	(	PUNCT
admet-154	121	12	cpt-11	cpt-11	NUM
admet-154	121	13	)	)	PUNCT
admet-154	121	14	after	after	ADP
admet-154	121	15	oral	oral	ADJ
admet-154	121	16	and	and	CCONJ
admet-154	121	17	intravenous	intravenous	ADJ
admet-154	121	18	(	(	PUNCT
admet-154	121	19	i.v	i.v	NOUN
admet-154	121	20	)	)	PUNCT
admet-154	121	21	administration	administration	NOUN
admet-154	121	22	.	.	PUNCT
admet-154	122	1	p	p	X
admet-154	122	2	-	-	PUNCT
admet-154	122	3	gp	gp	NOUN
admet-154	122	4	is	be	AUX
admet-154	122	5	present	present	ADJ
admet-154	122	6	in	in	ADP
admet-154	122	7	intestinal	intestinal	ADJ
admet-154	122	8	epithelium	epithelium	NOUN
admet-154	122	9	affecting	affect	VERB
admet-154	122	10	absorption	absorption	NOUN
admet-154	122	11	;	;	PUNCT
admet-154	122	12	in	in	ADP
admet-154	122	13	hepatocytes	hepatocyte	NOUN
admet-154	122	14	affecting	affect	VERB
admet-154	122	15	metabolism	metabolism	NOUN
admet-154	122	16	and	and	CCONJ
admet-154	122	17	at	at	ADP
admet-154	122	18	biliary	biliary	ADJ
admet-154	122	19	canalicular	canalicular	ADJ
admet-154	122	20	surface	surface	NOUN
admet-154	122	21	affecting	affect	VERB
admet-154	122	22	excretion	excretion	NOUN
admet-154	122	23	.	.	PUNCT
admet-154	123	1	in	in	ADP
admet-154	123	2	addition	addition	NOUN
admet-154	123	3	,	,	PUNCT
admet-154	123	4	gastro	gastro	NOUN
admet-154	123	5	-	-	PUNCT
admet-154	123	6	intestinal	intestinal	ADJ
admet-154	123	7	toxicity	toxicity	NOUN
admet-154	123	8	of	of	ADP
admet-154	123	9	irinotecan	irinotecan	NOUN
admet-154	123	10	is	be	AUX
admet-154	123	11	proposed	propose	VERB
admet-154	123	12	to	to	PART
admet-154	123	13	be	be	AUX
admet-154	123	14	caused	cause	VERB
admet-154	123	15	by	by	ADP
admet-154	123	16	biliary	biliary	ADJ
admet-154	123	17	excretion	excretion	NOUN
admet-154	123	18	of	of	ADP
admet-154	123	19	its	its	PRON
admet-154	123	20	major	major	ADJ
admet-154	123	21	active	active	ADJ
admet-154	123	22	(	(	PUNCT
admet-154	123	23	100	100	NUM
admet-154	123	24	-	-	SYM
admet-154	123	25	1000	1000	NUM
admet-154	123	26	times	time	NOUN
admet-154	123	27	)	)	PUNCT
admet-154	123	28	metabolite	metabolite	NOUN
admet-154	123	29	,	,	PUNCT
admet-154	123	30	sn-38	sn-38	NOUN
admet-154	123	31	;	;	PUNCT
admet-154	123	32	and	and	CCONJ
admet-154	123	33	its	its	PRON
admet-154	123	34	glucuronide	glucuronide	ADJ
admet-154	123	35	(	(	PUNCT
admet-154	123	36	sn-38	sn-38	NOUN
admet-154	123	37	g	g	NOUN
admet-154	123	38	)	)	PUNCT
admet-154	123	39	.	.	PUNCT
admet-154	124	1	p	p	X
admet-154	124	2	-	-	PUNCT
admet-154	124	3	gp	gp	NOUN
admet-154	124	4	inhibition	inhibition	NOUN
admet-154	124	5	at	at	ADP
admet-154	124	6	both	both	CCONJ
admet-154	124	7	intestine	intestine	ADJ
admet-154	124	8	and	and	CCONJ
admet-154	124	9	bile	bile	NOUN
admet-154	124	10	eliminates	eliminate	NOUN
admet-154	124	11	first	first	ADJ
admet-154	124	12	pass	pass	NOUN
admet-154	124	13	effect	effect	NOUN
admet-154	124	14	,	,	PUNCT
admet-154	124	15	resulting	result	VERB
admet-154	124	16	in	in	ADP
admet-154	124	17	increased	increase	VERB
admet-154	124	18	oral	oral	ADJ
admet-154	124	19	absorption	absorption	NOUN
admet-154	124	20	and	and	CCONJ
admet-154	124	21	systemic	systemic	ADJ
admet-154	124	22	exposure	exposure	NOUN
admet-154	124	23	.	.	PUNCT
admet-154	125	1	diarrhea	diarrhea	NOUN
admet-154	125	2	could	could	AUX
admet-154	125	3	also	also	ADV
admet-154	125	4	be	be	AUX
admet-154	125	5	ameliorated	ameliorate	VERB
admet-154	125	6	due	due	ADJ
admet-154	125	7	to	to	ADP
admet-154	125	8	inhibition	inhibition	NOUN
admet-154	125	9	of	of	ADP
admet-154	125	10	biliary	biliary	ADJ
admet-154	125	11	excretion	excretion	NOUN
admet-154	125	12	of	of	ADP
admet-154	125	13	metabolite	metabolite	NOUN
admet-154	125	14	causing	cause	VERB
admet-154	125	15	decreased	decrease	VERB
admet-154	125	16	accumulation	accumulation	NOUN
admet-154	125	17	in	in	ADP
admet-154	125	18	conclusion	conclusion	NOUN
admet-154	125	19	,	,	PUNCT
admet-154	125	20	p	p	NOUN
admet-154	125	21	-	-	PUNCT
admet-154	125	22	gp	gp	NOUN
admet-154	125	23	in	in	ADP
admet-154	125	24	the	the	DET
admet-154	125	25	gastro	gastro	ADJ
admet-154	125	26	-	-	PUNCT
admet-154	125	27	intestinal	intestinal	ADJ
admet-154	125	28	mucosa	mucosa	NOUN
admet-154	125	29	limits	limit	VERB
admet-154	125	30	the	the	DET
admet-154	125	31	absorption	absorption	NOUN
admet-154	125	32	of	of	ADP
admet-154	125	33	orally	orally	ADV
admet-154	125	34	administered	administer	VERB
admet-154	125	35	xenobiotics	xenobiotic	NOUN
admet-154	125	36	and	and	CCONJ
admet-154	125	37	at	at	ADP
admet-154	125	38	least	least	ADJ
admet-154	125	39	in	in	ADP
admet-154	125	40	part	part	NOUN
admet-154	125	41	,	,	PUNCT
admet-154	125	42	due	due	ADP
admet-154	125	43	to	to	ADP
admet-154	125	44	its	its	PRON
admet-154	125	45	high	high	ADJ
admet-154	125	46	affinity	affinity	NOUN
admet-154	125	47	for	for	ADP
admet-154	125	48	p	p	NOUN
admet-154	125	49	-	-	PUNCT
admet-154	125	50	gp	gp	NOUN
admet-154	125	51	efflux	efflux	NOUN
admet-154	125	52	pump	pump	NOUN
admet-154	125	53	.	.	PUNCT
admet-154	126	1	the	the	DET
admet-154	126	2	observed	observed	ADJ
admet-154	126	3	effect	effect	NOUN
admet-154	126	4	may	may	AUX
admet-154	126	5	be	be	AUX
admet-154	126	6	beneficial	beneficial	ADJ
admet-154	126	7	in	in	ADP
admet-154	126	8	a	a	DET
admet-154	126	9	way	way	NOUN
admet-154	126	10	to	to	PART
admet-154	126	11	develop	develop	VERB
admet-154	126	12	oral	oral	ADJ
admet-154	126	13	irinotecan	irinotecan	NOUN
admet-154	126	14	dosage	dosage	NOUN
admet-154	126	15	forms	form	NOUN
admet-154	126	16	using	use	VERB
admet-154	126	17	safe	safe	ADJ
admet-154	126	18	p	p	NOUN
admet-154	126	19	-	-	PUNCT
admet-154	126	20	gp	gp	NOUN
admet-154	126	21	inhibitors	inhibitor	NOUN
admet-154	126	22	to	to	PART
admet-154	126	23	improve	improve	VERB
admet-154	126	24	its	its	PRON
admet-154	126	25	oral	oral	ADJ
admet-154	126	26	bioavailability	bioavailability	NOUN
admet-154	126	27	.	.	PUNCT
admet-154	127	1	clinically	clinically	ADV
admet-154	127	2	,	,	PUNCT
admet-154	127	3	concomitant	concomitant	ADJ
admet-154	127	4	verapamil	verapamil	NOUN
admet-154	127	5	and	and	CCONJ
admet-154	127	6	irinotecan	irinotecan	ADJ
admet-154	127	7	treatment	treatment	NOUN
admet-154	127	8	would	would	AUX
admet-154	127	9	allow	allow	VERB
admet-154	127	10	dose	dose	NOUN
admet-154	127	11	reduction	reduction	NOUN
admet-154	127	12	(	(	PUNCT
admet-154	127	13	about	about	ADV
admet-154	127	14	50	50	NUM
admet-154	127	15	-	-	SYM
admet-154	127	16	80	80	NUM
admet-154	127	17	%	%	NOUN
admet-154	127	18	)	)	PUNCT
admet-154	127	19	and	and	CCONJ
admet-154	127	20	still	still	ADV
admet-154	127	21	achieve	achieve	VERB
admet-154	127	22	comparable	comparable	ADJ
admet-154	127	23	exposure	exposure	NOUN
admet-154	127	24	of	of	ADP
admet-154	127	25	irinotecan	irinotecan	NOUN
admet-154	127	26	.	.	PUNCT
admet-154	128	1	more	more	ADV
admet-154	128	2	importantly	importantly	ADV
admet-154	128	3	,	,	PUNCT
admet-154	128	4	the	the	DET
admet-154	128	5	risk	risk	NOUN
admet-154	128	6	of	of	ADP
admet-154	128	7	intestinal	intestinal	ADJ
admet-154	128	8	toxicity	toxicity	NOUN
admet-154	128	9	could	could	AUX
admet-154	128	10	be	be	AUX
admet-154	128	11	substantially	substantially	ADV
admet-154	128	12	reduced	reduce	VERB
admet-154	128	13	because	because	SCONJ
admet-154	128	14	of	of	ADP
admet-154	128	15	reduced	reduce	VERB
admet-154	128	16	dose	dose	NOUN
admet-154	128	17	and	and	CCONJ
admet-154	128	18	lowered	lower	VERB
admet-154	128	19	biliary	biliary	NOUN
admet-154	128	20	secretion	secretion	NOUN
admet-154	128	21	and	and	CCONJ
admet-154	128	22	accumulation	accumulation	NOUN
admet-154	128	23	(	(	PUNCT
admet-154	128	24	figure	figure	NOUN
admet-154	128	25	3	3	NUM
admet-154	128	26	)	)	PUNCT
admet-154	128	27	.	.	PUNCT
admet-154	129	1	the	the	DET
admet-154	129	2	results	result	NOUN
admet-154	129	3	of	of	ADP
admet-154	129	4	this	this	DET
admet-154	129	5	study	study	NOUN
admet-154	129	6	could	could	AUX
admet-154	129	7	be	be	AUX
admet-154	129	8	utilized	utilize	VERB
admet-154	129	9	to	to	PART
admet-154	129	10	evaluate	evaluate	VERB
admet-154	129	11	different	different	ADJ
admet-154	129	12	dosing	dosing	ADJ
admet-154	129	13	strategies	strategy	NOUN
admet-154	129	14	and	and	CCONJ
admet-154	129	15	methods	method	NOUN
admet-154	129	16	of	of	ADP
admet-154	129	17	administration	administration	NOUN
admet-154	129	18	for	for	ADP
admet-154	129	19	irinotecan	irinotecan	NOUN
admet-154	129	20	in	in	ADP
admet-154	129	21	humans	human	NOUN
admet-154	129	22	.	.	PUNCT
admet-154	130	1	oral	oral	ADJ
admet-154	130	2	formulations	formulation	NOUN
admet-154	130	3	of	of	ADP
admet-154	130	4	irinotecan	irinotecan	NOUN
admet-154	130	5	having	have	VERB
admet-154	130	6	better	well	ADJ
admet-154	130	7	efficacy	efficacy	NOUN
admet-154	130	8	and	and	CCONJ
admet-154	130	9	less	less	ADJ
admet-154	130	10	toxicity	toxicity	NOUN
admet-154	130	11	could	could	AUX
admet-154	130	12	be	be	AUX
admet-154	130	13	developed	develop	VERB
admet-154	130	14	using	use	VERB
admet-154	130	15	appropriate	appropriate	ADJ
admet-154	130	16	p	p	NOUN
admet-154	130	17	-	-	PUNCT
admet-154	130	18	gp	gp	NOUN
admet-154	130	19	inhibitor	inhibitor	NOUN
admet-154	130	20	.	.	PUNCT
admet-154	131	1	however	however	ADV
admet-154	131	2	,	,	PUNCT
admet-154	131	3	further	further	PROPN
admet-154	131	4	garg	garg	PROPN
admet-154	131	5	et	et	PROPN
admet-154	131	6	al	al	PROPN
admet-154	131	7	.	.	PROPN
admet-154	131	8	admet	admet	PROPN
admet-154	131	9	&	&	CCONJ
admet-154	131	10	dmpk	dmpk	PROPN
admet-154	131	11	3(1	3(1	NUM
admet-154	131	12	)	)	PUNCT
admet-154	131	13	(	(	PUNCT
admet-154	131	14	2015	2015	NUM
admet-154	131	15	)	)	PUNCT
admet-154	131	16	68	68	NUM
admet-154	131	17	-	-	SYM
admet-154	131	18	76	76	NUM
admet-154	131	19	76	76	NUM
admet-154	131	20	studies	study	NOUN
admet-154	131	21	are	be	AUX
admet-154	131	22	required	require	VERB
admet-154	131	23	to	to	PART
admet-154	131	24	compare	compare	VERB
admet-154	131	25	the	the	DET
admet-154	131	26	efficacy	efficacy	NOUN
admet-154	131	27	of	of	ADP
admet-154	131	28	verapamil	verapamil	NOUN
admet-154	131	29	with	with	ADP
admet-154	131	30	other	other	ADJ
admet-154	131	31	novel	novel	NOUN
admet-154	131	32	p	p	NOUN
admet-154	131	33	-	-	PUNCT
admet-154	131	34	gp	gp	NOUN
admet-154	131	35	inhibitors	inhibitor	NOUN
admet-154	131	36	to	to	PART
admet-154	131	37	enable	enable	VERB
admet-154	131	38	pharmacokinetic	pharmacokinetic	ADJ
admet-154	131	39	modulation	modulation	NOUN
admet-154	131	40	of	of	ADP
admet-154	131	41	irinotecan	irinotecan	NOUN
admet-154	131	42	and	and	CCONJ
admet-154	131	43	its	its	PRON
admet-154	131	44	metabolites	metabolite	NOUN
admet-154	131	45	.	.	PUNCT
admet-154	132	1	references	reference	NOUN
admet-154	132	2	[	[	X
admet-154	132	3	1	1	NUM
admet-154	132	4	]	]	X
admet-154	132	5	r.l	r.l	PROPN
admet-154	132	6	.	.	PROPN
admet-154	132	7	drengler	drengler	PROPN
admet-154	132	8	,	,	PUNCT
admet-154	132	9	j.g	j.g	PROPN
admet-154	132	10	.	.	PROPN
admet-154	132	11	kuhn	kuhn	PROPN
admet-154	132	12	,	,	PUNCT
admet-154	132	13	l.j	l.j	PROPN
admet-154	132	14	.	.	PROPN
admet-154	132	15	schaaf	schaaf	PROPN
admet-154	132	16	,	,	PUNCT
admet-154	132	17	g.i	g.i	PROPN
admet-154	132	18	.	.	PROPN
admet-154	132	19	rodriguez	rodriguez	PROPN
admet-154	132	20	,	,	PUNCT
admet-154	132	21	m.a	m.a	PROPN
admet-154	132	22	.	.	PROPN
admet-154	132	23	villalona	villalona	PROPN
admet-154	132	24	-	-	PUNCT
admet-154	132	25	calero	calero	PROPN
admet-154	132	26	,	,	PUNCT
admet-154	132	27	l.a	l.a	PROPN
admet-154	132	28	.	.	PROPN
admet-154	132	29	hammond	hammond	PROPN
admet-154	132	30	,	,	PUNCT
admet-154	132	31	j.a	j.a	PROPN
admet-154	132	32	.	.	PROPN
admet-154	132	33	stephenson	stephenson	PROPN
admet-154	132	34	jr	jr	PROPN
admet-154	132	35	,	,	PUNCT
admet-154	132	36	s.	s.	PROPN
admet-154	132	37	hodge	hodge	PROPN
admet-154	132	38	,	,	PUNCT
admet-154	132	39	m.a	m.a	PROPN
admet-154	132	40	.	.	PROPN
admet-154	132	41	kraynak	kraynak	PROPN
admet-154	132	42	,	,	PUNCT
admet-154	132	43	b.a	b.a	PROPN
admet-154	132	44	.	.	PROPN
admet-154	132	45	statona	statona	PROPN
admet-154	132	46	,	,	PUNCT
admet-154	132	47	g.l	g.l	PROPN
admet-154	132	48	.	.	PROPN
admet-154	132	49	elfring	elfring	PROPN
admet-154	132	50	,	,	PUNCT
admet-154	132	51	p.k	p.k	PROPN
admet-154	132	52	.	.	PROPN
admet-154	132	53	locker	locker	PROPN
admet-154	132	54	,	,	PUNCT
admet-154	132	55	l.l	l.l	PROPN
admet-154	132	56	.	.	PROPN
admet-154	132	57	miller	miller	PROPN
admet-154	132	58	,	,	PUNCT
admet-154	132	59	d.d	d.d	PROPN
admet-154	132	60	.	.	PROPN
admet-154	132	61	von	von	PROPN
admet-154	132	62	hoff	hoff	PROPN
admet-154	132	63	,	,	PUNCT
admet-154	132	64	m.l	m.l	PROPN
admet-154	132	65	.	.	PROPN
admet-154	132	66	rothenberg	rothenberg	PROPN
admet-154	132	67	,	,	PUNCT
admet-154	132	68	j.	j.	PROPN
admet-154	132	69	clin	clin	PROPN
admet-154	132	70	.	.	PUNCT
admet-154	133	1	oncol	oncol	PROPN
admet-154	133	2	.	.	PUNCT
admet-154	134	1	17(2	17(2	NUM
admet-154	134	2	)	)	PUNCT
admet-154	134	3	(	(	PUNCT
admet-154	134	4	1999	1999	NUM
admet-154	134	5	)	)	PUNCT
admet-154	134	6	685	685	NUM
admet-154	134	7	-	-	SYM
admet-154	134	8	696	696	NUM
admet-154	134	9	.	.	PUNCT
admet-154	135	1	[	[	X
admet-154	135	2	2	2	X
admet-154	135	3	]	]	X
admet-154	135	4	n.e	n.e	PROPN
admet-154	135	5	.	.	PROPN
admet-154	135	6	schoemaker	schoemaker	PROPN
admet-154	135	7	,	,	PUNCT
admet-154	135	8	i.e.	i.e.	X
admet-154	135	9	kuppens	kuppens	PROPN
admet-154	135	10	,	,	PUNCT
admet-154	135	11	w.w	w.w	PROPN
admet-154	135	12	.	.	PROPN
admet-154	135	13	huinink	huinink	PROPN
admet-154	135	14	,	,	PUNCT
admet-154	135	15	p.	p.	PROPN
admet-154	135	16	lefebvre	lefebvre	PROPN
admet-154	135	17	,	,	PUNCT
admet-154	135	18	j.h	j.h	PROPN
admet-154	135	19	.	.	PROPN
admet-154	135	20	beijnen	beijnen	PROPN
admet-154	135	21	,	,	PUNCT
admet-154	135	22	s.	s.	PROPN
admet-154	135	23	assadourian	assadourian	PROPN
admet-154	135	24	,	,	PUNCT
admet-154	135	25	g.j	g.j	PROPN
admet-154	135	26	.	.	PROPN
admet-154	135	27	sanderink	sanderink	PROPN
admet-154	135	28	,	,	PUNCT
admet-154	135	29	j.h	j.h	PROPN
admet-154	135	30	.	.	PROPN
admet-154	135	31	schellens	schellens	PROPN
admet-154	135	32	,	,	PUNCT
admet-154	135	33	cancer	cancer	NOUN
admet-154	135	34	chemother	chemother	PROPN
admet-154	135	35	.	.	PUNCT
admet-154	136	1	pharmacol	pharmacol	PROPN
admet-154	136	2	.	.	PUNCT
admet-154	137	1	55(3	55(3	X
admet-154	137	2	)	)	PUNCT
admet-154	137	3	(	(	PUNCT
admet-154	137	4	2005	2005	NUM
admet-154	137	5	)	)	PUNCT
admet-154	137	6	263	263	NUM
admet-154	137	7	-	-	SYM
admet-154	137	8	270	270	NUM
admet-154	137	9	.	.	PUNCT
admet-154	138	1	[	[	X
admet-154	138	2	3	3	X
admet-154	138	3	]	]	X
admet-154	138	4	o.	o.	NOUN
admet-154	138	5	soepenberg	soepenberg	PROPN
admet-154	138	6	,	,	PUNCT
admet-154	138	7	h.	h.	PROPN
admet-154	138	8	dumez	dumez	PROPN
admet-154	138	9	,	,	PUNCT
admet-154	138	10	j.	j.	PROPN
admet-154	138	11	verweij	verweij	PROPN
admet-154	138	12	,	,	PUNCT
admet-154	138	13	d.	d.	PROPN
admet-154	138	14	semiond	semiond	PROPN
admet-154	138	15	,	,	PUNCT
admet-154	138	16	m.j	m.j	PROPN
admet-154	138	17	.	.	PROPN
admet-154	138	18	de	de	PROPN
admet-154	138	19	jonge	jonge	PROPN
admet-154	138	20	,	,	PUNCT
admet-154	138	21	f.a	f.a	PROPN
admet-154	138	22	.	.	PROPN
admet-154	138	23	eskens	eskens	PROPN
admet-154	138	24	,	,	PUNCT
admet-154	138	25	j.	j.	PROPN
admet-154	138	26	ter	ter	PROPN
admet-154	138	27	steeg	steeg	PROPN
admet-154	138	28	,	,	PUNCT
admet-154	138	29	j.	j.	PROPN
admet-154	138	30	selleslach	selleslach	PROPN
admet-154	138	31	,	,	PUNCT
admet-154	138	32	s.	s.	PROPN
admet-154	138	33	assadourian	assadourian	PROPN
admet-154	138	34	,	,	PUNCT
admet-154	138	35	g.j	g.j	PROPN
admet-154	138	36	.	.	PROPN
admet-154	138	37	sanderink	sanderink	PROPN
admet-154	138	38	,	,	PUNCT
admet-154	138	39	a.	a.	NOUN
admet-154	138	40	sparreboom	sparreboom	NOUN
admet-154	138	41	,	,	PUNCT
admet-154	138	42	a.t	a.t	PROPN
admet-154	138	43	.	.	PROPN
admet-154	138	44	van	van	PROPN
admet-154	138	45	oosterom	oosterom	PROPN
admet-154	138	46	,	,	PUNCT
admet-154	138	47	j.	j.	PROPN
admet-154	138	48	clin	clin	PROPN
admet-154	138	49	.	.	PUNCT
admet-154	139	1	oncol	oncol	ADJ
admet-154	139	2	.	.	PUNCT
admet-154	140	1	23(4	23(4	NUM
admet-154	140	2	)	)	PUNCT
admet-154	140	3	(	(	PUNCT
admet-154	140	4	2005	2005	NUM
admet-154	140	5	)	)	PUNCT
admet-154	140	6	889	889	NUM
admet-154	140	7	-	-	SYM
admet-154	140	8	898	898	NUM
admet-154	140	9	.	.	PUNCT
admet-154	141	1	[	[	X
admet-154	141	2	4	4	NUM
admet-154	141	3	]	]	X
admet-154	141	4	c.f	c.f	PROPN
admet-154	141	5	.	.	PROPN
admet-154	141	6	stewart	stewart	PROPN
admet-154	141	7	,	,	PUNCT
admet-154	141	8	w.c	w.c	PROPN
admet-154	141	9	.	.	PROPN
admet-154	141	10	zamboni	zamboni	PROPN
admet-154	141	11	,	,	PUNCT
admet-154	141	12	w.r	w.r	PROPN
admet-154	141	13	.	.	PROPN
admet-154	141	14	crom	crom	PROPN
admet-154	141	15	,	,	PUNCT
admet-154	141	16	p.j	p.j	PROPN
admet-154	141	17	.	.	PROPN
admet-154	141	18	houghton	houghton	PROPN
admet-154	141	19	,	,	PUNCT
admet-154	141	20	cancer	cancer	NOUN
admet-154	141	21	chemother	chemother	PROPN
admet-154	141	22	.	.	PUNCT
admet-154	142	1	pharmacol	pharmacol	PROPN
admet-154	142	2	.	.	PUNCT
admet-154	143	1	40(3	40(3	NUM
admet-154	143	2	)	)	PUNCT
admet-154	143	3	(	(	PUNCT
admet-154	143	4	1997	1997	NUM
admet-154	143	5	)	)	PUNCT
admet-154	143	6	259	259	NUM
admet-154	143	7	-	-	SYM
admet-154	143	8	265	265	NUM
admet-154	143	9	.	.	PUNCT
admet-154	144	1	[	[	X
admet-154	144	2	5	5	X
admet-154	144	3	]	]	PUNCT
admet-154	144	4	t.	t.	NOUN
admet-154	144	5	bansal	bansal	PROPN
admet-154	144	6	,	,	PUNCT
admet-154	144	7	g.	g.	PROPN
admet-154	144	8	mishra	mishra	PROPN
admet-154	144	9	,	,	PUNCT
admet-154	144	10	m.	m.	NOUN
admet-154	144	11	jaggi	jaggi	PROPN
admet-154	144	12	,	,	PUNCT
admet-154	144	13	r.k	r.k	PROPN
admet-154	144	14	.	.	PROPN
admet-154	144	15	khar	khar	PROPN
admet-154	144	16	,	,	PUNCT
admet-154	144	17	s.	s.	PROPN
admet-154	144	18	talegaonkar	talegaonkar	PROPN
admet-154	144	19	,	,	PUNCT
admet-154	144	20	eur	eur	PROPN
admet-154	144	21	.	.	PUNCT
admet-154	144	22	j.	j.	PROPN
admet-154	144	23	pharm	pharm	PROPN
admet-154	144	24	.	.	PUNCT
admet-154	145	1	sci	sci	PROPN
admet-154	145	2	.	.	PUNCT
admet-154	146	1	36(4	36(4	NUM
admet-154	146	2	-	-	SYM
admet-154	146	3	5	5	NUM
admet-154	146	4	)	)	PUNCT
admet-154	146	5	(	(	PUNCT
admet-154	146	6	2009	2009	NUM
admet-154	146	7	)	)	PUNCT
admet-154	146	8	580	580	NUM
admet-154	146	9	-	-	SYM
admet-154	146	10	590	590	NUM
admet-154	146	11	.	.	PUNCT
admet-154	147	1	[	[	X
admet-154	147	2	6	6	NUM
admet-154	147	3	]	]	PUNCT
admet-154	147	4	t.	t.	NOUN
admet-154	147	5	bansal	bansal	PROPN
admet-154	147	6	,	,	PUNCT
admet-154	147	7	a.	a.	NOUN
admet-154	147	8	awasthi	awasthi	PROPN
admet-154	147	9	,	,	PUNCT
admet-154	147	10	m.	m.	NOUN
admet-154	147	11	jaggi	jaggi	PROPN
admet-154	147	12	,	,	PUNCT
admet-154	147	13	r.k	r.k	PROPN
admet-154	147	14	.	.	PROPN
admet-154	147	15	khar	khar	PROPN
admet-154	147	16	,	,	PUNCT
admet-154	147	17	s.	s.	PROPN
admet-154	147	18	talegaonkar	talegaonkar	PROPN
admet-154	147	19	,	,	PUNCT
admet-154	147	20	talanta	talanta	PROPN
admet-154	147	21	76(5	76(5	NUM
admet-154	147	22	)	)	PUNCT
admet-154	147	23	(	(	PUNCT
admet-154	147	24	2008	2008	NUM
admet-154	147	25	)	)	PUNCT
admet-154	147	26	1015	1015	NUM
admet-154	147	27	-	-	SYM
admet-154	147	28	1021	1021	NUM
admet-154	147	29	.	.	PUNCT
admet-154	148	1	[	[	X
admet-154	148	2	7	7	X
admet-154	148	3	]	]	X
admet-154	148	4	r.h	r.h	PROPN
admet-154	148	5	.	.	PROPN
admet-154	148	6	mathijssen	mathijssen	PROPN
admet-154	148	7	,	,	PUNCT
admet-154	148	8	r.j	r.j	PROPN
admet-154	148	9	.	.	PROPN
admet-154	148	10	van	van	PROPN
admet-154	148	11	alphen	alphen	PROPN
admet-154	148	12	,	,	PUNCT
admet-154	148	13	j.	j.	PROPN
admet-154	148	14	verweij	verweij	PROPN
admet-154	148	15	,	,	PUNCT
admet-154	148	16	w.j	w.j	PROPN
admet-154	148	17	.	.	PROPN
admet-154	148	18	loos	loos	PROPN
admet-154	148	19	,	,	PUNCT
admet-154	148	20	k.	k.	PROPN
admet-154	148	21	nooter	nooter	PROPN
admet-154	148	22	,	,	PUNCT
admet-154	148	23	g.	g.	PROPN
admet-154	148	24	stoter	stoter	NOUN
admet-154	148	25	,	,	PUNCT
admet-154	148	26	a.	a.	NOUN
admet-154	148	27	sparreboom	sparreboom	NOUN
admet-154	148	28	,	,	PUNCT
admet-154	148	29	clin	clin	PROPN
admet-154	148	30	.	.	PUNCT
admet-154	149	1	cancer	cancer	NOUN
admet-154	149	2	res	re	NOUN
admet-154	149	3	.	.	PUNCT
admet-154	150	1	7(8	7(8	NUM
admet-154	150	2	)	)	PUNCT
admet-154	150	3	(	(	PUNCT
admet-154	150	4	2001	2001	NUM
admet-154	150	5	)	)	PUNCT
admet-154	150	6	2182	2182	NUM
admet-154	150	7	-	-	SYM
admet-154	150	8	2194	2194	NUM
admet-154	151	1	[	[	X
admet-154	151	2	8	8	NUM
admet-154	151	3	]	]	X
admet-154	151	4	r.	r.	PROPN
admet-154	151	5	perez	perez	PROPN
admet-154	151	6	-	-	PUNCT
admet-154	151	7	tomas	tomas	PROPN
admet-154	151	8	,	,	PUNCT
admet-154	151	9	curr	curr	PROPN
admet-154	151	10	.	.	PUNCT
admet-154	151	11	med	med	PROPN
admet-154	151	12	.	.	PROPN
admet-154	151	13	chem	chem	PROPN
admet-154	151	14	.	.	PUNCT
admet-154	152	1	13(16	13(16	NUM
admet-154	152	2	)	)	PUNCT
admet-154	152	3	(	(	PUNCT
admet-154	152	4	2006	2006	NUM
admet-154	152	5	)	)	PUNCT
admet-154	152	6	1859	1859	NUM
admet-154	152	7	-	-	SYM
admet-154	152	8	1876	1876	NUM
admet-154	152	9	.	.	PUNCT
admet-154	153	1	[	[	X
admet-154	153	2	9	9	NUM
admet-154	153	3	]	]	X
admet-154	153	4	l.p	l.p	PROPN
admet-154	153	5	.	.	PROPN
admet-154	153	6	rivory	rivory	PROPN
admet-154	153	7	,	,	PUNCT
admet-154	153	8	j.r	j.r	PROPN
admet-154	153	9	.	.	PROPN
admet-154	153	10	bowles	bowles	PROPN
admet-154	153	11	,	,	PUNCT
admet-154	153	12	j.	j.	PROPN
admet-154	153	13	robert	robert	PROPN
admet-154	153	14	,	,	PUNCT
admet-154	153	15	s.m	s.m	PROPN
admet-154	153	16	.	.	PROPN
admet-154	153	17	pond	pond	PROPN
admet-154	153	18	,	,	PUNCT
admet-154	153	19	biochemical	biochemical	ADJ
admet-154	153	20	pharmacology	pharmacology	NOUN
admet-154	153	21	,	,	PUNCT
admet-154	153	22	52(7	52(7	NUM
admet-154	153	23	)	)	PUNCT
admet-154	153	24	(	(	PUNCT
admet-154	153	25	1996	1996	NUM
admet-154	153	26	)	)	PUNCT
admet-154	153	27	1103–1111	1103–1111	NUM
admet-154	153	28	.	.	PUNCT
admet-154	154	1	©	©	PROPN
admet-154	154	2	2015	2015	NUM
admet-154	154	3	by	by	ADP
admet-154	154	4	the	the	DET
admet-154	154	5	authors	author	NOUN
admet-154	154	6	;	;	PUNCT
admet-154	154	7	licensee	licensee	PROPN
admet-154	154	8	iapc	iapc	PROPN
admet-154	154	9	,	,	PUNCT
admet-154	154	10	zagreb	zagreb	PROPN
admet-154	154	11	,	,	PUNCT
admet-154	154	12	croatia	croatia	PROPN
admet-154	154	13	.	.	PUNCT
admet-154	155	1	this	this	DET
admet-154	155	2	article	article	NOUN
admet-154	155	3	is	be	AUX
admet-154	155	4	an	an	DET
admet-154	155	5	open	open	ADJ
admet-154	155	6	-	-	PUNCT
admet-154	155	7	access	access	NOUN
admet-154	155	8	article	article	NOUN
admet-154	155	9	distributed	distribute	VERB
admet-154	155	10	under	under	ADP
admet-154	155	11	the	the	DET
admet-154	155	12	terms	term	NOUN
admet-154	155	13	and	and	CCONJ
admet-154	155	14	conditions	condition	NOUN
admet-154	155	15	of	of	ADP
admet-154	155	16	the	the	DET
admet-154	155	17	creative	creative	ADJ
admet-154	155	18	commons	common	NOUN
admet-154	155	19	attribution	attribution	NOUN
admet-154	155	20	license	license	NOUN
admet-154	155	21	(	(	PUNCT
admet-154	155	22	http://creativecommons.org/licenses/by/3.0/	http://creativecommons.org/licenses/by/3.0/	PROPN
admet-154	155	23	)	)	PUNCT
admet-154	155	24	http://creativecommons.org/licenses/by/3.0/	http://creativecommons.org/licenses/by/3.0/	PROPN